BIOPHYSICAL FEATURES OF THE EXTRACELLULAR MATRIX DIRECT BREAST CANCER METASTASIS by Schwartz, Alyssa
University of Massachusetts Amherst 
ScholarWorks@UMass Amherst 
Doctoral Dissertations Dissertations and Theses 
November 2018 
BIOPHYSICAL FEATURES OF THE EXTRACELLULAR MATRIX 
DIRECT BREAST CANCER METASTASIS 
Alyssa Schwartz 
Follow this and additional works at: https://scholarworks.umass.edu/dissertations_2 
 Part of the Biochemical and Biomolecular Engineering Commons, Biological Engineering Commons, 
Biomaterials Commons, and the Molecular, Cellular, and Tissue Engineering Commons 
Recommended Citation 
Schwartz, Alyssa, "BIOPHYSICAL FEATURES OF THE EXTRACELLULAR MATRIX DIRECT BREAST CANCER 
METASTASIS" (2018). Doctoral Dissertations. 1458. 
https://scholarworks.umass.edu/dissertations_2/1458 
This Open Access Dissertation is brought to you for free and open access by the Dissertations and Theses at 
ScholarWorks@UMass Amherst. It has been accepted for inclusion in Doctoral Dissertations by an authorized 
administrator of ScholarWorks@UMass Amherst. For more information, please contact 
scholarworks@library.umass.edu. 
 
 
 
 
 
BIOPHYSICAL FEATURES OF THE EXTRACELLULAR  
MATRIX DIRECT BREAST CANCER METASTASIS 
 
 
 
 
A Dissertation Presented 
By 
ALYSSA DANIELLE SCHWARTZ 
 
 
 
 
 
Submitted to the Graduate School of the  
University of Massachusetts Amherst in partial fulfillment  
of the requirements for the degree of  
 
DOCTOR OF PHILOSOPHY 
 
September 2018 
Department of Chemical Engineering  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Copyright by Alyssa D. Schwartz 2018 
All Rights Reserved 
 
 
Portions of Chapter 2 © The Royal Society of Chemistry 2017,  
© American Chemical Society 2018 
Portions of Chapter 3 © Elsevier 2018
 Biophysical Features of the Extracellular  
Matrix Direct Breast Cancer Metastasis 
 
 
 
A Dissertation Presented 
 
By 
 
ALYSSA DANIELLE SCHWARTZ 
 
 
 
 
 
 
 
Approved as to style and content by: 
 
 
 
_________________________________________ 
Shelly R. Peyton, Chair 
 
 
 
_________________________________________ 
Michael A. Henson, Member 
 
 
 
_________________________________________ 
Courtney C. Babbitt, Member 
 
 
 
_________________________________________ 
Peter Chien, Member 
 
 
 
 
 
_________________________ 
John Klier, Department Head 
Department of Chemical Engineering 
 
 
DEDICATION 
 
To my family for supporting me every step of the way. 
 
To the 14 year-old girl admitted to Black Lion Hospital with aggressive breast cancer. 
 
v 
 
ACKNOWLEDGEMENTS 
 
I want to acknowledge the incredible commitment that my advisor, Dr. Shelly 
Peyton, has made to my success in graduate school. The energy that Shelly puts into her work 
is always apparent, and she has motivated and supported me to do high quality science, travel 
to conferences to share my work, and helped me be a better mentor to students in STEM. 
Before I even joined the lab, she invested her most precious resource (time – hers and Lauren 
Jansen‟s!) into my GRFP application. It‟s not that hard to understand how Shelly‟s passion 
inspired me to follow her halfway around the world (literally) to learn from and teach 
graduate students in Ethiopia, which started a project that still has a lot of potential and I have 
high hopes for its impact.   
 I also want to sincerely thank my dissertation committee for the time and energy they 
have invested in me. Dr. Courtney Babbitt taught me everything that I know about genetics 
and bioinformatics, and then some. She has been incredibly patient every time I needed help 
troubleshooting a new process, and has dedicated time and resources to my success. Dr. Peter 
Chien and Dr. Michael Henson have provided tremendous insight into my project during our 
meetings. Peter always provided a fresh perspective on my data, and I quickly learned to take 
notes when he was suggesting new experiments! Mike has challenged me to rethink data and 
dig deeper to understand the implications of my analysis. 
 I would not have accomplished as much, or enjoyed myself as much as I did, if it 
were not for the other members of the Peyton lab. Dr. Will Herrick, Dr. Thuy Nguyen, Dr. 
Lauren Barney, and Dr. Lauren Jansen paved the way for a fun and cooperative environment, 
and dedicated tons of time to training me and helping me troubleshoot problems along the 
way. I especially appreciate that Lauren Barney is still my sounding board to this day. I want 
to thank Elizabeth Brooks for being my lab twin and support system as our lab went through 
some growing pains. I have also really enjoyed having Sualyneth Galarza as my conference 
vi 
 
buddy for the last few years. Everyone in the lab has been helpful with ideas, 
troubleshooting, and coffee or ice cream breaks where necessary! Thank you Yen Tran, 
Ning-Huang Tseng, Dr. Katie Bittner, Dr. Chris Hall, Dr. Maria Gencoglu, Carey Dougan, 
Aritra Kundu, and Hyuna Kim. I have also had the opportunity to work with and mentor 
several undergraduate students, and I am particularly grateful for Sarah Duquette‟s passion 
for learning and the energy she invested in doing all of that cell culture on gels! 
I would not be where I am today without fantastic mentors along the way, especially 
Dr. Melissa Kosinski-Collins and Dr. Dave Foster who encouraged me to apply to graduate 
school, and Dr. Bing Xu and Dr. Dania Rabah, who helped me realize that goal. I also want 
to thank all of the other faculty and staff members that have gone out of their way to help me 
during my time at UMass. In particular, Shana Passonno and Dr. Heidi Bauer-Clapp in the 
Office of Professional Development have been instrumental in honing my networking and 
mentoring skills, which I see myself using for the rest of my career. I greatly appreciate 3 
years of funding from the National Science Foundation, as well as travel support from the 
Society for Biomaterials, American Society for Matrix Biology, and the Chemical Biological 
interface.  
 I also want to acknowledge all of the friends that I have made during my time at 
UMass. There are so many people who have made my time during graduate school wonderful 
– doing everything from playing softball, to game nights, and BBQs at the East St. house(s). I 
am so happy to have had wonderful roommates through the years (Kerianne, Celina, Sarah, 
Laura, Zoey), a great class (Vivek, Ashish, Ray, Kerianne, Elizabeth, Nancy), and our own 
little Boston sports fan club (Raghu, Anish, Shoshie). And finally, I want to thank Hayden for 
being my quirky partner through it all. Even though he was initially caught off guard when I 
needed „happy stories‟ after quals, he has been instrumental in cheering me up and helping 
me take breaks when I needed it the most.  
vii 
 
Last, but not least, I want to thank my family for their unwavering support. My parents 
have encouraged me to pursue my interests every step of the way; from cultivating my early 
love for science, to helping me pick out the right college, and providing me with love and 
support through graduate school. I also want to acknowledge Brianna and Jason for pushing 
me to be the best version of myself. It‟s been fun to watch their successes come from hard 
work and it motivates me to work hard and play hard too. 
  
viii 
 
ABSTRACT 
 
BIOPHYSICAL FEATURES OF THE EXTRACELLULAR MATRIX 
 DIRECT BREAST CANCER METASTASIS 
SEPTEMBER 2018 
ALYSSA DANIELLE SCHWARTZ, B.S., UNIVERSITY OF ROCHESTER 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Shelly Peyton 
 
Breast cancer is plagued by two key clinical challenges; drug resistance and 
metastasis. Most work to date probes these events on an extremely rigid plastic surface, 
which recapitulates few aspects of these processes in humans. A malignant cell first resides 
in breast tissue, then likely travels to the bone, brain, liver, or lung, each of which has a 
distinct mechanical and biochemical profile. Cells transmit mechanical forces into 
intracellular tension and biochemical signaling events, and here we hypothesize that this 
mechanotransduction influences drug response, growth, and migration. 
 To probe the impact of extracellular matrix on drug resistance, we defined a set of 
biomaterials that allowed us to independently tune stiffness, dimensionality, and cell-cell 
contact. We screened response to therapeutics across these material systems, and found that 
these environments increased resistance to targeted, but not cytotoxic, therapies compared to 
traditional screening on plastic. A systems biology analysis was applied to signaling data 
across platforms to identify MEK phosphorylation as a key driver of resistance. Comparing 
robust biomaterial screening to traditional plastic, we identified the role individual features of 
the tumor microenvironment in adaptive resistance. 
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 The drug response study systematically varied several biomaterial parameters, but the 
remainder of this work isolated tissue stiffness as a driving force behind metastasis. Here we 
identified two mechanosensitive proteins that are at least partially responsible for adhesion 
and motility in breast cancer cells. On soft matrices, integrin α6 and laminin production 
mimic the aggressive cell behavior induced by epidermal growth factor (EGF). Integrin α6 
and the EGF receptor then coordinate to activate calpain 2, which is necessary for migration 
to distant sites. However, cells likely reside at a metastatic site for long times, so we probed 
the effect of extended mechanical cues on cell behavior. On biomaterials, cells are selected 
for phenotypes that mirror primary tumor cells that have never been grown on plastic. This 
work shows that cells retain memory of their previous mechanical environment, even after 
being re-challenged with culture in very rigid environments. Using biomaterials, we captured 
physiological aspects of drug resistance and metastasis, to better understand and ultimately 
treat breast cancer.  
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CHAPTER 1 
THE PROCESS OF METASTASIS AND CURRENT MODELS 
 
1.1 The Clinical Problem of Advanced Breast Cancer 
Patients diagnosed with localized breast cancer have a 5-year survival rate of 99% 
compared to the general population, but that drops to less than 30% for patients diagnosed 
with metastatic disease. This highlights the need for improved treatment options, and 
currently very few therapeutic interventions target either the mechanical or biochemical 
features of the extracellular matrix (ECM). This work seeks to understand the intersection of 
cancer genetics and tissue mechanics in metastatic breast cancer to identify potential drug 
targets to improve patient outcomes.  
Cancer is the result of accumulating a set of genetic mutations that induce several specific 
hallmarks in order to drive uncontrolled proliferation into a tumor mass [4]. There are several 
driver mutations which can be acquired randomly, through exposure to toxins, or conferred 
through increased familial or personal risk [6, 7]. The most significant clinical risk factor for 
developing breast cancer is having dense breast tissue, which is thought to assist the process 
of malignant transformation [8]. Further, dense breast tissue can promote invasion and 
metastasis, and tumor stiffness can be further increased through a feedback loop of cancer 
cells and local stroma depositing and crosslinking additional matrix proteins [9]. This 
intersection of genetic drivers and mechanical feedback warrants exploration to better 
understand and combat the process of breast cancer metastasis.  
Breast cancer presents many clinical challenges because it is highly heterogeneous in 
genetic make-up, tissue mechanics, and receptor status both within a single tumor and across 
patient populations. Each of these factors can impact the propensity of any given patient to 
develop metastases in critical organs, such as the bone, brain, liver, or lung. However, there 
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is no clear pattern to predict where any given patient‟s primary tumor will metastasize to. In 
addition to the heterogeneity at the primary tumor site, each of the most common secondary 
sites also has a distinct mechanical and biochemical profile [1-3, 10-12]. Different cells or 
cell subpopulations preferentially proliferate or migrate on different stiffness substrates, 
which can be correlated with their metastasis to specific tissues [13].  
Most researchers in the field acknowledge the “seed and soil hypothesis” that there are 
features of both the tumor cells (seed) and properties of the secondary site (soil) that are 
necessary for the formation of metastases [14]. However, most previous research has focused 
on the properties of the cancer cells themselves, not the role of the extracellular matrix in 
driving tumor progression and metastasis. For example, when a patient is initially diagnosed 
with breast cancer, the first action is to determine the clinical subtype; luminal (A/B), HER2 
overexpressing, or triple negative. More recently, in depth analysis of the cells via genetic 
sequencing or more stringent molecular subtyping have been employed. While these 
classifications have been used to predict the optimal therapy options for a given patient (with 
varied success), they revolve exclusively around the properties of the cancer cell, without any 
examination of the extracellular space. Given appropriate work on the subject, drugs that are 
already clinically approved could be used to target tissue stiffness. For example, Tamoxifen 
treatment can reduce overall breast density, which might improve outcomes for some patients 
[15]. More work is needed to relate properties of the extracellular matrix to certain features of 
the cancer cell to better understand and treat metastasis.  
1.1.1 An Overview of Metastasis 
Metastasis contributes to 90% of cancer deaths, as dissemination can be unpredictable 
and difficult to treat. Cells undergo malignant transformation at the primary site, where breast 
epithelial cells acquire a set of driver mutations that lead them to experience uncontrolled 
growth either innately or in response to factors in the microenvironment (Figure 1-1) [16]. 
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The tumor also recruits stroma [17] to assist in the deposition and crosslinking of matrix 
proteins, which results in tumor stiffening [9]. Cell clusters and individual tumor cells likely 
invade the surrounding tissue during all stages of tumor development and stiffening, where 
they eventually intravasate into blood or lymphatic vessels [18]. These circulating tumor cells 
then adhere to the vessel wall and extravasate into the surrounding tissue (Figure 1-1) [19]. 
Tumor cells likely reach a diverse set of secondary sites, but successful colonization of breast 
cancer cells is largely limited to the bone, brain, liver, and lungs. While this process has been 
well characterized, we still have limited knowledge of how the interaction of tissue 
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mechanics with chemokinetic factors, ECM proteins, and the timing of dissemination drive 
invasion and successful metastasis.  
1.1.2 Clinical Information Derived from Biopsies and Genetic Panels 
An MRI or mammographic imaging plus the initial biopsy provide most of the 
information prior to the oncologist deciding on a course of treatment. This provides key 
information like the clinical diagnosis, subtype, stage, and proliferation status of the sample 
[20]. Some pathology reports also include amplification or mutation status of other common 
driver genes in breast cancer including BRCA, ATM, p53, CHK2, PTEN, and CDH1 [21]. 
Figure 0-1. Schematic of the Metastatic Cascade. First, breast epithelial cells undergo 
malignant transformation, which is catalyzed by oncogenic driver genes that can vary within 
and across populations. After diagnosis, patients receive a course of treatment that initially 
shrinks the tumor, but over time the tumor may recur and/or spread to secondary site via the 
development of resistance by altering kinase signaling.  The process of metastasis is 
mechanosensitive, and the stiffening tumor microenvironment can alter cell adhesion to the 
ECM and migration via focal adhesion- associated proteins, integrin α6 and calpain 2. Cells 
are exposed to increased shear forces interstitially as the tumor mass increases, and in the 
vascular system during metastasis, which enhances cell motility. Finally, cancer cells reside 
in tissues for extended lengths of time before and during metastatic outgrowth, and this 
length of exposure to varied mechanical cues selects for a unique subpopulation of cells. 
Adapted from Barney, Jansen, et al. [5] 
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Many treatment options target receptors identified by the subtype, so this limited clinical 
information has been deemed sufficient to make a first pass at patient treatment, although 
anecdotal evidence from oncologists indicates there is still plenty of room for improvement. 
Treatments targeting processes associated with the tumor microenvironment, such as 
angiogenesis and chemotaxis [22, 23], have seen little clinical success thus far.   
1.1.3 The Healthy and Tumor Microenvironments 
 Healthy breast tissue is comprised of soft fatty tissue, epithelial glandular tissue and 
ducts, and fibrous tissue and ligaments [24]. The amount and dispersal of these tissues can 
vary both within a single person, as well as between individuals [25].  Additionally, healthy 
breast tissue contains many different cell types, including epithelial cells, stem cells [26], fat 
cells [27], fibroblasts [28], immune cells [29], and others, each with distinct roles in 
maintaining homeostasis. Specifically, healthy glandular tissue maintains organized duct-like 
morphology, with distinct layers of epithelial cells, myoepithelial cells, basement membrane, 
and then stroma [30]. However, during malignant transformation, the healthy cells can be 
coopted by the cancer to promote tumorigenesis and suppress anti-tumor activity [31, 32]. 
For example, fibroblasts in healthy tissue secrete sufficient collagen to supply structure and 
density to the tissue, and play key roles in normal processes like wound repair [33]. However, 
fibroblasts often facilitate the process of epithelial cells undergoing malignant transformation 
and growth into a tumor mass. Either local or recruited fibroblasts become cancer associated 
fibroblasts (CAFs), which supply the tumor microenvironment with increased collagen 
deposition and crosslinking, and thus increased stiffness [34].   
Cells sense the stiffness of their local microenvironment, which results in genetic and 
phenotypic changes [35-38]. For example, fibroblasts can adapt to the stiffness of their 
substrate by altering intracellular tension [39]. Cells respond to a change in mechanics via 
focal adhesion proteins, which undergo conformational changes to enhance cell structure by 
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linking to the actin cytoskeleton and revealing cryptic kinase domains to initiate downstream 
signaling [40, 41]. Additionally, forces originating from the ECM can directly pull on the 
nucleus to initiate changes in gene expression [42]. The ability of cells to translate 
mechanical information from the microenvironment into biochemical signaling events is 
called mechanotransduction. Changes in ECM stiffness alter mechanical forces and substrate 
adhesivity experienced by the cancer cells [43], which ultimately impacts cell motility [44, 
45].  These processes, which are partially controlled by the stiffness of the surrounding 
matrix, are important for dissemination of cancer cells, as they respond to signals from the 
microenvironment in order to invade the surrounding tissue and migrate to a secondary site.  
1.2 Malignant transformation at the Primary Tumor Site 
1.2.1 Genetic Drivers of Breast Tumorigenesis 
New data-intensive methods have been developed to characterize gene expression 
profiles (RNAseq transcriptome profiling), mutations in protein coding regions of the 
genome (whole exome sequencing) and mutations across the entire genome (whole genome 
DNA sequencing). These methods provide large data sets that allow for a top-down approach 
to understanding both global and local changes that drive tumor formation. For example, 
sequencing, at high enough coverage, can provide information on all of the mutations in a 
tumor biopsy, although not all might contribute to the oncogenic nature of that cell. 
Significant work has been done to identify driver mutations, which actually push a cell 
towards being cancerous, as opposed to passenger mutations, which are incidental mutations 
that happen to be present in a cancer cell, but do not contribute to the characteristic 
uncontrolled growth. Such oncogenes can have one of two main functions; either an 
inactivating mutation of a tumor suppressor gene, or an increase of a tumor promoting gene. 
During any single cell division, on average one out of every ten billion bases copied will be 
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mutated and not repaired by standard machinery. In the 3.1 billion base pairs of the human 
genome, a cell will acquire a new mutation with approximately every 3 divisions. 
Many risk factors for breast cancer are heritable, with the most well-known mutations 
being those of the BRCA DNA-repair family [6]. Those mutations are well characterized 
because of their high penetrance in the population, which is defined as the proportion of 
individuals carrying a mutation that also show the associated phenotype, in this case, breast 
cancer. Interestingly, not all heritable risk factors are in specific oncogenes. For example, 
both obesity and breast density are significant contributors to breast cancer risk [46-48]. 
Tumors have one or more driver mutations that cause malignant transformation, and tumors 
with subclonal populations that contain distinct driver mutations can act cooperatively to 
worsen patient prognosis [49]. While there are hundreds of well-evidenced driver genes, 
some of the most common in breast cancer are; p53 (cell cycle regulator), PTEN (tumor 
suppressor), KRAS (growth factor response), AKT1 (proliferation signaling), and BRCA1/2 
(DNA repair) (Figure 1-2 a).  
1.2.2 The Primary Tumor Stiffens During Cancer Progression  
The primary tumor is a rigid mass of cells and matrix that is so closely packed that 
even oxygen and small molecule drugs face extreme diffusion limitations [50]. Researchers 
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have engineered a plethora of systems to capture select features of this environment, such as 
stiffness, protein composition, dimensionality, cell-cell contacts, and nutrient availability 
(Figure 1-2 b). 2D systems have been designed to capture a range of stiffnesses that spans 
physiological relevance [51], to study aspects of mechanobiology that impact drug response 
[52], cell migration [45, 53], proliferation [13], and gene expression [47, 54]. Both ECM 
mechanics [13] and protein composition [55] impact breast cancer cell tropism, defined as 
cell propensity to metastasize preferentially to specific tissues. Recent work has examined the 
role of dimensionality in cell behavior, particularly in the area of drug resistance. For 
Figure 0-2. Mechanisms of Cancer Initiation and Progression span genetic mutations 
and mechanical pathways. a. Several oncogenes have been implicated in various stages 
during the cell cycle, in processes such as DNA repair, cell cycle checkpoints, and 
quiescence. b. Fibroblasts and other stroma in the tumor microenvironment can deposit and 
crosslink extracellular matrix proteins, like collagens. Cancer cells respond to the resulting 
increase in stiffness through mechanosensitive pathways. Integrins transduce extracellular 
signals intracellularly, where they bind both chemical signaling moieties and proteins that 
serve as linkers to the actin cytoskeleton. c. Tumors also contain a high amount of 
heterogeneity that evolves with the tumor, over time. As the tumor progresses, subclones 
emerge and metastasize, further altering the genomic and mechanical landscapes. 
 
9 
 
example, cells cultured in 3D spheroid-like environments are more resistant to doxorubicin 
[56] and paclitaxel [57] than cells assayed as a 2D monolayer. Additionally, in a spheroid 
model, the matrix deprived cells on the interior were more sensitive to a PI3K inhibitor [58]. 
Other areas of study concerning 3D systems examine confined cell motility [59], and clonal 
cell expansion [60]. In addition to understanding the cell-ECM interactions, cells also 
communicate with one another physically (via cell junctions) and chemically (via soluble 
factors and receptors). These signals from the microenvironment contribute to drug resistance 
and collective cell motility and warrant further examination.  
The systems described above are all user defined, as the parameters are tuned in the 
lab. Another promising method is to allow tissue-specific stem cells to define the architecture 
through the creation of organoids [61]. Although such systems provide less capacity for 
engineering, they better capture the native architecture and spatial organization of healthy 
and diseased tissues [62], which can then be used to study disease progression and off-target 
drug effects on healthy tissues. Combining both user-defined and cell-defined systems, these 
tissue mimics can be connected in sequence or series to create a model human-on-a-chip 
[63]. Providing this interaction between organs can simulate often overlooked processes in 
tumor development, such as the recruitment of bone-derived stem cells [64] and fibroblasts 
[65] to the primary tumor site. Finally, several systems have been designed to mimic the 
hypoxic environment of a tumor mass [66-68]. Independently, each system described and 
referenced above provides a unique contribution to understanding the role of tissue 
mechanics in cancer progression, but more systematic analyses that compare these features to 
optimize the balance of simplicity and relevance are needed.   
1.3 Dissemination to the Secondary Site 
1.3.1 Genetic Heterogeneity and Cell lineages  
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Distinct gene expression programs contribute to metastatic success of an initial 
heterogeneous cell population at different secondary sites (Figure 1-2 c) [1-3]. Work in the 
field has contributed several genes that assist in cell invasion and motility at the secondary 
site, as well as growth and survival genes.  For example, integrins are a class of surface 
receptors that bind to extracellular matrix proteins to transduce physical and biochemical 
information into intracellular signaling and tension generation. Changes in the 
microenvironment are mirrored by changes in the expression of different integrin subunits 
[69, 70]. In addition to changes in gene expression, cancer cells can have point mutations or 
copy number enhancements to increase signaling from soluble factors to promote tumor 
growth. One example of this is the epidermal growth factor receptor (EGFR), where more 
copies of the gene increases expression, and thus the ability of cancer cells to grow rapidly in 
the epidermal growth factor-rich tumor environment.  
Lineage tracing of cells at the primary tumor and at metastases has revealed distinct 
mechanisms of metastatic spread. Conventionally, researchers believed that a primary tumor 
developed and stiffened over time, nurturing aggressive cells until they spread to a secondary 
site. This has been challenged by genomic analysis, demonstrating that single cells or small 
clumps of cells are disseminated early, and that metastases likely progress in parallel with the 
primary tumor [71, 72]. Drug treatment further complicates this analysis and promotes the 
rise of distinct populations over time [73]. This contributes to a growing body of work that 
suggests that cancer cells can metastasize early in tumor development, so disseminated tumor 
cells likely already exist at the time of diagnosis of the primary tumor [74, 75]. This 
highlights the critical need to 1) understand variation of the primary tumor site and cell 
populations that drive persister cells after treatment with drugs and 2) understand the features 
of the secondary tissue sites that enable the survival and outgrowth of disseminated cells. 
1.3.2 The Biochemical and Mechanical Microenvironment Facilitates Metastasis 
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1.3.2.1 Tissue Biochemical Properties Contribute to Tropism 
 The extracellular matrix of each tissue is composed of a unique set of proteins at 
different concentrations, which has been well characterized by the human protein atlas 
project [76]. For example the brain generally has few extracellular matrix proteins, but a 
large amount of that protein is laminin, especially near the blood-brain-barrier. On the other 
hand, bone marrow is more collagen rich. These distinctions are important in considering 
interactions between features of the cell, like integrins, and features of the extracellular space, 
like the matrix proteins, that drive metastasis [77, 78]. Prostate cancer metastasis to the bone 
depends on the surface expression of integrin α2β1, a collagen binding integrin dimer [79]. 
Additionally, a specific spliced isoform of a laminin binding integrin subunit, α6B, alters 
motility and disseminated tumor cell survival [80, 81]. Despite compiling information on 
components of both the cancer cell “seed” and the secondary site microenvironmental “soil”, 
why cancer cells exhibit tropism is still poorly understood.  
Several groups have demonstrated that recruitment of immune cells [82] and stem 
cells [83, 84], as well as the secretion and deposition of proteins, such as fibronectin [85] and 
myeloperoxidase [86] assist in the formation of a pre-metastatic niche before tumor cells 
reach the secondary tissue. Engineers have modeled this niche using biomaterials by 
capturing early tumor cells from circulation on implanted scaffolds and tuning the chemical 
and physical parameters to enhance capture [87, 88]. Recent work has also shown that small 
extracellular vesicles allow communication from tumor cells to distant healthy tissue that 
contributes to this pre-metastatic niche [85].This niche is further modified by other factors, 
such as obesity, which causes chronic lung inflammation and the resident immune cells 
secrete cytokines locally, which enhances breast-to-lung metastasis [89].  Distinct from the 
pre-metastatic niche, tissues can also be primed with a dormant niche, which facilitates 
cellular or tumor dormancy when cancer cells arrive at the secondary site [90]. While cellular 
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dormancy is characterized by non-proliferative cell or cells, tumor-level dormancy occurs 
when the rate of cell proliferation and cell death are roughly equal. Both of these processes 
can delay the onset and detection of metastases, but survival in this state requires a unique 
extracellular niche that doesn‟t promote net cell growth or death [90, 91]. Diverse 
biochemical profiles contribute to tissue specific metastasis, but must also be contextualized 
within the physical properties of those tissues, as many of these processes are 
mechanosensitive.  
1.3.2.2 Secondary Site Tissue Mechanics Vary Widely 
The primary tumor site and each preferred secondary site for metastasis spans a 
physiological range of moduli. While health breast tissue can range from 1 kPa to over 15 
kPa [47, 92-95] based on factors like breast density and obesity, primary breast tumors tend 
to be stiffer, ranging from 10 to 50 kPa (Figure 1-3) [92]. These measurements can be 
dramatically different for tissue at a largely healthy secondary site, where brain tissue is 
usually less than 1 kPa [96, 97], bone marrow and liver tissue is less than 4 kPa [11, 98, 99], 
while lung tissue has been reported from 2 kPa to almost 100 kPa [12, 100, 101]. Of note 
here is that the mechanical properties of the lung can be particularly heterogeneous due to its 
need to undergo cyclic breathing motion and have a high contact area between alveoli and 
capillaries [102]. While the above discussion is on a whole-organ level, other groups have 
also noted that the stiffness of cells, such as fibroblasts, changes to mimic the substrate 
stiffness, due to changes in cytoskeletal assembly and other stress fibers [39]. Because tissue 
mechanics vary widely during progression and a pre-metastatic niche at each secondary site 
will be mechanically unique, evaluating the timing of metastasis is crucial to an 
understanding of the physical background and current mechanical environment of a cell.  
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As mentioned briefly above, breast cancer likely metastasizes early, although work in 
breast cancer to date has focused on HER2 overexpressing breast cancer [74, 75, 103]. These 
new mouse models out of the Aguirre-Ghiso group are the first robust systems used to 
demonstrate early metastasis, where the cancer cell derives important mechanical and 
biochemical cues from the secondary site. Other groups have separately examined the role of 
timing on ECM mechanics and cell phenotype. For example, cells can stiffen biomaterials by 
producing and crosslinking collagenous matrices and can increase the young's modulus from 
200 to 800 kPa over 12 weeks [104]. While in vitro systems have been used to examine the 
impact of matrix stiffness and culture time on stem cell differentiation [105] and mechanical 
Figure 0-3. Substrate Stiffness Drives Mechanical and Genetic Changes. Mechanics: 
Cells respond to the mechanical environment via changes in focal adhesion formation and 
turnover, changes in downstream signaling, and tension generation. On Soft surfaces, cells 
form transient adhesions and have fewer actin stress fibers. At intermediate stiffnesses, cells 
exhibit the fastest migration through optimal catch-bond formation of key 
mechanotransducers. On stiff surfaces, cells receive proliferation signals via ERK and Akt 
pathways, and cells have a high degree of actin polymerization via RhoA-ROCK 
phosphorylation, resulting in more cell spreading and traction. Genetics: On soft materials, 
cells retain a stem-like morphology, as identified by markers for pluripotency. As the 
stiffness begins to increase, cells begin expressing more integrins that bind to structural 
extracellular matrix proteins, such as fibronectin and collagen. Additionally, stem cells 
preferentially differentiate down an osteogenic lineage on these stiffer surfaces. Of critical 
importance to cancer research, is that cells undergo a transition from an epithelial state (with 
markers like E-cadherin and laminins) to a mesenchymal-like state (with markers like N-
Cadherin and fibronectin). This epithelial to mesenchymal transition has been implicated in 
processes like metastasis and drug resistance. 
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memory [106], one study determined how cancer cells modify their gene expression over 9 
days of culture to optimize expression of genes responsible for growth and response to the 
tumor microenvironment [107]. Recent work has scaled culture time to 3 passages of priming 
on polyacrylamide biomaterials, and found that many phenotypes, including proliferation and 
morphology were still changing after 9 days [108]. This suggests that analyses over longer 
time periods would be necessary to capture the full range of behavior alterations. While these 
and other biomaterial models have provided a valuable framework to relate stiffness, ECM 
composition, and metastasis, existing studies do not consider the length of biomaterial 
exposure on cell behavior beyond a time scale of days. This dissertation aims to fill a 
knowledge gap, examining the scale from the early minutes while cells are initially adhering 
to the biomaterials, to several months where cells have an opportunity to fully adapt to a 
different mechanical environment.  
1.3.2.3 Shear Forces are Present at Many Stages of Metastasis 
While the stiffness of the microenvironment is important to examine, other physical 
forces, such as shear stress, can influence the metastatic cascade. Tumors are often regions of 
high fluid pressure, as the increased mass grows to fill in a small volume and develops leaky 
vasculature, generating a net flow away from the primary tumor. This shear force imparts 
physical pressure that can alter cell migration (known as rheokinesis) [109], and can also 
create an autocrine signaling gradient, where cell-secreted soluble factors flow downstream, 
creating a chemical attractant that can influence migration (known as chemokinesis) [110]. 
This flow also impacts the local stroma, including fibroblasts [111], where they are 
increasingly activated in response to the shear forces and can provide protection against 
therapeutics for cancer cells [112]. Together, these physical forces encourage cell migration 
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away from the primary tumor by directly facilitating directional cancer cell motility, or by 
activating fibroblasts to deposit more matrix to indirectly enhance cell motility.  
 Cancer cells reach distant tissues via the vascular or lymphatic systems [113], where 
they experience additional shear flow. Cancer cells or clusters of cells must adhere to the 
vascular wall and extravasate across the endothelial layer to successfully colonize the 
underlying tissue. Researchers have engineered vascularized tissue models to mimic and 
study that process [19, 114], but there is limited information on the response of cancer cells 
to shear forces and the impact those forces have on cells ability to successfully colonize 
secondary sites.  
1.4 Selection of Appropriate Models to Study Breast Cancer Metastasis 
The choice of parameters that are defined in a biomaterial model can impact the 
results of studies. At least partially due to inconsistencies in model selection, the existing 
literature on breast cancer metastasis contains many conflicting reports with contradictory 
conclusions. Much of current cancer knowledge derives from biological assays that seek to 
understand the relationship between genetic mutations and uncontrolled proliferation. Two 
primary model systems are cancer cells cultured in vitro, which are simple and link the 
genotype of a single cell or population to its phenotype, and in vivo mouse models that add 
complexity and are more similar to the human body, although it is more difficult to isolate 
single parameters. While researchers have become experts in curing mouse cancer, there are 
significant limitations on the applicability of these systems to human cancer.  
1.4.1 Identification of Genetic Models that Capture Global Heterogeneity 
Genetic mutations introduced to a cell population or animal can either be forced, by 
altering a targeted gene, or spontaneous by providing a general pressure for cells to undergo 
malignant transformation (Figure 1-4 a). Forced mutations employ techniques such as 
lentivirus transduction to increase or block gene copies, small interfering RNA molecules to 
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block translation, or targeted CRISPR loci to knock out or knockin/constitutively activate the 
gene(s) of interest [115-118]. Spontaneous mutations can be induced by culture or feeding 
with low doses of a toxin, like a cancer drug, or providing other stimuli from the 
microenvironment to select for cells with a growth advantage [119]. For example, the 
Massagué lab generated stable cells lines that each metastasize repeatedly to the brain [1], 
bone [2], or lung [3], through multiple rounds of selection. This spontaneous methodology is 
a top-down approach, where researchers identify a phenotype, and back out the relevant 
genetic information, while targeted mutation methods work from the bottom up by first 
identifying an oncogene of interest. While this bottom up method allows for an in depth 
analysis of a specific target, it has limited utility in identifying new tumor suppressor or 
promoters that may be impacted by environmental factors. On the other hand, working with a 
spontaneous tumor model can provide large amounts of information with new sequencing 
technologies, making it challenging to identify the true cause or causes. Genetic models of 
tumor initiation and metastasis provide a platform to examine cancer cell behavior, and in 
combination with models of the tumor microenvironment can further elucidate what 
microenvironmental factors contribute to cancer progression.  
1.4.2 Optimization of Mechanical Models to Answer Biological Questions 
Several important parameters dictate the ease of use and relevance of data derived 
from any experimental model, such as; stiffness [120], ECM proteins and density [55], 
dimensionality [121], pore size [122], time [106], material stability [123], water content, 
homo- or heterotypic cell-cell interactions [60], medium, and others (Figure 1-4 b). 
Biomaterial platforms provide an excellent base system, with water content greater than 90%, 
on which these other parameters can be layered. These systems can be comprised of either 
naturally derived materials (like collagen or fibrin) or from synthetic polymers (like 
poly(ethylene glycol (PEG) or polyacrylamide (PAA)). Natural polymers easily recapitulate 
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several aspects of native tissue mechanics, structure, and biochemical moieties and are 
inherently non-toxic and optimized for use at physiological pH. Cells can remodel these 
biomaterials in the same manner as the in vivo microenvironment, leading to changes in 
mechanical properties, and the adhesion and mobility of cells [124]. Despite the inherent 
functionality of natural biomaterials, synthetic hydrogels present a different set of 
advantages, and thus are often the model of choice for engineers. Unlike naturally derived 
materials, synthetic materials have selectivity and tunability, as the user can determine 
polymer chain length, crosslink density, and stability with a high degree of batch-to-batch 
consistency that is not attainable in poorly-defined materials derived from living organisms.  
Figure 0-4. Variables that Determine Model Selection for Genetic and Extracellular 
Matix Studies. a. Genetics: In order to select an optimal genetic profiling technique and 
subsequent cell model, several parameters need to be considered. Adapted from the 
„Hallmarks of Cancer‟ [4], breast cancer cells can use several genetic techniques to engage 
in the uncontrolled growth that is characteristic of tumors. Determining appropriate driver 
genes and the corresponding mutations can allow researchers to select genetic features that 
are most appropriate to answer the question at hand. These parameters include, but are not 
limited to; Surface-Receptor Overexpression, Population Heterogeneity, Genomic 
Instability, Tumor Promoter Genes, Reduced Tumor Suppressor Genes, and Replicative 
Immortality. b. Extracellular Matrix: Several features of the tumor microenvironment can 
be modified by natural or synthetic extracellular systems. These parameters greatly impact 
cell phenotype and must be carefully considered; Material Stiffness, Chemokinetic Factors, 
Protein Type, Protein Density, Model Dimensionality, and Time of Exposure to the 
Material.  
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In natural systems the density of biofunctional moieties, such as binding sites, is dependent 
on the amount of protein, so the ligand density is inherently linked to stiffness, making it 
impossible to tune each parameter independently.   
Further, models of the tumor microenvironment need to address contradictions in the 
literature on the role of certain features, like stiffness, on cancer cell aggression. Some work 
reports that compliant primary tumors are more likely to be latent and metastatic [9, 125, 
126]. One potential population is comprised of stem-like cancer cells, which flourish in a 
softer microenvironment [127] and are of particular concern due to their contribution to drug 
resistance and tumor recurrence. On the other hand, stiffer environments are known to confer 
drug resistance and a growth advantage to tumor cells [128-130]. The primary tumor is 
highly heterogeneous, suggesting that several populations may arise within a single tumor 
[131]. This intratumor heterogeneity, where both genetic subclones and mechanics vary 
between different parts of the tumor [132], can influence drug response [133], metastasis, and 
ultimately patient prognosis [134]. This work will investigate these competing hypotheses 
across several times scales and mechanical microenvironments.  
1.5 Hypothesis 
Many features of breast tumor cells (gene expression changes) and the surrounding 
ECM (protein composition and mechanical changes) have been identified. However, previous 
studies have been largely limited in both looking at the primary tumor over common 
metastatic sites and only examining short term or transient cell behaviors. I believe that we 
can expand the current working knowledge of breast cancer progression and metastasis by 
challenging these current model limitations. Here, I hypothesize that by using biomaterial 
models I can uncover new genetic and mechanical contributors to breast cancer metastasis 
and drug resistance. Specifically, I postulate that matrix stiffness and dimensionality will 
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alter cell growth and signaling to drives changes in drug response. I further hypothesize that 
creating and employing mechanical models of metastatic sites will alter and select for cancer 
cell behavior that cannot be identified using hard plastic and other non-physiological models.  
1.6 Objectives 
The following were objectives of this dissertation: 
1. Design a robust set of biomaterial platforms to screen for and overcome mechanisms of 
drug resistance mediated by the tumor microenvironment. 
2. Identify mechanically responsive proteins that facilitate the cell adhesion and motility 
necessary for breast cancer spread. 
3. Drive the selection of cancer cell subpopulations that preferential migrate on softer 
materials by creating mimics of the extracellular tumor environment. 
4. Characterize tumor cell mechanical memory by challenging primary cells and cell lines 
selected on biomaterials with culture on rigid plastic. 
1.7 Significance 
The work in this dissertation expands the knowledge base surrounding mechanical 
regulation of drug resistance and metastasis. First, kinase targeting therapies are an emerging 
class of drugs, but they are plagued by the frequent development of resistance. One proposed 
mechanism to overcome this resistance is the use of combination therapies to prevent cell and 
tumor adaptation. Most drug screening to date has occurred on rigid plastic, but adaptive 
kinase signaling is dependent on the extracellular context, so the development and testing of 
biomaterial environments that are extremely tunable and reproducible is essential to move 
this field forward. However, such materials add a lot of cost to drug screening, so 
discriminating between conditions where these platforms add value is essential. Second, 
oncogenic signaling is complex and this work seeks to understand new mechanisms of cell 
mechanosensing used to facilitate growth and motility. Using techniques like RNA 
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Sequencing and functional assays, genes and proteins that respond to extracellular mechanics 
were identified, which could be potential new therapeutic targets that are more specific to 
cells in stiff tumor environments. Cells also experience tissue stiffness over time, and this 
work seeks to understand behaviors that respond to these mechanics at later time points and 
also exhibit mechanical memory. Finally, these additions to the field should be 
contextualized within the framework of intratumor heterogeneity, where both genetic clones 
and tissue mechanics can vary across a single lesion and varied cell culture methods or 
experimental set ups may incidentally assay only a fraction of the original tumor cell 
population. This work challenges the notion that cells selected for growth advantage on hard 
plastic over several years present perfect physiological information when exposed to 
biomaterials for a day, or even a week.  This work explores the timeframe for which a 
population begins to acquire new behaviors in soft systems and the contributions that 
individual clones might make to those phenotypes. In sum, this work examines genetic and 
mechanical variations across heterogeneous populations and within a single clone to produce 
new knowledge on aggressive breast cancer and introduce new paradigms for optimizing 
treatment. 
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CHAPTER 2 
A BIOMATERIAL SCREENING APPROACH REVEALS 
MICROENVIRONMENTAL MECHANISMS OF DRUG RESISTANCE 
  
2.1 Abstract 
Traditional drug screening methods lack features of the tumor microenvironment that 
contribute to resistance. Most studies examine cell response in a single biomaterial platform 
in depth, leaving a gap in understanding how extracellular signals such as stiffness, 
dimensionality, and cell-cell contacts act independently or are integrated within a cell to 
affect either drug sensitivity or resistance. This is critically important, as adaptive resistance 
is mediated, at least in part, by the extracellular matrix (ECM) of the tumor 
microenvironment. We developed an approach to screen drug responses in cells cultured on 
2D and in 3D biomaterial environments to explore how key features of the ECM mediate 
drug response. This approach uncovered that cells on 2D hydrogels and spheroids 
encapsulated in 3D hydrogels were less responsive to receptor tyrosine kinase (RTK)-
targeting drugs sorafenib and lapatinib, but not cytotoxic drugs, compared to single cells in 
hydrogels and cells on plastic. We found that transcriptomic differences between these in 
vitro models and tumor xenografts did not reveal mechanisms of ECM-mediated resistance to 
sorafenib. However, a systems biology analysis of phospho-kinome data uncovered that 
variation in MEK phosphorylation was associated with RTK-targeted drug resistance. Tissue 
culture plastic, the 2D hydrogels, and at least one 3D condition were necessary for this 
systems biology analysis to achieve significance. We identified 2 unique mechanisms of 
spheroid formation that may contribute to drug resistance; cells either upregulate genes 
associated with cell-cell contacts, or genes associated with increased ECM production and 
binding, which is the likely mechanism here.  Using sorafenib as a model drug, we found that 
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co-administration with a MEK inhibitor decreased ECM-mediated resistance in vitro and 
reduced in vivo tumor burden compared to sorafenib alone.  
Many factors of the ECM are known to influence cell signaling and drug response. 
However, the goal of this work was to systematically vary specific parameters in order to 
compare drug response across many ECM features, which has been lacking in many previous 
studies. In order to achieve that goal, we selected three specific parameters with robust 
evidence of altering kinome signaling, biomaterial stiffness, dimensionality, and the presence 
or absence of mitogenic factors (Figure 2-1). While those features are the focus of this work, 
it is important to note that other parameters play a role in how cells respond to biomaterials. 
For example, in the 3D hydrogel we included protein fragments (peptides) to stimulate cell 
binding and signaling, which can be altered to tune response, similarly to changing the full 
length proteins available to cells on 2D hydrogels. Additionally, while we didn‟t explicitly 
change the length of the assays, we identified two phenotypes where the timing likely plays a 
Figure 0-1. Exploring the role of the 
Extracellular Matrix in Resistance to 
Targeted Therapeutics. Several 
components of the extracellular matrix 
drive signaling changes and alter drug 
response. We selected 3 components of 
the microenvironment to probe the range 
of stiffness, dimensionality, and growth 
factors on drug response. Previous work 
from the Peyton lab has demonstrated that 
higher substrate stiffness increases 
resistance to sorafenib. Additionally, the 
group has identified heterogeneous 
responses to drugs when cells are grown 
into spheroids and encapsulated in a 3D 
hydrogel. Finally, signaling that drives 
changes in drug response can also be 
triggered by exogenous mitogenic factors, 
so we tracked the role of chemokine-rich 
serum on drug response.  
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role. First, is that the spheroids were grown over 14 days, which provides opportunities for 
cells to secrete and bind to ECM proteins, so we evaluated drug response in spheroids that 
were dissociated back onto plastic for the assay, and found that drug response in those cells 
looked most similar to cells grown entirely on plastic. Second, in clustering of cell gene 
expression across our set of biomaterial platforms, in the SkBr3 cells, a mouse xenograft 
tumor (which required 21 days to grow) is most distantly related to the other samples, while 
in the MDA-MB-231 cells, the spheroid samples were most different from the others 
(spheroids grew over 14 days, MDA-MB-231 xenograft only required 10 days to grow). In 
sum, we provide a novel strategy for identifying and overcoming ECM-mediated resistance 
mechanisms by performing drug screening, phospho-kinome analysis, and systems biology 
across specifically selected biomaterial environments.  
2.2 Introduction 
Adaptive resistance poses a significant challenge for targeted drugs as tumor cells can 
alter their signaling pathways to bypass the effect of therapeutics. This adaptive signaling 
occurs quickly and independently of acquired mutations, making the timing of therapeutics 
critical to sensitize tumor cells to drugs via rewiring from an oncogene-addicted state [135]. 
For instance, triple-negative breast cancer cells treated with a MEK inhibitor undergo a rapid 
kinome reprogramming of many receptor tyrosine kinases (RTKs), cytokines, and 
downstream signaling pathways [136]. Inhibition of this adaptive response by lapatinib 
prevents downstream Src, FAK, and Akt signaling [137]. Mechanistically, kinase inhibitor 
treatment can decrease shedding of RTKs, thus enhancing bypass signaling [138]. Drug 
treatment can also cause changes in the cell cycle, promoting resistance in the quiescent cells 
adapting to the treatment [139]. These examples demonstrate that quick and widespread 
changes in signaling can occur in response to anti-cancer drugs.  
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The tumor microenvironment is a complex, heterocellular system with known roles in 
modulating tumor progression and drug response [16]. The extracellular matrix (ECM) is one 
feature of the microenvironment that can alter cell signaling and facilitate adaptive resistance. 
For example, ECM stiffness can activate RTKs and engage integrin binding to promote cell 
growth and survival through the Raf/MEK/ERK and PI3K/Akt/mTOR pathways [9, 140]. 
Our group and others have employed engineered biomaterials to elucidate drug resistance in 
response to biophysical and biochemical stimuli from the ECM. Two-dimensional (2D) 
hydrogels allow for the presentation of controlled integrin binding, a physiological stiffness, 
and are amenable to drug screening. Three-dimensional (3D) hydrogels also present 
physiological dimensionality and biochemistry through matrix degradability, matrix 
adhesion, and homotypic or heterotypic cell-cell interactions. No single system can capture 
all features of the tumor microenvironment, and complex systems do not allow for isolation 
of the effect of individual cues. Here, we propose a biomaterial-based method to 
systematically vary stiffness, dimensionality, and cell-cell contacts to analyze matrix-
mediated adaptive resistance by measuring genetic and phospho-signaling changes. 
All of these extracellular cues can alter the signaling networks targeted by cancer 
therapeutics. For example, β1 integrin-mediated tolerance to a BRAF inhibitor in vivo can be 
recapitulated by stiff synthetic matrices in vitro [141]. We recently developed a high-
throughput drug screening platform based on a poly(ethylene glycol)-phosphorylcholine 
(PEG-PC) hydrogel and identified that increased substrate stiffness imparts cellular resistance 
to sorafenib [51, 52]. Similarly, others have demonstrated decreased drug sensitivity in 3D 
hydrogels compared to 2D hydrogels and tissue culture polystyrene (TCPS) [130]. These 
studies demonstrate the vast opportunities that synthetic biomaterials provide for exploring 
drug resistance and kinome rewiring mediated by features of the ECM but have yet to 
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capitalize on the potential for a systematic analysis of stiffness, geometry, and cell-cell 
contacts afforded by such systems to understand mechanisms of ECM-mediated resistance.  
Many systems have been implemented to create multicellular tumor spheroids 
(MCTS) to understand tumor biology and increase complexity in drug screening, but most 
scientific studies select a single method without regard for how the formation impacts 
experimental results [142-144]. Some research focuses on the inherent cell-cell contacts 
present in MTCS [145], which is more representative of an epithelial cell phenotype, while 
others examine the role of increased ECM production in facilitating the structure [146], 
which is more similar to a tumor-like microenvironment. Tight junctions and cell-cell 
contacts lend themselves to limited diffusion of nutrients and drugs [146], while changes to 
the ECM are known to regulate drug resistance via intracellular signaling [147]. Therefore, a 
robust examination of multiple methods of spheroid formation may better explain observed 
phenomena in drug resistance of MCTS. 
It is imperative to consider multiple components of the ECM while studying drug 
response, as variations in matrix complexity can produce considerably different predictions 
for in vivo drug response to anti-cancer drugs. Since no single system can capture all features 
of the tumor ECM, we investigated drug resistance and adaptive reprogramming of breast 
cancer cells across multiple biomaterial microenvironments to analyze the genetic and 
phospho-signaling contributions to adaptive resistance. Multiple linear regression modeling 
revealed that MEK signaling explained the difference in RTK-targeted drug response across 
the ECMs, and co-administering a MEK inhibitor with sorafenib improved efficacy of the 
single agent in vitro and in vivo. This is the first report to combine systems biology analysis 
with screening across biomaterial platforms to identify MEK as a mediator of ECM-driven 
resistance to RTK inhibitors.  
2.3 Materials and Methods 
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2.3.1 Cell culture 
All supplies were purchased from Thermo Fisher Scientific (Waltham, MA) unless 
otherwise noted. Human breast cancer cell lines MDA-MB-231 and SkBr3 cells were 
generous gifts from Dr. Sallie Smith Schneider at the Pioneer Valley Life Sciences Institute 
and Dr. Shannon Hughes at the Massachusetts Institute of Technology, respectively, and 
were cultured in Dulbecco‟s Modified Eagle‟s Medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S) at 37ºC and 5% CO2. 
2.3.2 Polymerization of 2D and 3D PEG hydrogels  
2D PEG-phosphorylcholine (PEG-PC) hydrogels were prepared and protein was 
coupled as described previously [52]. Glass-bottom 96-well plates (no. 1.5 coverslip glass; In 
Vitro Scientific, Sunnyvale, CA) were plasma treated (Bioforce Nanosciences, Salt Lake 
City, UT) and subsequently methacrylate-silanized with 2 vol % 3-(trimethoxysilyl) propyl 
methacrylate (Sigma-Aldrich, St. Louis, MO) in 95% ethanol (pH 5.0) for 5 min, washed 3 
times with 100% ethanol, and dried at 40°C for 30 minutes. PEGDMA (Mn 750, Sigma-
Aldrich), is added at 1.1 wt % (10 kPa, 0.015 M) or 3.2 wt % (33 kPa, 0.043 M) to a solution 
of 17 wt % 2-methacryloyloxyethyl phosphorylcholine (PC) (Sigma-Aldrich) in phosphate-
buffered saline (PBS). Solutions were sterilized with a 0.2 μm syringe filter (Thermo) and 
degassed by nitrogen sparging for 30 seconds. Free-radical polymerization was induced by 
addition of 0.05 wt % ammonium persulfate (APS, Bio-Rad Laboratories, Hercules, CA) and 
0.125 vol % tetramethylethylenediamine (TEMED, Sigma-Aldrich). Hydrogels of 40 μL per 
well in the 96-well plates were polymerized under nitrogen for 30 minutes. Post-
polymerization, hydrogels were allowed to swell for 24 hours in PBS, then treated with 100 
μL of sulfo-SANPAH (ProteoChem, Denver, CO; 0.6 mg/mL in pH 8.5 HEPES buffer) under 
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UV light for 20 minutes, rinsed twice with HEPES buffer, and followed immediately by 
incubation with type I collagen at 3.3 μg/cm2 (Thermo) overnight.  
3D PEG-maleimide (PEG-MAL) hydrogels were prepared at 10 wt % (3 kPa) and 20 
wt % (5 kPa) solution with a 20K 4-arm PEG-MAL (Jenkem Technology, Plano, TX) and 
2mM of the cell binding peptide CRGD (Genscript, Piscataway, NJ), and was crosslinked at 
a 1:1 ratio with 1K linear PEG-dithiol (Sigma-Aldrich) in 2mM triethanolamine (pH ~ 7.4) 
[148]. Hydrogels were polymerized in 10 μL volumes for 5 minutes before swelling in cell 
culture medium.  
Bulk diffusion of Rhodamine 6G (R6G) (Stokes‟ radius 0.76 nm, Sigma-Aldrich) in 
3D PEG-MAL hydrogels was measured by encapsulating 0.1 g/L R6G in the hydrogel and 
sampling the supernatant at 5-minute intervals. The samples were analyzed on a fluorescent 
plate reader at excitation: 526 nm/emission: 555nm. The diffusion coefficient of R6G was 
calculated using the Stokes‟-Einstein equation.  
2.3.3 Formation of uniform tumor spheroids 
To make polyNIPAAM spheroids, lyophilized poly(N-isopropylacryamide)-
poly(ethylene glycol) (polyNIPAAM, Cosmo Bio USA, Carlsbad, CA) was reconstituted in 
cell culture medium according to the manufacturer‟s instructions and kept at 4ºC until use. 
Cells were suspended in polyNIPAAM solution placed on ice at a density of 100,000 
cells/mL for SkBr3 cells and 167,000 cells/mL for MDA-MB-231 cells, and each gel was 
made at a volume of 150 μL. Gelation occurred after 5 minutes at 37ºC, and gels were 
swollen in cell culture medium. Single cells were grown into spheroids for 14 days in the gels 
with regular medium changes. Spheroids were either dissociated back onto TCPS (for RNA-
Seq and drug dosing) or encapsulated in 3D PEG-MAL gels (for RNA-Seq, drug dosing, and 
signaling) for 24 hours.  
To make microwell spheroids, square pyramidal microwells (400 μm side-wall 
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dimension) were fabricated as described previously [149, 150] or purchased (AggreWell, 
Stem Cell Technologies, Canada). For fabrication, master molds containing square-pyramidal 
pits were generated by anisotropic etching of 100 crystalline silicon in potassium hydroxide 
(KOH). Microwell surfaces for tissue culture were then generated from 
poly(dimethylsiloxane) (PDMS) using a two-stage replica molding process of the master 
mold as described previously. Microwells were arranged in a square array with no space 
between adjacent wells and placed in 6 or 12-well plates. To prepare microwells for cell 
seeding, microwell surfaces were UV sterilized and pretreated with 5% Pluronic F-127 
(Sigma-Aldrich) for 30 min at room temperature and then washed twice with sterile water. 
Cells were distributed over microwell surfaces at concentrations of 1.03 × 105 cells/cm2 or 
1.00 × 104 cells/cm2. After 24 h, spheroids were collected by shaking the plate gently to 
dislodge most of them, and gently aspirating medium and spheroids. Spheroid solution was 
spun down at 400 rpm for 5 min. Medium was removed, and the spheroid pellet was lysed for 
RT-PCR, or encapsulated in 3D hydrogels. Spheroids were handled using cut pipet tips to 
minimize shear stress. 
 To make spheroids using suspension culture, single cells were seeded at 1.05 × 104 
cells/cm2, 1.05 × 103 cells/cm2, or 1.05 × 102 cells/cm2 in a 6-well flat ultralow attachment 
plate (Corning, Tewksbury, MA). After 3 days, spheroids were collected by aspiration of 
medium and spheroids. Spheroid solution was spun down at 400 rpm for 5 min. Medium was 
removed, and the spheroid pellet was lysed for RT-PCR or encapsulated in 3D hydrogels. 
Spheroids were handled using cut pipet tips to minimize shear stress. 
2.3.4 Characterization of Gene Expression by RT-PCR 
The expression of cell−cell adhesion molecules and ECM mRNA transcripts was measured 
by quantitative RT-PCR. Total RNA was isolated using the GenElute mammalian total RNA 
kit (Sigma-Aldrich) and 0.5 μg total RNA was reverse transcribed using the RevertAid 
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reverse transcription system (Thermo Fisher). Ten ng cDNA was then amplified using 10 
pmol of integrin-specific primers (Table 2-1) and the Maxima SYBR green master mix 
(Thermo Fisher) on a Rotor-Gene Q thermocycler (Qiagen, Valencia, CA) as follows: 50 °C 
for 2 min, 95 °C for 10 min followed by 45 cycles at 95 °C for 10 s, 58 °C for 30 s, and 72 °C 
for 30 s. Both β-actin and ribosomal protein S13 were included as reference genes to permit 
gene expression analysis using the 2−ΔΔCt method [151]. 
2.3.5 Hydrogel mechanical characterization  
Mechanical compression testing for 2D and 3D hydrogels was performed with a TA 
Instruments AR-2000 rheometer (New Castle, DE) at a 2 μm/s strain rate and analysis as 
previously described [51]. Indentation testing for polyNIPAAM hydrogels was performed  
 
Table 0-1. Characterization of gene expression by RT-PCR. 
Gene 
Accession 
Number 
Forward Sequence Reverse Sequence 
CLDN4 NM_001395.4 CAAGGCCAAGACCATGATCG GAGTAAGGCTTGTCTGTGCG 
CDH3 NM_001793.5 GGAGGTGGAGAAAGAGGCTT ACTCCTCAGCCTCCTCAGTA 
CDH5 NM_001795.4 TACCAGGACGCTTTCACCAT AAAGGCTGCTGGAAAATGGG 
ITGB4 NM_000213.3 ACTACACCCTCACTGCAGAC TCTGGCTTGCTCCTTGATGA 
ITGA2 NM_002203.3 GGGCATTGAAAACACTCGAT TCGGATCCCAAGATTTTCTG 
ITGB1 NM_002211.3 CATCTGCGAGTGTGGTGTCT GGGGTAATTTGTCCCGACTT 
FN1 NM_212482.2 CGGTGGCTGTCAGTCAAA AATCCTCGGCTTCCTCCATAA 
RPS-13 NM_001017.2 AAGTACGTTTTGTGACAGGCA CGGTGAATCCGGCTCTCTATTAG 
β-Actin NM_001101.3 GGACTTCGAGCAAGAGATGG AGCACTGTGTTGGCGTACAG 
 
using a custom-built instrument previously described [11]. For this application, a flat punch 
probe with a diameter of 1.5 mm was applied to samples at a fixed displacement rate of 5 
μm/s, for maximum displacement of 100 μm.  PolyNIPAAM samples were placed on a 
heated surface to maintain a sample temperature between 37-40°C throughout testing.  
2.3.6 Quantification of drug response  
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At 24 hours post-seeding, cells on biomaterials were treated with lapatinib (0-64 μM, 
LC Laboratories, Woburn, MA), sorafenib (0-64 μM, LC Laboratories), temsirolimus (0-80 
μM, Selleckchem, Houston, TX), doxorubicin (0-32 μM, LC Laboratories), or dimethyl 
sulfoxide (DMSO, Sigma-Aldrich) as a vehicle control. Where noted, inhibitors were 
included in the medium: PD0325901 (3 μM, Sigma-Aldrich), SP600125 (20 μM, LC 
Laboratories). After 48 hours of drug treatment, cell viability was quantified by CellTiter Glo 
Luminescent Cell Viability Assay (Promega, Madison, WI), and luminescence was read on a 
Biotek Synergy H1 plate reader after incubation for 10 minutes. Separately, at 24 hours, 
viability of untreated cells was determined via CellTiter Glo for a measurement of initial 
seeding density. IC50 and GR50 [152] values were calculated using the initial seeding density 
and drug treated measurements using GraphPad Prism v6.0h.  
2.3.7 Cell seeding on biomaterials   
Cells were seeded on and in biomaterial microenvironments in serum-free DMEM 
(1% P/S, 20 ng/mL of epidermal growth factor (EGF), R&D Systems, and 20 ng/mL of 
platelet-derived growth factor BB (PDGF-BB), R&D Systems, Minneapolis, MN) or serum 
containing DMEM (1% P/S and 10% FBS) where noted. Cells were seeded at 30,000 
cells/cm2 on PEG-PC gels and on tissue culture plastic (TCPS), or as single cells at 500 
cells/μL in 3D PEG gels. Spheroids were recovered via addition of cold serum free medium 
(1% P/S) on ice for 5 minutes for gel dissolution, and then gravity sedimentation for 30 
minutes on ice. The supernatant was removed and the spheroids collected from each 
polyNIPAAM gel were re-suspended in PEG-MAL solution to make 9 3D hydrogels.  
2.3.8 RNA Sequencing 
Total RNA was isolated using Gen Elute mammalian total RNA miniprep kit (Sigma-
Aldrich). The Illumina TRUseq RNA kit was used to purify and fragment the mRNA, 
convert it to cDNA, and barcode and amplify the strands. Quality and length of the inserts 
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was confirmed with an Agilent Genomics 2100 bioanalyzer, followed by single-end reads on 
a NextSeq 500 to generate a complete transcriptome from each sample. Transcripts were 
aligned to the hg19 human reference genome using the Tuxedo Suite pathway [153]. 
2.3.9 Gene Set Enrichment Analysis  
Aligned samples were converted to GCT and CLS file formats using useGalaxy.org 
[154]. Samples were separated by material condition across both cell lines to determine 
biomaterial microenvironment-specific gene categories. GSEA software was used to analyze 
enriched KEGG pathways as previously described [155], and pathways with significant 
enrichment of expressed genes were selected [156]. 
2.3.10 Multiplex phospho-protein quantification  
Cells were seeded onto 2D hydrogels at 56,600 cells/cm2, or into 3D gels at 200,000 
single cells in 20 μL volume gel. Spheroids were grown for 14 days in polyNIPAAM, and 
then transferred to 3D PEG-MAL gels, where spheroids from three polyNIPAAM gels were 
transferred to four 20 μL 3D PEG-MAL gels. Samples were seeded in serum free DMEM. 
After 24 hours, cells were dosed with either 8 μm sorafenib, 8 μm lapatinib, 25 μm 
temsirolimus, or DMSO control in serum free medium (or serum containing medium where 
noted) for 4 hours, then washed once with ice cold PBS and lysed in RIPA buffer 
supplemented with protease (EDTA-free protease inhibitor cocktail tablets, 1 tablet in 10 ml, 
Roche, Indianapolis, IN) and phosphatase (1x phosphatase inhibitors cocktail-II, Boston 
Bioproducts, Boston, MA) inhibitors, 1 mM phenylmethylsulfonyl fluoride (Thermo Fisher 
Scientific), 5 μg/ml pepstatin A (Thermo Fisher Scientific), 10 μg/ml of leupeptin (Thermo 
Fisher Scientific), 1 mM sodium pyrophosphate (Thermo Fisher Scientific), 25 mM β-
glycerophosphate (Santa Cruz, Dallas, TX). Protein concentration was determined with a 
BCA assay (Sigma-Aldrich). PEG-MAL gels were manually dissociated with a pipet tip for 
30 seconds after addition of lysis buffer.  
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Lysate concentrations were adjusted to 520 μg/ml and then analyzed with the 
MILLIPLEX MAP Multi-Pathway Magnetic Bead 9-Plex - Cell Signaling Multiplex Assay 
(Millipore, Billerica, MA; analytes: CREB (pS133), ERK (pT185/pY187), NFκB (pS536), 
JNK (pT183/pY185), p38 (pT180/pY182), p70 S6K (pT412), STAT3 (pS727), STAT5A/B 
(pY694/699), Akt (pS473) supplemented with additional EGFR (pan Tyr) and MEK1 
(pS222) beads according to the manufacturer‟s instructions, with the exception that beads and 
detection antibodies were diluted four-fold. Controls were performed to ensure that samples 
were within the linear dynamic range. Data is reported as the Mean Fluorescent Intensity 
(MFI) or fold change in MFI relative to the vehicle control.   
SkBr3 cells on TCPS, 33 kPa 2D gels, and spheroids in 3 kPa PEG-MAL were serum 
starved for 24 h and then stimulated with 100 ng/mL of EGF (R&D Systems, Minneapolis, 
MN), and cell lysates were collected at 0, 5, 15, 60 minutes, and 24 hour time points. Lysate 
concentrations were adjusted to 160 μg/mL, and samples were quantified the MILLIPLEX 
MAP Phospho Mitogenesis RTK Magnetic Bead 7-Plex Kit (Millipore; analytes: c-
Met/HGFR (panTyr), EGFR (panTyr), ErbB2/HER2 (panTyr), ErbB3/HER3 (panTyr), 
ErbB4/HER4 (panTyr), IR (panTyr), and IGF1R (panTyr) according to the manufacturer‟s 
instructions, with the exception that beads and detection antibodies were diluted four-fold. 
2.3.11 Experimental Model And Subject Details  
Multiple linear regression modeling was performed using „stats::lm‟ within R, 
regressing each compendium of signaling measurements against the corresponding viability 
measured in the same conditions. All relationships were assumed to be additive, and no 
interaction or intercept terms were included in the models. Each measurement was z-score 
normalized before regression. The two-sided p-values presented were calculated based upon 
the significance of each parameter being non-zero. The overall performance of each model 
(as calculated by the F-statistic) corresponded well to the significance of individual terms. All 
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code and raw measurements for model development are available on Github 
(https://github.com/meyer-lab/Barney-Peyton). 
2.3.12 Immunofluorescence and immunohistochemistry  
 Cells were grown in serum for 24 h in the indicated material condition, fixed, and 
stained for Ki67. Cells were serum-starved and stimulated with EGF as described above, and 
stained according to standard protocols for total EGFR or HER2. The following antibodies 
were used for immunofluorescence: Ki67 (ab16667, 1:200, Abcam), EGFR (D38B1, 1:100, 
Cell Signaling Technology), and HER2 (29D8, 1:200, Cell Signaling Technology). All tumor 
samples were fixed and paraffin embedded. Ki67 staining (ab16667, 1:100, Abcam) was 
done on 6 μm tissue slices. All AlexaFluor secondary antibodies (Thermo Fisher Scientific) 
were used at 1:500. Samples were imaged on a Zeiss Cell Observer SD (Carl Zeiss AG, 
Oberkochen, Germany).  
2.3.13 Animal Xenografts  
All animal experiments were in accordance with institutional guidelines and approved 
by the Institutional Animal Care and Use Committee at the University of Massachusetts 
Amherst. UMass has an approved Animal Welfare Assurance (#A3551-01) on file with the 
NIH Office of Laboratory Animal Welfare. MDA-MB-231 cells were suspended in Matrigel 
(Corning, Corning, NY), and 106 cells were subcutaneously injected into the mammary fat 
pad of 8-10 week old female NOD scid gamma mice from a breeding colony. Each mouse 
was injected with two tumors. All mice were housed in ventilated cages with sterile bedding, 
food, and water. Injected cells were grown in vivo for 7 days then drugs were suspended in 
DMSO and administered with an intraperitoneal (IP) injection daily for 14 days using a 27-
gauge needle.  Mice received 100 μL of one of five different treatments: vehicle (100% 
DMSO), sorafenib at 10 mg/kg, PD0325901 at 10 mg/kg, or a combination of the drugs at 5 
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or 10 mg/kg each. A minimum of 4 mice were analyzed for each drug dosing condition, and 
each tumor was considered one replicate. 
2.3.14 Quantification And Statistical Analysis  
Prism v5.04 (GraphPad Software) was used to perform unpaired Student's t-test, a 
one-way analysis of variance (ANOVA) with a Tukey post-test. A two-way ANOVA 
determined how the IC50 changed with respect to material modulus, geometry, and medium 
condition, with a Bonferroni post-test (GraphPad Prism v5.04).  A two-way ANOVA, 
performed in R, was used to determine drug contribution to tumor burden. Data are reported 
as mean ± standard error, where p ≤ 0.05 is denoted with *, ≤ 0.01 with **, and ≤ 0.001 with 
***. 
2.4 Results 
2.4.1 Geometry impacts innate breast cancer cell response to RTK-targeting drugs 
Distinct differences across in vitro screening methods, including stiffness, 
dimensionality, and cell-cell interactions prevent comparisons across existing studies. 
Therefore, we developed a system to independently evaluate the effects of both the geometry 
and stiffness of the microenvironment on breast cancer cell response to targeted and non-
targeted drugs. We measured the GR50 (concentration of drug which dampens growth by 
50%) [152] for four drugs (sorafenib, lapatinib, temsirolimus, and doxorubicin) across 
multiple biomaterials: TCPS, a 2D PEG-PC hydrogel, and a 3D PEG-MAL hydrogel with 
encapsulated single cells or tumor spheroids (Figure 2-2 a). To create tumor spheroids, single 
cells were encapsulated sparsely in polyNIPAAM hydrogels and grown into uniform clonal 
spheroids over 14 days in culture (Figure 2-2 b-d). This 14 day endpoint achieves a relatively 
homogeneous population of viable multicellular tumor spheroids with an average diameter 
less than 100 μm (Figure 2-2 b-c) [60]. This diameter was chosen to ensure drug [50] and 
oxygen diffusion into the spheroids. Spheroids were transferred to PEG-MAL hydrogels for 
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dosing, where bulk diffusion measurements of rhodamine 6G suggest small molecules diffuse 
through the 3D hydrogel at 2.5x10-6 cm2/s (data not shown), which means that the drug will 
reach the cells within 10 seconds. Further, immunofluorescent staining of Ki67 expression 
revealed that there were proliferating cells throughout the entire spheroid, suggesting there 
were no significant nutrient or oxygen diffusion limitations within the 3D PEG hydrogel 
(data not shown).  
We previously found that breast cancer cells on stiffer substrates were more resistant 
to sorafenib [52], so we included two different moduli for the 2D and 3D hydrogels. 
Although the effect of altered proliferation across the biomaterials (Figure 2-3) would 
confound comparisons of traditional IC50 calculations, it is accounted for in the GR50 
Figure 0-2. Characterization of Multiple Biomaterial Platforms. a. Schematic of 
biomaterial drug screening platforms, including TCPS, 2D hydrogels linked with collagen I, 
and 3D hydrogels with RGD for cell adhesion, either with encapsulated single cells or tumor 
spheroids. Each hydrogel condition was screened at two different moduli (2D: 10 or 33 kPa, 
3D: 3 or 5 kPa). b. Quantification of mean spheroid diameter for MDA-MB-231 spheroid 
growth in polyNIPAAM gels over 14 days. c. Viability of MDA-MB-231 spheroid after 14 
days of growth in polyNIPAAM, and encapsulation in 3 kPa 3D PEG-MAL hydrogel for 3 
days. Green: live cells, red: dead cells. Scale: 100 μm. d. Experimental time investment 
required for the different screening platforms. Timeline displays preparation time required 
for each system prior to treating with varying concentrations of drug. Figure produced in 
collaboration with Dr. Lauren Barney. 
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calculation [152]. Therefore, the differences we report in drug response are a direct result of 
ECM-driven resistance, independent of a growth advantage. In Figure 2-3, drug response is 
reported as a fold change in GR50 from the indicated condition compared to TCPS, where red 
indicates resistance and blue indicates sensitivity compared to TCPS. Response to 
doxorubicin did not vary significantly across geometry, modulus, or medium (with or without 
serum, varied for the spheroid model only) in either cell line (Figure 2-3). MDA-MB-231 
response to temsirolimus was not dependent on the biomaterial platform we tested, while 
SkBr3 GR50 had small but significant changes. However, sorafenib and lapatinib response 
varied considerably across the biomaterial platforms, particularly in the MDA-MB-231 cells 
(Figure 2-3). It is notable that the SkBr3 response to sorafenib was only dependent on 
geometry, and not the addition of serum, suggesting a unique role for the ECM in mediating 
drug response, independent of exogenous mitogenic factors.  A two-way analysis of variance 
(ANOVA) showed that the changes in geometry and medium had a larger effect on total 
variance than the change in modulus as reported by the percent of variation across 
biomaterial platforms (Table 2-2). Within each geometry, we observed no significant 
difference in drug response at either stiffness, but our analysis indicated that cancer cell  
Table 0-2. Two-way ANOVA of drug resistance across biomaterial microenvironments. 
Percent of total variation (%). * denotes significance by two-way ANOVA. Data gathered in 
collaboration with Dr. Lauren Barney and Dr. Thuy Nguyen.  
 
 SkBr3 (%)  MDA-MB-231 (%) 
 
Culture Format 
All Conditions 
Only 3D 
Spheroids 
 
Culture Format  
All Conditions 
Only 3D 
Spheroids 
 Geometry Modulus Medium Modulus  Geometry Modulus Medium Modulus 
Proliferation 35* 10* 57* 3  49* 0.8 59* 28* 
Doxorubicin 8 2 49 0.01  1 11 27 37 
Temsirolimus 80* 3 87* 0.3  11 22 22 10 
Sorafenib 51* 3 81 2  91* 2 96* 2* 
Lapatinib 35 10 28 0.08  76* 14* 86* 9* 
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resistance to sorafenib and lapatinib was most sensitive to changes in geometry within this 
modest stiffness range.  
2.4.2 Gene expression is not responsible for ECM-driven differences in drug response  
We performed RNA-Seq on MDA-MB-231 and SkBr3 cells cultured on TCPS, on 
2D hydrogels, as tumor spheroids, and as a tumor xenograft (Figure 2-4 a). Hierarchical 
clustering of differentially expressed genes first separated samples by the cell line, then by 
material platform, which we used as a guide to order the ECMs in Figure 2-4 a. The 
biomaterial platform dictated clustering within each cell line and dimensionality had greater 
influence on clustering than stiffness. Gene expression on the 2D hydrogels (10 and 33 kPa) 
was similar for both cell lines, and these samples were closely related to cells on TCPS. 
Toward understanding whether this was an immediate effect of signals from the ECM or 
Figure 0-3. Drug Response Varies with Biomaterial Platforms. a-b. SkBr3 (a) and 
MDA-MB-231 (b) proliferation after 3 days of culture (top row), and GR50 in response to 
doxorubicin, temsirolimus, sorafenib, and lapatinib across the different biomaterial 
platforms. Red: increase from TCPS control (resistance compared to TCPS), blue: decrease 
from TCPS control (sensitivity compared to TCPS). TC: TCPS, 10: 10 kPa 2D hydrogel, 33: 
33 kPa 2D hydrogel, 3: 3 kPa 3D hydrogel, 5: 5 kPa 3D hydrogel, +FBS: cells were treated 
in 10% serum-containing medium. Unless noted by +FBS, all cells were treated with drugs 
in serum-free medium containing EGF and PDGF-BB. Data gathered in collaboration with 
Dr. Lauren Barney and Dr. Thuy Nguyen.  
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from selective growth of a subset of cells in different environments, we also analyzed cells 
initially grown into spheroids, but then dissociated and cultured back on TCPS for 24 hours. 
The gene expression profile from these dissociated spheroids was also closely related to the 
other 2D conditions, indicating this expression was likely derived from the assay platform, 
rather than the culture platform (Figure 2-4 a).  
Gene set enrichment analysis (GSEA) identified several significantly enriched pathways 
in one or more of the biomaterials. For example, genes associated with the regulation of 
growth and receptor-linked signal transduction were upregulated in MDA-MB-231 cells on 
plastic compared to MDA-MB-231 cells in 3D spheroids (Figure 2-4 b). While this is not an 
exhaustive list, cells on TCPS expressed more cytokine and associated receptor genes and 
cells in the xenograft upregulated expression of ECM components, particularly collagens and 
keratins.  In Figure 2-4 c and d, the normalized enrichment scores are plotted as pairwise 
comparisons, enriched in the row condition over the column platform in red for MDA-MB-
231 cells and in blue for SkBr3 cells.  As expected, both cell lines upregulated genes 
associated with growth regulation on TCPS compared to all the other conditions we 
examined (Figure 2-3, Figure 2-4 b-c). Furthermore, the MDA-MB-231 xenograft tumors 
upregulated growth-related genes compared to cells grown in vitro as spheroids, suggesting 
that the mouse host environment provided additional growth cues (Figure 2-4 c). However, 
both geometry and stiffness influenced surface receptor linked signal transduction. For 
example, cells on TCPS universally showed enrichment for these genes compared to the 
other biomaterials, and our spheroids showed enrichment over the 2D hydrogels in the SkBr3 
cells (Figure 2-4 d).  
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We then used this expression data to determine if ECM-mediated drug response was a 
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result of changes in the gene expression of drug targets for lapatinib and sorafenib across the 
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biomaterials (Figure 2-3). We found no correlation between expression of these target genes 
Figure 0-4. Expression of growth and signal transduction genes distinguishes screening 
platforms but does not explain drug response. a. Clustering and normalized expression 
values of significantly differentially expressed genes across the biomaterial platforms for 
MDA-MB-231 and SkBr3 cell lines. Platforms were ordered according to the above 
hierarchical clustering, and genes were ordered by expression on TCPS, and each cell line 
was independently filtered for the top 250 genes by maximum expression across all 
platforms. All significantly differentially expressed genes (p<0.01) are shown in Figure S4. 
MDA-MB-231 order of platforms: spheroids, xenograft, 2D hydrogels at 10 kPa, and 33 
kPa, spheroids reseeded to TCPS, TCPS. SkBr3 order of platforms: xenograft, 2D hydrogels 
at 10 kPa, and 33 kPa, spheroids, spheroids reseeded to TCPS, TCPS.  Blue: low expression, 
red: high expression b. Representative gene set enrichment curves for regulation of growth 
(MDA-MB-231, TCPS over 3D spheroids) and cell surface receptor linked signal 
transduction (MDA-MB-231, TCPS over 3D spheroids). c-d. Normalized enrichment scores 
in pairwise platform comparisons for (c) regulation of growth (d) and cell surface receptor 
linked signal transduction. MDA-MB-231 comparisons are enriched in red and SkBr3 
comparisons are in blue. Comparisons are shown as ROW condition over COLUMN (i.e., 
Top row shows MDA-MB-231 enrichment on TCPS over other platforms). – indicates  no 
data. e-h. Expression of known targets for (e) lapatinib and (g) sorafenib and previously 
published off-target genes for (f) lapatinib and (h) sorafenib across the biomaterial platforms 
with linear correlations. Data gathered in collaboration with Dr. Thuy Nguyen.  
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and the GR50 (Figure 2-4 e,g). However, both of these drugs are known to alter signaling of 
many other pathways, and a literature search identified several known unintentional targets or 
resistance mechanisms for each drug [157-161] (Figure 2-4 f,h). Although many of these 
genes showed little to no change in expression across the biomaterials, we did note that AXL 
expression showed a slight positive trend, but not a significant correlation, with lapatinib 
response in the MDA-MB-231 cells (Figure 2-4 f). AXL has previously been shown to 
predict drug resistance to ErbB targeted inhibitors in many cancer types [161], but does not 
appear to significantly contribute to the drug responses examined here.  
2.4.3 Fibronectin and claudin 4 expression depend on spheroid formation method 
To better understand the processes involved in forming cancer cell spheroids, we 
compared three distinct methods of formation; 1) encapsulating single cells into 
polyNIPAAM, as described above, 2) seeding cells into microwells and allowing for cell 
aggregation over 24 hours, or 3) suspending cells in a non-adherent plate and allowing them 
to aggregate and grow over 3 days. Gene expression was quantified in breast, prostate, and 
ovarian cancer cell lines in the three spheroid formation methods and compared to basal gene 
levels in cells on TCPS. To select the relevant genes for this study, the RNA-Seq data from 
breast cancer cell lines MDA-MB-231 and SkBr3 was analyzed, after cells were grown on 
TCPS, in polyNIPAAM for 14 days, or grown in polyNIPAAM and then dissociated and 
plated back onto TCPS, as described above (Figure 2-5). Using Gene Set Enrichment 
Analysis, we observed that cell surface receptor-linked signal transduction genes, including 
several integrins, were enriched on TCPS when compared to spheroids formed in 
polyNIPAAM for 14 days, whereas cell–cell adhesion genes, such as claudin 4, were 
enriched in cells grown into spheroids in polyNIPAAM compared to TCPS (Figure 2-5 b-c). 
From this data set, we selected a subset of cell adhesion genes including integrin subunits 
(α2 (ITGA2), β1 (ITGB1) and β4 (ITGB4)), cell–cell junction proteins (cadherin 3 (CDH3) 
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and 5 (CDH5) and claudin 4 (CLDN4)), and the ECM protein, fibronectin (FN1), to examine 
in each spheroid formation method. 
We found that either claudin 4 or fibronectin were upregulated in all spheroid 
formation methods compared to TCPS (Figure 2-6 a) with the few exceptions of OVCAR-3 
in polyNIPAAM, and BT549 and PC-3 in microwells. Gene expression patterns varied with 
the time required for robust spheroid development across the three methods. Fibronectin was 
downregulated for all the cell lines in microwells, while claudin 4 was upregulated in the 
Figure 0-5. RNA-Seq on Breast Cancer Cells Reveals Enrichment of Surface Receptor 
Linked Signal Transduction. a. Principal Component Analysis shows separation by cell 
type and cell format of MDA-MB-231 and SkBr3 cells grown on TCPS or in polyNIPAAM. 
b. Gene Set Enrichment Analysis shows cell surface receptor linked signal transduction is 
enriched on TCPS over spheroids and cell-cell adhesion is enriched in spheroids as 
compared to TCPS, in MDA-MB-231 and SkBr3 cells. c. Several gene set categories are 
significantly enriched on TCPS (positive values) or in spheroids in 3D (negative values). 
Data gathered in collaboration with Dr. Thuy Nguyen.  
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polyNIPAAM method for all the cells lines, except for AU565 and OVCAR-3. These gene 
expression changes were dependent on the cell line as well as the spheroid establishment 
method. Variations in gene expression with each method was confirmed by dendrogram 
clustering for all combinations of examined cell lines and methods, which revealed that cells 
that have likely reached some homeostasis on TCPS or in polyNIPAAM primarily clustered 
together, and the shorter methods of microwells and suspension also clustered together 
(Figure 2-6 b). This was further confirmed by principal component analysis (PCA), which 
revealed that samples did not cluster by cell line or cancer type (data not shown), but rather 
that PC1 separated samples by method, with those that had the shortest and longest times of 
culture being the most distinct from one another (Figure 2-6 c). Although all of these systems 
formed spheroids of similar size, the expression of cell-cell contact genes varied across 
methods, which may have affected the compactness of these spheroids.  
Figure 0-6. Spheroid formation method determines expression of cell–ECM and cell–
cell adhesion genes. a. RT-PCR of genes collected from 2 breast (AU565 and BT549), 2 
prostate (PC3 and LNCaPcol), and 2 ovarian (SKOV-3 and OVCAR-3) cell lines reported 
as log2(fold change from TCPS). Genes are ordered based on expression clustering. Shades 
of red indicate gene upregulation compared to TCPS and shades of blue indicate gene 
downregulation compared to TCPS. b. Dendrogram of RT-PCR data by platform in TCPS 
(black), in polyNIPAAM (green), in microwells (red), and in suspension (blue). c. Principal 
component analysis (PCA) of gene expression by MCTS formation method. Ovals represent 
0.5 probability for each group of polyNIPAAM (green triangle), microwells (red circle), and 
suspension (blue square), N ≥ 3. Data Gathered in collaboration with Dr. Maria Gencoglu 
and Dr. Christopher Hall.  
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These contrasting phenomena of ECM production or cell-cell interactions have been 
previously demonstrated in other cell types, although to the best of our knowledge, this is the 
first work to identify these independent behaviors across breast, prostate, and ovarian cancer 
cells. Fibronectin 1 is a cell secreted protein that is important in the invasive phenotype [162] 
and metastasis via collective invasion [163]. Fibronectin also lends structure to cell clusters 
to facilitate cell adhesion and signal transduction, as previously demonstrated in fibroblasts, 
where integrin binding to fibronectin was necessary for fibroblast activation [164]. Claudin 4 
is essential for tight junctions is expressed in the majority of ovarian cancers [165], 
particularly in multicellular  ovarian cancer patient ascites and knockdown slowed the rate of 
in vitro spheroid formation [166]. Meanwhile, breast cancer cells grown into spheroids using 
the overlay method, which is most similar to our microwell and suspension methods, for 6 
days downregulated integrin α2, while they upregulated several cell-cell adhesion genes, 
including claudin 4 [167]. We thus hypothesized that the spheroids that upregulated cell–cell 
contact genes and took longer times to form, may be more resistant to drugs than cells on 
TCPS because of their compact morphology. 
2.4.5 Multiple linear regression reveals that using a MEK inhibitor with sorafenib is an 
effective combination therapy 
Since there were large differences in GR50 across the screening microenvironments, 
and known drug targets were not responsible for ECM-mediated resistance, we hypothesized 
that plasticity in intracellular signaling networks was responsible for the differential 
responses. We measured a panel of phospho-proteins associated with RTK signaling at basal 
levels and in response to drug treatment across the biomaterial ECMs. Here, we chose to 
closely examine sorafenib and lapatinib across material platforms, and added temsirolimus to 
compare to a drug whose response was largely independent of ECM (Figure 2-3).  
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Initial signaling data provided a complex and inconsistent picture of cell response to 
biomaterial, and linear regression modeling yielded no analytes whose phosphorylation 
varied significantly with platform. Several challenges are present in this system, including 
dose timing and difficulty of harvesting sufficient amounts of protein from 3D biomaterials 
to generate a robust signaling. To that end, I will outline here some of the troubleshooting 
techniques employed to ultimately optimize the process. First, the final optimized system 
demonstrated that the phosphorylation of EGFR in response to dosing cells with EGF is 
dependent on the environment. While cells on TCPS, a 2D hydrogel, and in a 3D hydrogel all 
exhibited pEGFR after 5 minutes, the magnitude was diminished on 2D biomaterials 
compared to TCPS, and in 3D compared to both other systems (Figure 2-7 a). Several pieces 
of this process were optimized; the first being the lysing process as demonstrated here. For 
the original samples, gels were collected from the well plates at the appropriate time, and 
immediately frozen to -80°C, and then partially thawed before adding lysis buffer containing 
protease inhibitors and phosphatase inhibitors (process labeled freeze). For comparison, a 
separate lysing protocol was employed, where gels were washed, and then transferred from 
Figure 0-7. Optimization of lysing protocols. a. Phosphorylation of EGFR was measured 
in the MDA-MB-231 cells using the Luminex MAGPix system from cells on TCPS, cell on 
33 kPa PEG-PC hydrogels, and from cells encapsulated in a 3 kPa hydrogel. Lysing cells off 
the 2D surfaces (TCPS and 33 kPa), was performed as described in the text. Lysing of cells 
encapsulated in 3D is further explained by parts b and c of this figure. b-c. Phosphorylation 
of EGFR (b) and HER2 (c) was measured after preparing samples using multiple protocols 
as described, where gels containing cells were either immediately frozen or treated with 
lysis buffer. Data gathered in collaboration with Dr. Lauren Barney.  
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the plate immediately into lysis buffer before freezing and mechanical dissociation of the gel 
(process labeled lyse). Both processes yielded some signal in pEGFR, but the maximal signal 
from first freezing the 3D samples (~100 MFI, achieved at 15 minutes), was about 6-fold 
lower than using the lysing protocol (~600 MFI, achieved at 5 minutes) (Figure 2-7 b). 
Further, the freezing protocol resulted in almost no pHER2 signal, compared to a clear and 
robust signal from the lysing process (Figure 2-7 c). Other components of the process were 
also optimized, such as the amount of total protein loaded was increased from 3 µg to 4 µg, 
after confirming that this still fell within the linear range of read out on the MAGPix. After 
optimization of 3D phospho-protein extraction, we compared signaling across our 
biomaterials to characterize the varied cell response to drug.  
The basal levels of nearly every analyte were significantly lower in 3D than on 2D 
ECMs (Figure 2-8), which matches growth and signal transduction gene signatures from our 
expression data (Figure 2-4 c-d). As expected, drug treatment reduced the phosphorylation 
level of the intended targets (Figure 2-10 a-b). However, we only observed significant 
reduction in known targets and increases in adaptive pathways in 2D, suggesting that the 3D 
environment suppresses drug efficacy through dampened signaling and kinome rewiring.  
Figure 0-8. 3D biomaterials generally suppress signaling. a-b. Basal p-ERK 
(pT185/pY187), p-Akt (pS473), and p-JNK (pT183/pY185) signaling for MDA-MB-231 (a) 
and SkBr3 (b) cell lines across the five screening microenvironments. Black: TCPS, dark 
blue: 2D gel, green: 3D gel with single cells, teal: 3D gel with spheroids, red: 3D gel with 
spheroids in serum. 2D hydrogel: 33 kPa, 3D hydrogel: 3 kPa. Data gathered in 
collaboration with Dr. Lauren Barney.  
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Our lab has previously demonstrated the role of JNK in stiffness-dependent sorafenib 
resistance [52]. Because we observed increased pJNK in response to the drug treatments in 
both cell lines, we hypothesized that JNK may mediate drug response across the biomaterials. 
Co-administration of JNK inhibitor SP600125 sensitized the MDA-MB-231 cells to sorafenib 
on 2D biomaterials, as spheroids with serum, and on TCPS (Figure 2-10 c). SP600125 only 
sensitized the SkBr3 cells in the spheroid and 2D hydrogel conditions, but not the stiff TCPS 
environment, perhaps a result of the very high increase in pJNK in the sorafenib-treated 
SkBr3 cells in that environment (Figure 2-19 e). As an additional control, we quantified JNK 
phosphorylation after treatment with doxorubicin, a drug that was associated with low GR50 
variability across platforms, and found that JNK signaling was still altered by this non-
specific drug treatment (Figure 2-9). Combined with our signaling data from the targeted 
therapeutics, we hypothesize that JNK phosphorylation is indirectly sensitive to drug-induced 
stress, but does not significantly contribute to the ECM-mediated resistance observed here 
(Figure 2-9, Figure 2-10 a-b)[168, 169]. Importantly, the efficacy of the JNK inhibitor in the 
Figure 0-9. Doxorubicin treated cells show limited change in phosphorylation of key 
signaling analytes. a-b. The log2 fold change of cells treated with doxorubicin (Dox) 
compared to the vehicle control (DMSO) across 5 screening environments; TCPS (black), 
2D gel (dark blue), single cells in 3D (green), spheroids in a 3D gel (light blue) and 3D gel 
spheroids with serum (red) in MDA-MB-231 cells (a) and SkBr3 cells (b).  
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MDA-MB-231 spheroids in the 3D hydrogel was captured in the TCPS assay, and did not 
need screening across biomaterials for discovery. Thus, we sought to identify an efficacious 
combination therapy using this multi-environment screening approach that could not be 
identified through simple TCPS screening.  
Multiple linear regression (MLR) models revealed non-intuitive relationships 
between the sorafenib-, lapatinib-, and temsirolimus-treated signaling and drug-treated 
viability data for both cell lines across the biomaterials. This model was constructed from 
phosphorylation data of 10 analytes after 4 hours of targeted drug treatment across all 15 
conditions (3 drugs and 5 biomaterial platforms per drug). Although targeting the MEK/ERK 
pathway was not an obvious choice from the signaling data (Figure 2-10 a-b), these models 
revealed that variability in MEK phosphorylation was the key factor associated with viability 
in response to drug treatment in MDA-MB-231 cells (Figure 2-10 d,f).  It is important to note 
that the MLR output includes the contribution of each signaling analyte to drug response, and 
while MEK was identified as the key contributor to variance, other analytes have non-zero 
contributions to the model. To determine the necessity of each component to the model 
prediction, a subsequent analysis was performed where we independently excluded either all 
3D conditions (single cells, spheroids, spheroids with serum) or two of the drugs (lapatinib 
and temsirolimus). Neither of these modified models were able to achieve significance 
(Figure 2-11 a). Returning to our model that includes all three drugs in the MDA-MB-231 
cells, we determined that each 3D condition could be excluded independently, but that TCPS, 
2D biomaterials, and at least one 3D condition were necessary to predict MEK  
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phosphorylation as a likely mechanism of ECM-mediated resistance (Figure 2-11 b).  
We next co-administered both sorafenib and the MEK inhibitor PD0325901 to cells 
in the different biomaterials. In both cell lines, there was no improved efficacy when co-
treating sorafenib and PD0325901 on TCPS (Figure 2-10 c,e). However, both cell lines were 
sensitized to sorafenib when co-administered with PD0325901 in the 2D hydrogel and 
spheroid conditions (Figure 2-10 c,e). This suggests MEK may be a more physiological 
Figure 0-10. Systems analysis reveals that MEK regulates ECM-mediated sorafenib 
efficacy. a-b. Phospho-signaling in response to drug treatment and GR50 for MDA-MB-
231 (a) and SkBr3 (b) cell lines. TC: tissue culture polystyrene, 2D: 2D PEG-PC hydrogel, 
3D: single cells encapsulated in 3D hydrogels, Sp: spheroids encapsulated in 3D 
hydrogels, +: spheroids in 3D hydrogels in serum containing medium. Phospho-proteins 
measured include: CREB (pS133), ERK (pT185/pY187), NFκB (pS536), JNK 
(pT183/pY185), p38 (pT180/pY182), STAT3 (pS727), STAT5A/B (pY694/699), Akt 
(pS473), EGFR (pan Tyr), and MEK1 (pS222). Red: increase compared to vehicle control, 
blue: decrease from vehicle control. c,e. Sorafenib GR50 alone or in combination with 
SP600125 (JNK inhibitor, 20 μM) or PD0325901 (MEK inhibitor, 3 μM) for MDA-MB-
231 (c) and (e) SkBr3 cell lines. Black: control, blue: SP600125, red: PD0325901. d,f. 
MLR models of signaling data for MDA-MB-231 (d) and SkBr3 (f). Data gathered and 
analyzed in collaboration with Dr. Lauren Barney and Dr. Aaron Meyer.  
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resistance mechanism to sorafenib, as SkBr3 cells did not show significant variability of 
MEK across platforms, but were still responsive to co-treatment in our biomaterials. 
Interestingly, the MDA-MB-231 cells are KRAS mutant, while the SkBr3 cells are not, 
meaning this treatment is independent of both this mutation and their clinical subtype. 
Altogether, the identification of MEK as an effective target for combination therapy was only 
realized through screening across many biomaterials and using a systems approach to analyze 
a phospho-signaling dataset. Likewise, the efficacy of the MEK inhibitor in combination with 
sorafenib was only achieved through screening in the more complex 2D or 3D biomaterial 
microenvironments, and would be missed using TCPS or via genetic analysis alone.  
2.4.5 MEK inhibition improves sorafenib efficacy in vivo  
Figure 0-11. Multiple biomaterials are required for success of the multiple linear 
regression. a. Exclusion of either all 3D conditions or lapatinib and temsirolimus increase 
the p-value of the overall model and MEK in MDA-MB-231 cells. b. The impact of 
exclusion of each individual biomaterial (x-axis) on the p-value of the overall model (y-axis: 
2D or 3D indicated the geometry of the hydrogel, N/A is the complete model with no 
conditions removed, Sph is spheroids, +FBS is spheroids in serum, and TCPS is tissue 
culture polystyrene). Data analyzed in collaboration with Dr. Aaron Meyer.  
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Given the promising in vitro results with the MEK inhibitor, we tested PD0325901 as 
a combination therapy with sorafenib in an in vivo model. MDA-MB-231 tumors were 
inoculated in the mammary fat pad of NSG mice and allowed to grow for 7 days, at which 
point all mice had palpable tumors.  From days 7 to 21, we treated daily with one of four 
regimens: 1) vehicle control (DMSO), 2) 10 mg/kg sorafenib, 3) 10 mg/kg PD0325901, or 4) 
co-treatment of 10 mg/kg each sorafenib and PD0325901 (Figure 2-12 a). As combination 
therapies are often associated with increased adverse events [170], we also included a fifth 
treatment group which received a lower dose of the combination therapy at 5 mg/kg each of 
sorafenib and PD0325901. All of these doses were found to be well tolerated by mice (data 
not shown), although future work will need to better optimize the doses of this combination 
therapy to optimally minimize the dose while maintaining tumor burden reduction.  
PD0325901 was the most effective single agent inhibitor and, as predicted in the 2D hydrogel 
and spheroid screening models, co-treating mice with PD0325901 and sorafenib had the most 
significant reduction in tumor burden, cellularity, and proliferation (Figure 2-12 b-d). In the 
lower concentration combination therapy (5 mg/kg each), reduction in tumor weight was 
comparable to 10 mg/kg PD0325901 alone (Figure 2-12 b). A two-way ANOVA showed that 
PD0325901 (Fvalue=54.7, p<0.001) contributed more to the decrease in tumor burden than 
sorafenib (Fvalue=8.2, p<0.01). The combination therapy of sorafenib and PD0325901 
additively decreased tumor burden (Fvalue=0.3, p=0.6).  
2.5 Discussion 
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By screening drug response across many ECMs, we identified that breast cancer cell 
response to sorafenib (Ras/Raf/MEK/ERK targeted) and lapatinib (EGFR-HER2 targeted)  
was significantly dependent upon the biomaterial environment (Figure 2-3). Gene expression 
of known drug targets was unchanged across the ECMs (Figure 2-4 e-h), but a systems 
analysis of phospho-kinome signaling in response to drug treatment across our different 
biomaterials revealed MEK as a key contributor to the variation in observed ECM-mediated 
resistance (Figure 2-10 d,f). Although the combination therapy did not improve drug 
response in cells on TCPS, a MEK inhibitor in combination with sorafenib eliminated the 
matrix-mediated response in biomaterials in vitro and reduced tumor burden in vivo (Figure 
2-12). 
Figure 0-12. PD0325901 and sorafenib are an effective combination therapy to reduce 
in vivo tumor burden. a. Schematic for tumor induction of the MDA-MB-231 cells, grown 
first for 7 days, followed by daily drug dosing for 14 days until a 21-day endpoint. b. Final 
tumor weight for each drug dosing condition (C: control, S: 10 mg/kg sorafenib, PD: 10 
mg/kg PD0325901, and co-dosing at either 5 mg/kg or 10 mg/kg of each therapeutic, p = 
0.05; two-tailed t-test on log transformed data). c. Representative images for Ki67 staining 
in tumors and d. quantification of Ki67 positive cells in drug treatment groups (S/PD is the 
10 mg/kg combination therapy). Scale bar is 50 μm. e. Screening for ECM-mediated 
resistance in drugs like sorafenib can be used in combination with multiple linear regression 
modeling to find combination therapies with the MEK inhibitor PD0325901. Error bars 
represent mean and SEM, N≥4. Data gathered by Dr. Christopher Hall and Dr. Lauren 
Jansen.   
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While most current literature examines signaling changes within a single platform 
[57, 58, 171, 172], we applied MLR across five ECM conditions and three targeted drug 
treatments to determine which phospho-proteins varied significantly with ECM-mediated 
drug response. This approach captures multiple aspects of the ECM that may contribute to 
drug response in vivo, including ECM stiffness, dimensionality, and cell-cell contacts using 
both 2D and 3D biomaterials. Synthetic 2D biomaterials allow for the presentation of full-
length proteins, while spheroids encapsulated in 3D better recapitulate tumor geometry. In 
our experiments, cells seeded onto 2D biomaterials or as single cells in 3D resided in those 
environments for 24 hours, so they likely relied exclusively on the provided collagen I (2D) 
or RGD (3D) for integrin-mediated signaling. However, breast cancer cells grown as 
spheroids upregulate ECM genes, such as fibronectin, suggesting additional ECM proteins, 
not provided by us initially, contribute to the observed cell response [60]. Recent work has 
shown that the ECM-mediated signaling can impart resistance to combined inhibition of 
PI3K and HER2 [173], but our method identified that targeting two nodes in the same 
pathway, Raf with sorafenib and MEK with PD0325901, is a promising combination therapy 
for breast cancer. This non-intuitive co-treatment, which would not be identified by screening 
on traditional TCPS, suggests a similar approach may be beneficial in identifying 
combination therapies for kinome-targeting drugs, where adaptive resistance is frequently 
mediated by the ECM [52, 130]. 
Combination therapies with MEK inhibition are effective in many cancer types [174-
177]. In fact, MEK inhibition is currently under evaluation in clinical trials because many 
cancers activate MEK signaling as a form of acquired resistance [178]. Such combination 
therapies are often designed to limit adaptive survival signaling, and generally target two 
distinct pathways. Interestingly, in our work, co-targeting MEK improved sorafenib efficacy 
in vitro and in a pre-clinical in vivo tumor regression model, even though both drugs target 
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the same pathway (Figure 2-12). Others have seen similar improved efficacy in HER2+ 
breast cancer when co-treating the HER2-targeted drugs lapatinib and trastuzumab, 
suggesting that combination therapies targeting the same pathway can have improved effects 
by overcoming acquired resistance [179]. Emerging work also demonstrates that co-targeting 
RAF and MEK is an effective strategy in liver, breast, and other cancers [180-182]. Further 
targeting strategies, like using nanoparticles to co-deliver sorafenib and a MEK inhibitor are 
also gaining traction [183]. However, not all cells within a tumor contribute equally to drug 
response. Tumors are highly heterogeneous and composed of cell subpopulations that can 
evade both cytotoxic and targeted therapeutics via up-regulation of drug transporters, 
mutations of drug targets, adaptive signaling, and other mechanisms [136, 184, 185]. Here we 
identified the additive effect of co-dosing sorafenib with a MEK inhibitor on the bulk tumor, 
but further work is necessary to understand the contribution of individual populations to 
resistance. 
We measured a large panel of phospho-proteins to see if the biomaterial environment 
facilitated phospho-signaling changes in response to the drug treatments that were associated 
with drug sensitivity or resistance. In our soft 3D environments, basal and drug-stimulated 
signaling were significantly suppressed, in agreement with other data in spheroids and on soft 
substrates [186-188]. JNK appears to be a broad adaptive response [189, 190]; however, 
MLR identified MEK as the most significant driver of ECM-mediated resistance to sorafenib. 
ERK is downstream of both the lapatinib and sorafenib targets, which may explain why 
MEK/ERK signaling was so critical to drug response in our data. In agreement with our 
findings, myeloid leukemia cells have a stiffness-dependent response to drugs, including 
sorafenib and a MEK inhibitor, which target the RAF/MAPK pathway [129, 191]. We have 
previously shown that sorafenib resistance increased with increasing hydrogel stiffness [52], 
and many others have also demonstrated that stiffness is a significant driving force for drug 
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resistance [52, 141, 171, 172, 192-195]. Thus, we were surprised to find that drug resistance 
was only minimally affected by stiffness within the modest range examined here (Figure 2-
3). However, in our data, dimensionality contributed more to drug resistance than stiffness.  
Previous work has similarly shown that cancer cell spheroids are more resistant to paclitaxel 
than a monolayer [57], and the matrix-attached cells in spheroids are resistant to PI3K/mTOR 
inhibition [58].  
Because cells are less able to form cell-matrix adhesions on soft versus stiff 2D 
substrates, and in 3D versus 2D environments [196], genes associated with integrin-mediated 
adhesion and cell-surface receptor linked signal transduction are varied across our 
biomaterials (Figure 2-4 b-d). Matrix adhesion via integrins mediates survival and drug 
resistance through activation of survival signaling, such as FAK, Src, and ERK [197-199]. 
Disruption of cell adhesion can sensitize tumor cells to drug treatments [52, 173, 200-202]. In 
3D, we generally observed greater drug sensitivity for single cells compared to spheroids 
(Figure 2-3), perhaps because single cells have lower overall adhesion to surrounding cells 
and matrix [130]. Spheroids and tumors can also exhibit multicellular drug resistance through 
either cell-cell contact-mediated signaling or drug diffusion limitations [203], and often co-
targeting multiple pathways is required to sensitize the outer, matrix-attached cells [58]. 
While our spheroid size was intentionally kept small to minimize diffusion limitations, the 
cell-cell contact inherent to the spheroid structure may provide survival signaling, resulting in 
increased resistance to the RTK-targeted drugs.  
In our hands, gene expression of drug targets was relatively unchanged across our 
materials. Previous work has reported significant changes in gene expression profiles of cell 
lines cultured in 2D and 3D laminin-rich ECM [204]. This is similar to our own data, where 
we observed that surface receptor linked signal transduction genes vary with both geometry 
and stiffness, and are universally upregulated during culture on TCPS compared to the other 
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biomaterials (Figure 2-4 b). Also, several ligand-receptor pairs were co-expressed and 
enhanced in vivo, including BMP and IL6 signaling (Figure 2-13). We found that growth 
context determined the expression of cell surface receptors, while expression of the 
associated ligands was dependent on the current assay platform and was more sensitive to 
stiffness.  
Interestingly, both gene expression and drug sensitivity were regained when cells 
grown as spheroids were dissociated and seeded back onto TCPS (Figure 2-4 a, Figure 2-13 
c). This demonstrates that drug response in the timeframe we examined is dependent on the 
current environment and not necessarily a result of stable genetic alterations or 
subpopulations resulting from a previous growth condition. In our gene expression data, the 
xenograft was the most distant from other samples for the SkBr3 cells, but not for the MDA-
MB-231 cells. This is likely due to the differences in length of time required for the 
xenografts to reach a similar size. The MDA-MB-231 xenograft tumor reached 50 mm3 
Figure 0-13. Gene expression of growth factors and receptors reveals possible 
reversible autocrine signaling in drug resistance across biomaterials. a. Differentially 
expressed soluble factors across in vitro and in vivo culture conditions. b. Expression of 
receptors and resulting sample clustering. c. Sorafenib IC50 for cells treated on TCPS, 
treated as spheroids, or grown as spheroids, dissociated, and re-seeded onto TCPS. Data 
gathered in collaboration with Dr. Thuy Nguyen.  
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within 10 days, and the SkBr3 xenograft took 3 weeks to reach 50 mm3. In an in vivo 
microenvironment, xenograft tumors derived from highly lung metastatic clones of the 
MDA-MB-231 breast cancer cell line have a distinct ECM signature that up-regulates growth 
factor signaling including TGF-β and VEGF [78]. We conclude that although gene 
expression may be useful to inform patient treatment [205], it was not sufficient to predict in 
vitro or pre-clinical drug efficacy here. 
Our data suggested that cells employ one of two possible mechanisms for spheroid 
formation: they either secrete their own local matrix to provide binding sites and structure, or 
they rely on cell–cell contacts. In spheroids formed in the microwells (briefest culture time), 
claudin 4 was upregulated, whereas those formed using the polyNIPAAM method (longest 
culture time), upregulated fibronectin and integrins (Figure 2-6 a). Immunofluorescence 
staining has shown that in spheroid configurations that are loosely connected and have more 
void space, fibronectin is distributed within the intercellular space throughout the spheroid. 
However, in compact spheroids, fibronectin is found on the outer edge [206]. This can be 
compared with our suspension and polyNIPAAM spheroids, respectively. On the other hand, 
knocking down claudin 4 reduces in vitro spheroid formation [166] because it is essential for 
tight junctions. Interestingly, claudin 4 is expressed in the majority of ovarian cancers 
[165], and also in SKOV-3 and OVCAR-3 spheroids. Additionally, breast cancer cells grown 
into spheroids using the overlay method, similar to our suspension method, upregulated 
claudin 4 and several other cell–cell adhesion genes [167]. Our results are largely cell-line 
dependent, without any correlation to cancer type, so this contribution can be applied in other 
tumor spheroid models. For example, ovarian cancer metastasizes through the abdominal 
lining and into the abdominal cavity, where fluid contains high numbers of spheroids, called 
ascites [207]. Understanding the relationship between the spheroid structure and drug 
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resistance may lead to better therapeutic development and optimization of patient-specific 
treatment options.  
2.6 Conclusions 
Though the ECM can impart resistance to some RTK inhibitors (sorafenib and 
lapatinib), MLR modeling of phospho-signaling identified combinatorial strategies to combat 
this resistance (Figure 2-12 e). This approach could provide insight into other anti-cancer 
drugs with varied clinical success, such as neratinib [208, 209] and sunitinib [210, 211]. 
However, not all the drugs we tested showed ECM-dependent responses, and response to a 
cytotoxic drug, such as doxorubicin, would have been predicted in a simple, quick, cost-
effective TCPS assay. It is therefore critical to weigh the monetary cost and time burden of 
the screening approach against the potential benefits. The efficacy of the PD0325901 and 
sorafenib combination therapy would not have been realized using only one screening 
environment or without a systems biology analysis. We envision this approach can be used to 
identify drugs with poor in vivo efficacy early in the drug development pipeline and identify 
novel drug combinations to overcome ECM-induced resistance.  
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CHAPTER 3 
INTEGRIN α6 AND EGFR SIGNALING CONVERGE AT 
MECHANOSENSITIVE CALPAIN 2 
 
3.1 Abstract 
Cells sense and respond to mechanical cues from the extracellular matrix (ECM) via 
integrins. ECM stiffness is known to enhance integrin clustering and response to epidermal 
growth factor (EGF), but we lack information on when or if these mechanosensitive growth 
factor receptors and integrins converge intracellularly. Towards closing this knowledge gap, 
we combined a biomaterial platform with transcriptomics, molecular biology, and functional 
assays to link integrin-mediated mechanosensing and epidermal growth factor receptor 
(EGFR) signaling. We found that high integrin α6 expression controlled breast cancer cell 
adhesion and motility on soft, laminin-coated substrates, and this mimicked the response of 
cells to EGF stimulation. The mechanisms that drove both mechanosensitive cell adhesion 
and motility converged on calpain 2, an intracellular protease important for talin cleavage and 
focal adhesion turnover. EGF stimulation enhanced adhesion and motility on soft substrates, 
but required integrin α6 and calpain 2 signaling. In sum, we identified a new role for integrin 
α6 mechanosensing in breast cancer, wherein cell adhesion to laminin on soft substrates 
mimicked EGF stimulation. We identified calpain 2, downstream of both integrin α6 
engagement and EGFR phosphorylation, as a common intracellular signaling node, and 
implicate integrin α6 and calpain 2 as potential targets to inhibit the migration of cancer cells 
in stiff tumor environments.  
In the previous section we identified changes in dimensionality and biomaterial 
platform as the main contributors of ECM-mediated drug resistance, and saw relatively little 
response to stiffness across the range examined. However, stiffness is known to contribute to 
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tumor cell aggression, so this work was broadly motivated by the changes in stiffness that 
occur during cancer progression as the primary tumor stiffens and cells disseminate to distant 
metastatic cites. However, the impact of stiffness does not occur in a vacuum, so we 
employed an extracellular matrix model where varied stiffness in a 2D hydrogel system was 
complimented by varied full-length proteins for cell adhesion and growth factors to stimulate 
aggressive cell phenotypes (Figure 3-1). Our system allows for independent tuning of each of 
these parameters, and modifications to the optimal ECM model were generated iteratively 
through experimental exploration. For example, as we found that cells produce laminin on 
soft biomaterial systems, we sought to include that signal to determine its functional impact 
on cell phenotype. Together, this demonstrates that we have compiled an ECM model that is 
physiologically relevant to understand mechanosensing in the tumor microenvironment and 
the role of other biochemical signals in altering that cascade.  
3.2 Introduction 
Figure 0-1. Exploring the role of the 
Extracellular Matrix in 
Mechanosensitive Adhesion and 
Motility. Breast cancer cells experience a 
range of stimuli during primary tumor 
progression and cell dissemination. In 
order to better understand how tumor 
cells experience and respond to these 
stimuli, specifically through 
mechanosensitive pathways, we explored 
the impact of stiffness, epidermal growth 
factor and ECM proteins, like collagen 1 
and laminin on cell adhesion and motility. 
Cells interact with their surroundings 
through surface receptors, and one class 
of those receptors, integrins, bind 
specifically to the type of protein, and 
have also been shown to respond to tissue 
mechanics. Integrins also cluster with 
growth factor receptors on the cell 
surface, so these 3 parameters were 
selected for further exploration. 
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Carcinoma progression is associated with deposition of ECM that stiffens the local 
microenvironment [212, 213]. This tissue stiffening results in deposition of additional matrix 
proteins, initiating a positive feedback loop between cells and the evolving stroma [32]. Cells 
sense and respond to the stiffness of their environment via RhoA GTPase activation, which 
feeds back to increase cell contractility via activation of myosin light chain kinase [214]. 
These ECM-driven changes in cytoskeletal tension regulate motility in a cell-type specific 
manner [44]. In vitro, synthetic biomaterials have revealed that the type of material, stiffness, 
and biochemical surface modifications alter the attachment and motility of cells [45, 215-
217]. We therefore hypothesized that independently tuning stiffness, while altering integrin-
binding sites and the availability of epidermal growth factor could reveal new 
mechanosensitive proteins that drive adhesion and motility in cancer cells.  
Several mechanically responsive genes and proteins have been implicated in breast 
cancer metastasis [47]. For example, extracellular mechanical forces in the tumor 
microenvironment alter nuclear stiffness and gene expression [54] and activate adhesion 
proteins, including focal adhesion kinase (FAK) and talin [8, 40, 218], leading to increased 
motility. One class of surface receptors, integrins, translate extracellular forces to 
downstream signaling cascades in a process called mechanotransduction. Increasing substrate 
stiffness increases integrin binding and clustering, which has implications for several 
pathways in breast cancer metastasis, including FAK and PI3K signaling [9, 219]. However, 
most cancer mechanobiology research has focused on collagen- and fibronectin-binding 
integrins. Integrins that bind to other ECM proteins,  including laminin investigated here, 
have largely been neglected, despite the prevalence of laminins, such as laminin-111 and -
511, in the ECM of many tumor types, including breast and prostate cancers [69, 220, 221]. 
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In the breast cancer cell line, MDA-MB-231, laminin-511 enhances cell adhesion and 
migration [222], while laminin-322 promotes cell survival [223].  
EGFR has recently emerged as mechanosensitive [186, 224], and this process is 
critically relevant to cancer progression, given the known abundance of EGF in breast tumors 
[225] and frequent acquired resistance to EGFR inhibitors [137]. Residues on EGFR can be 
phosphorylated by αVβ3 integrin clustering [226], so we postulated that there could be a role 
for integrins in facilitating EGFR mechanosensing [227].  
To uncover whether such a relationship exists, we created a biomaterial system to 
identify mechanoresponsive proteins working cooperatively downstream of EGFR 
phosphorylation and laminin-binding integrin engagement in breast cancer. Through a 
combination of transcriptomics, molecular biology, and quantification of cell adhesion and 
motility, we found that the intracellular protease calpain 2 is one of these links.  Gene 
expression quantification revealed that both calpain 2 and integrin α6 had an inverse 
relationship with ECM stiffness. Cell adhesion and motility experiments demonstrated that 
engagement of integrin α6 resulted in mechanosensitive effects on adhesion and motility in 
the same manner as EGF stimulation. This suggested coordination of integrin α6 with EGFR 
and that calpain 2 is downstream of both EGFR phosphorylation and integrin α6 engagement. 
Further, this indicated that calpain 2 is a common signaling node in the cell that regulates 
motility and cell adhesion in a mechanosensitive manner. In sum, we highlight the utility of 
tunable biomaterials systems to uncover previously unrealized relationships between 
different classes of proteins in breast cancer mechanobiology.  
3.3 Materials and Methods 
3.3.1 Cell Culture  
All cell culture reagents were purchased from Thermo Fisher Scientific (Waltham, 
MA) unless otherwise specified. MDA-MB-231 cells were a generous gift from Sallie 
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Schneider at the Pioneer Valley Life Sciences Institute. Highly metastatic and tropic MDA-
MB-231 variants were kindly provided by Joan Massagué at the Memorial Sloan Kettering 
Cancer Center. These cell lines preferentially metastasize to the bone (1833 BoM [2]) brain 
(831 BrM2a [1]) or lung (4175 LM2 [3]). All cells were cultured in Dulbecco‟s modified 
eagle medium (DMEM) with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin 
(P/S) at 37°C and 5% CO2. 
3.3.2 Synthesis of Poly(ethylene glycol)-phosphorylcholine (PEG-PC) Gels. 
PEG-PC gels were formed as previously described [51]. For this application, a 
17wt% solution of 2-methacryloyloxyethyl phosphorylcholine (PC) (730114-5g, Sigma 
Aldrich, St. Louis, MO) in pH 7.4 phosphate buffered saline (PBS) was mixed with varying 
concentrations of poly(ethylene glycol) dimethacrylate (PEGDMA) (Sigma Aldrich). This 
solution was filtered through a 0.22 µm PVDF syringe filter, and excess oxygen was 
removed by degassing with nitrogen for 30 seconds. 20wt% Irgacure 2959 (BASF, Florham 
Park, NJ) was dissolved in 70% ethanol and added to the polymer solution in a ratio of 40 µL 
Irgacure to 1 mL of polymer solution. 50 µL of this final hydrogel precursor solution was 
sandwiched between a 3-(trimethoxysilyl)propyl-methacrylate treated 15mm diameter 
coverslip and an untreated coverslip and UV polymerized for 20 minutes. Gels were swelled 
in PBS for at least 48 hours before functionalizing the surface using 0.3 mg/mL Sulfo-
SANPAH (c1111-100mg, ProteoChem, Hurricane, UT) in 50 mM HEPES buffer at pH 8.5, 
under UV for 10 minutes. Gels were then flipped onto droplets to achieve a theoretical final 
concentration of either 10 µg/cm² collagen 1 (A1048301, Thermo Fisher Scientific), 10 
µg/cm² collagen 1 + 0.5 µg/cm² β1-chain-containing laminin isoforms (AG56P, Millipore, 
Billerica, MA), or 10 µg/cm² collagen 1 + 20 ng/cm² EGF (R&D Systems, Minneapolis, 
MN), binding via primary amines. These theoretical values are calculated based on the 
surface area of each hydrogel and amount of protein we supply for functionalization. Gels 
65 
 
were incubated with protein overnight in a hydrated chamber at room temperature, washed in 
PBS, and sterilized under germicidal UV for 1 hour before cell seeding. For mechanical 
testing, gels were formed in a cylindrical mold (5µm high, 5µm diameter), allowed to swell 
for at least 48 hours and compression rheology was performed using an AR2000 (TA 
Instruments, New Castle, DE), as previously described [51]. 
3.3.3 RNA Sequencing 
Total RNA was isolated using GenElute mammalian total RNA Miniprep kit 
(RTN70, Sigma Aldrich). The TRUseq stranded RNA LT kit (15032612, Illumina, San 
Diego, CA) was used to purify and fragment the mRNA, convert it to cDNA, and barcode 
and amplify the strands. Quality and length of the inserts was confirmed with an Agilent 
Genomics 2100 bioanalyzer, followed by single-end 75 base pair reads on the MiSeq 
(Illumina) to generate a complete transcriptome from each sample. Transcripts were aligned 
to the hg19 human reference genome using the Tuxedo Suite pathway [153, 228-230]. 
Cufflinks was used to determine statistically significant differential expression of genes 
(p<0.05) [231-233].   
3.3.4 qRT-PCR 
Total RNA was isolated from two biological replicates as previously described [55]. 
50 ng cDNA was then amplified using 10 pmol specific primers (Table S1) and the Maxima 
Sybr green master mix (Thermo Fisher Scientific) on a Rotor-Gene Q thermocycler (Qiagen, 
Valencia, CA) as follows:  50°C for 2 minutes, 95°C for 10 minutes followed by 45 cycles at 
95°C for 10 seconds, 58°C for 30 seconds, and 72°C for 30 seconds.  Both β-actin and 
ribosomal protein S13 were included as reference genes to permit gene expression analysis 
using the 2-ddCt method.   
3.3.5 Cell Adhesion Quantification 
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MDA-MB-231 cells were seeded at a final density of 5,700 cells/cm2. Cells were 
either seeded immediately, or pretreated for 30 minutes before seeding with 20 µM ERK 
inhibitor FR180204 (Sigma Aldrich), 10 µg/mL calpain inhibitor IV (208724, Millipore), 20 
µM lapatinib (LC Laboratories, Woburn, MA), or 100 ng/mL EGF. The plate was pre-
incubated on the Zeiss Axio Observer Z1 microscope (Carl Zeiss AG, Oberkochen,  
Table 0-1. RT-PCR Primers used for gene expression quantification. 
Gene Accession number position Forward sequence, 5‟-3‟ position Reverse sequence, 5‟-3‟ 
ITGA3 NM_002204.3 4451 
TCTCTCCTTGGCCAC
AGACT 
4655 
TTCTGAGGCTGGCT
GGTAGT 
ITGA6 NM_000210.3 747 
TTGGAGCTTTTGTGA
TGGGC 
967 
GCTCAGTCTCTCCA
CCAACT 
ITGB1 NM_002211.3 2054 
CATCTGCGAGTGTGG
TGTCT 
2262 
GGGGTAATTTGTCC
CGACTT 
ITGB4 NM_000213.3 2946 
ACTACACCCTCACTG
CAGAC 
3154 
TCTGGCTTGCTCCTT
GATGA 
EGFR NM_005228.3 1728 
AGGTGAAAACAGCT
GCAAGG 
1957 
AGGTGATGTTCATG
GCCTGA 
CAPN2 NM_001748.4 1533 
CCAGAGGAGTTAAG
TGGGCA 
1733 
AGAAAAGACCCGG
ATGCAGA 
MMP-1 NM_002421.3 739 AAGATGAAAGGTGG
ACCAACAATT 
817 CCAAGAGAATGGCC
GAGTTC 
Talin 1 NM_006289.3 351 
CACCATGGTTGCACT
TTCAC 
582 
CCCATTTCGGAGCA
TGTAGT 
Vinculin NM_014000.2 3203 
GCCAAGCAGTGCAC
AGATAA 
3387 
AGGTTCTGGGCATT
GTGAAC 
MAPK1 NM_002745.4 766 
CCAGACCATGATCAC
ACAGG 
928 
CTGGAAAGATGGGC
CTGTTA 
RPS-13 NM_001017 217 
AAGTACGTTTTGTGA
CAGGCA 
403 
CGGTGAATCCGGCT
CTCTATTAG 
β-actin NM_001101 747 
GGACTTCGAGCAAG
AGATGG 
 
980 
AGCACTGTGTTGGC
GTACAG 
 
 
Germany) for 1 hour, then cells were seeded onto gels functionalized with 10 µg/cm² 
collagen 1, 10 µg/cm² collagen 1 + 0.5 µg/cm² laminin, or 10 µg/cm² collagen 1 + 20ng/cm2 
bound EGF and imaging was started within 10 minutes of seeding. Images were taken with a 
20x objective every 5 minutes for at least 2 hours. Cells were manually traced using Image J 
(NIH, Bethesda, MD). n ≥ 50 cells per condition. 
3.3.6 Cell Migration 
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Cells were seeded onto gels functionalized with 10 µg/cm² collagen 1 or 10 µg/cm² 
collagen 1 + 20ng/cm² EGF at a density of 5,700 cells/cm2 and allowed to adhere for 24 
hours. For inhibitor conditions, cells were treated 2 hours prior to the start of imaging with 10 
µg/mL calpain inhibitor IV, 20 µM ERK inhibitor FR180204, 20 µM lapatinib, or 10 ng/mL 
EGF (R&D Systems). Cells were imaged at 15 minute intervals for 12 hours on the Zeiss 
Axio Observer Z1 microscope (Carl Zeiss AG). n≥ 48 cells per condition were quantified 
using the manual tracking plugin for Image J (NIH, Bethesda, MD).  
3.3.7 Generation of ITGA6 and CAPN2 shRNA transduced cells 
The shRNA sets specific to human ITGA6 (Sequence: 
CCGGCGGATCGAGTTTGAT 
AACGATCTCGAGATCGTTATCAAACTCGATCCGTTTTTG) and CAPN2 (sequence: 
CCGGCAGGAACTACCCGAACACATTCTCGAGAATGTGTTCGGGTAGTTCCTGTTT
TTG) were purchased from Sigma-Aldrich (St. Louis, MO).  Plasmids (in pLKO.1-puro) 
were packaged into virus particles according to manufacturer‟s instructions and used to 
transduce MDA-MB-231-luciferase cells.  Stable pools were selected using 1 mg/mL 
puromycin (Invivogen, San Diego, CA).  Cells transduced with a non-targeting shRNA 
served as a control. 
3.3.8 Immunofluorescent Staining and Imaging 
28,500 cells/cm2 were seeded and fixed at 24 hours in 4% formaldehyde. Cells were 
permeabilized in Tris-Buffered Saline (TBS) with 0.5% Triton-X and washed 3 times in TBS 
with 0.1% Triton-X (TBS-T). Blocking was done for 1 hour at room temperature in TBS-T + 
2%w/v Bovine serum albumin (BSA, Sigma Aldrich) (AbDil). Cells were then incubated in 
primary antibody in AbDil for 1 hour at room temperature using 1 or more of the following 
antibodies; vinculin (V9264-200UL, 1:200, Sigma Aldrich), pEGFR-Y1068 (ab32430, 1:200, 
Abcam, Cambridge, MA), total EGFR (D38B1, 1:200, Cell Signaling, Danvers, MA), 
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integrin α6 (ab134565, 1:200, Abcam), integrin α3 (ab131055, 1:200, Abcam), ERK 
(ab54230, 1:200, Abcam), calpain 2 (MABT505, 1:200, Millipore), or phalloidin 647 
(A22287, Thermo Fisher Scientific). For insoluble fractions, cells were permeabilized in cold 
Tris-Buffered Saline (TBS) with 0.5% Triton-X at 4°C for 1 minute prior to fixing. For 
immunofluorescent imaging of ECM proteins, cells were fixed at 24 hours (57,000 cells/cm2) 
or 6 days (11,400 cells/cm2) before staining with a  pan-laminin antibody (ab11575, 1:100, 
Abcam), collagen 1 antibody (ab6308, 1:200, Abcam), or Fibronectin-488 antibody (563100, 
1:200, BD Biosciences, San Jose, CA). Molecular Probes secondary antibodies were used at 
a 1:500 dilution (goat anti-mouse 555 (A21422) and goat anti-rabbit 647 (A21244) or goat 
anti-rabbit 488 (A11008), Thermo Fisher Scientific). Cells were then treated with DAPI at a 
1:5,000 dilution for 5 minutes, and washed in PBS prior to imaging of 2 biological replicates 
on a Zeiss Cell Observer Spinning Disk (Carl Zeiss AG).  
3.3.9 Matrix Decellularization 
Cells were cultured on PEG-PC gels of 1, 4, 8, and 41 kPa for 24 hours or 6 days, and 
the resulting matrix created by the cells was visualized by adapting a previously published 
protocol [234]. Briefly, cells were washed with warm PBS, then lysed with 500µL warm 
extraction buffer (PBS with 0.5% Triton-X with 20 mM ammonium hydroxide) for 10 
minutes at room temperature. 1 mL of PBS was added and the gels were stored overnight at 
4°C before staining as described above.  
3.3.10 Protein and Phospho-protein Quantification 
Autolyzed calpain 2 was analyzed via western blot. Cells were cultured on PEG-PC 
gels of 1 or 41 kPa for 24 hours, then lysed in RIPA buffer with protease inhibitors: 1 
cOmplete Mini EDTA-free Protease inhibitor cocktail tablet per 10 mL (Roche, Indianapolis, 
IN) 1 mM phenylmethylsulfonyl fluoride (Thermo Fisher Scientific), 5 μg/mL pepstatin A 
(Thermo Fisher Scientific), 10 μg/mL of leupeptin (Thermo Fisher Scientific), and 
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phosphatase inhibitors: Phosphatase inhibitors cocktail-II (Boston Bioproducts, Boston, MA), 
1 mM sodium pyrophosphate (Thermo Fisher Scientific), 25 mM β-glycerophosphate (Santa 
Cruz, Dallas, TX). Lysates were prepared in a 5x reducing sample buffer (39000, Thermo 
Fisher Scientific), run on Tris-Glycine gels in an Invitrogen mini-Xcell Surelock system, and 
then transferred to nitrocellulose membranes (88018, Life Technologies, CA). Membranes 
were blocked with AbDil for 1 hour, then stained overnight at 4°C with antibodies against 
calpain 2 (MABT505, 1:1000, Millipore), integrin α6 (ab134565, 1:2000, Abcam), EGFR 
(D38B1, 1:1000, Cell Signaling Technology, Danvers, MA), integrin α3 (343802, 1:1000, 
Biolegend, San Diego, CA), integrin β4 (ab29042, 1:1000, Abcam), GAPDH (ab9485, 
1:2000, Abcam) or β-actin (ab75186, 1:1000, Abcam). Membranes were washed 3 times with 
TBS-T, stained in secondary antibody (Goat anti-rabbit 680 (926-68021, 1:20,000) and 
Donkey anti-mouse 800 (926-32212, 1:10,000), LiCor, Lincoln, NE) for 1 hour at room 
temperature, protected from light, and washed 3 times in TBS-T with a final wash in TBS. 
Membranes were imaged on the Odyssey CLx (LiCor).  
2 biological replicates of lysates were collected during cell adhesion at time 0, at 5 
minutes, and at 24 hours. At 5 minutes, the adhered fraction was lysed off the surface, while 
suspended cells were pelleted, then lysis buffer was added. These 2 fractions were combined 
for analysis. Phospho-protein levels were quantified with the MAGPIX system (Luminex, 
Austin, Texas) with MILLIPLEX MAP Multi-Pathway Magnetic Bead 9-Plex - Cell 
Signaling Multiplex Assay (48-681MAG, Millipore) and added beads against p-EGFR (pan-
tyrosine, 46-603MAG, Millipore), p-MEK (Ser222, 46-670MAG, Millipore), and p-ERK1/2 
(Thr185/Tyr187, 46-602MAG, Millipore), following the manufacturer‟s protocols, with 
beads and antibodies used at 0.25x.  
3.3.11 Co-Immunoprecipitation 
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MDA-MB-231 cells were grown to confluence in a T-75 cell culture flask. Cells were 
treated with 10 mL of fresh media containing 10% FBS, with or without an additional 100 
ng/mL EGF for 10 minutes. Flasks were lysed in 4.5 mL of lysis buffer, comprised of 50 mM 
Tris (pH 7.4), 0.15 M NaCl, 0.1% Triton-X, with protease and phosphatase inhibitors as 
described above. 1 mL of lysate was immunoprecipitated with 10 µL agarose beads (Thermo 
Fisher Scientific) with either 5 µL rabbit IgG (ab6718, Abcam), 10 µL anti-EGFR (D38B1, 
Cell Signaling), or with 10 µL anti-EGFR pre-conjugated to sepharose beads (5735S, Cell 
Signaling). Lysates were precipitated on beads overnight at 4°C on a rotating platform and 
spun down. Beads (with protein) were washed 3x with TBS, and boiled in 70 µL of DiH2O 
and sample buffer. Blotting was done as described above for pEGFR (ab32430, Abcam) and 
integrin α6 (ab134565, Abcam).  
3.3.12 Statistical Analysis 
One-way Analysis of Variance (ANOVA) with a Tukey post-test was performed on 
paired samples using Prism v5.04  (GraphPad software, La Jolla, CA). Data reported is the 
mean and reported error is standard deviation with significance values of p ≤ 0.05 as *, p ≤ 
0.01 as **, and p ≤ 0.001 as ***. 
3.4 Results 
 
3.4.1 Cells Maximize Expression of Integrin α6 and Extracellular Laminin on Soft 
Substrates 
To identify ECM and integrin-associated genes involved in breast cancer 
mechanosensing, we performed whole transcriptome sequencing (RNA-Seq) on MDA-MB-
231 cells cultured on collagen 1-functionalized PEG-PC hydrogels ranging in stiffness from 1 
to 41 kPa for either 24 hours or 6 days (Figure 3-2). The tumor microenvironment is rich in 
collagen, which provides structural and biochemical signals to tumor cells to facilitate 
migration and metastasis [235]. Further, The stiffness range chosen spans that of several 
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tissues in the body where breast cancer metastasizes (1 kPa- brain [10], 4 kPa- bone marrow 
[11], 8 kPa- lung [12]), as well as a supra-physiological stiffness (41 kPa) that approximates 
extremely stiff breast tumors [92] and a tissue culture polystyrene (TCPS) control. 
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Because the ECM is known to regulate the ability of cancer cells to migrate and 
metastasize, we focused our in-depth analysis of this RNA-Seq data set on genes that regulate 
interaction with the ECM. We found that the expression of integrins, other focal adhesion  
Figure 0-2. RNA-Seq implicates several integrin-signaling related mechano-sensitive 
genes. Genes related to ECM, integrins and downstream signaling identified from RNA-Seq 
performed on MDA-MB-231 cells cultured on 2D PEG-PC gels after 24 hours or lysed 
directly from TCPS. Gene names are given above each plot, with different isoforms (if 
applicable) as different colored lines. The y-axis is expression (log 10 scale) and the x-axis 
denotes the different stiffnesses of gel upon which cells were cultured (+ the TCPS 
comparison as a very stiff control). Genes identified are: integrin α3 (ITGA3), integrin α6 
(ITGA6 with A and B isoforms), integrin β1 (ITGB1), integrin β4 (ITGB4), integrin αv 
(ITGAV), integrin β3 (ITGB3), epidermal growth factor receptor (EGFR), integrin-linked 
kinase (ILK), mitogen-activated protein kinase 1 (MAPK1), calpain 2 (CAPN2), talin 1 
(TLN1), vinculin (VCL), laminin (LAM, A5, B1, C1 isoforms), collagen 1A1 (COL1A1), 
fibronectin 1 (FN1), and matrix metalloproteinase 1 (MMP1). Data analyzed in 
collaboration with Dr. Courtney Babbitt.  
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complex genes, and genes downstream of EGFR phosphorylation became sensitive to 
stiffness over time (Figure 3-3 a-b). Short-term (24 hour) decreases in expression were clear 
in integrin α6, calpain 2, and integrin β4. However, integrin β4 expression was 3-fold higher 
on gels than on TCPS after 6 days of culture, which we confirmed at the protein level (Figure 
3-4 a). This implies a switch in dimer pairs, as integrin α6 preferentially dimerizes with 
integrin β4 over integrin β1 [236]. This is an important finding, as α6β4 is known to be 
important in cancer cell motility and invasion [237]. We compared the day 6 gene expression 
data from Figure 3-3 b to that at 24 hours from Figure 3-3 a and found that the expression of 
this subset of genes was generally higher at day 6, suggesting a time-dependent 
mechanosensing event related to this set of integrins, focal adhesion proteins, and EGFR. 
Given that integrin α6β4 is laminin-binding, and that we saw mechanosensitive 
changes in α6 gene and protein expression (Figure 3-4 b), we hypothesized that we could tune 
integrin α6 mechanosensing on these surfaces by supplementing the collagen-functionalized 
hydrogel surfaces with β1-chain-containing laminins. On soft gels, integrin α6 protein 
Figure 0-3. Cells on soft substrates have increased integrin α6 expression. a-b. Log2(fold 
change) of gene expression from cells cultured on gels of stiffnesses 1, 4, 8 or 41 kPa 
relative to expression on TCPS of genes after 24 hours (a) or 6 days (b), determined through 
qRT-PCR. Decreased expression = green and increased expression = red. N=2. Data 
gathered in collaboration with Dr. Christopher Hall.  
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expression was higher at 24 hours with added laminin compared to collagen 1 only, and it 
was also high after 6 days of culture, even in the absence of supplemented laminin (Figure 3-
4 c, Figure 3-5 a). This mechanosensitivity appears to be specific to integrin α6 as other 
laminin-binding integrins (e.g. integrin α3) did not follow this trend (Figure 3-4 d-e).  
As we noted this integrin α6 effect when we supplied only collagen 1, we 
hypothesized that cells might be producing their own laminin to support integrin α6 binding 
at the longer culture times. Immunofluorescent staining revealed that laminin, but not 
collagen 1 (Figure 3-5 b) or fibronectin (Figure 3-6 a), was upregulated on the softer gels at 6 
Figure 0-4. Cells express integrin α6, but not α3 in a stiffness-sensitive manner. a. 
Western blot for protein expression of integrin β4 and integrin β1 on gels of 1, 4, 8, and 41 
kPa after 24 hours, compared to TCPS. b. Protein expression of integrin α6 in MDA-MB-
231 cells determined via western blot. Cells were cultured on gels or 1, 4, 8, and 41 kPa for 
24 hours before lysis and blotting. c. Unmerged images of MDA-MB-231 cells 6 days after 
plating on gels of 1 or 41 kPa functionalized with collagen 1 only. Vinculin staining is in 
red and integrin α6 staining in green. Scale bar = 20 µm. d. MDA-MB-231 cells were 
cultured on gels of 1 or 41 kPa functionalized with 10 µg/cm2 for 6 days before fixing. Cells 
were stained for vinculin (red) and integrin α3 (green) and nuclei were labeled with DAPI 
(blue). Scale bar = 20 µm. e. Western blot for integrin α3 on gels of 1 kPa, 41 kPa, and on 
TCPS after 24 hours. 
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days. We separately confirmed that differential staining was not due to ECM proteins 
crosslinked to the gels or from serum (Figure 3-6 b). Cultures that were decellularized after 6 
days showed the highest amount of extracellular laminin on the softest, 1 kPa gels (Figure 3-
5 b), concordant with the increase in integrin α6 expression in Figure 3-5 a.  
To understand the impact of laminin and integrin α6 expression on cell phenotype, we 
quantified cell spreading during initial adhesion to the hydrogel surfaces.  We found cells 
spread to similar extents across the 4 stiffnesses examined here when only collagen 1 was 
present (Figure 3-5 c). However, when laminin (0.5µg/cm2) was added to the collagen     
(10µg/cm2) on the gel surfaces, cell spreading was mechanosensitive (Figure 3-5 d). We 
Figure 0-5. Cells on soft substrates produce extracellular laminin. a. Representative 
immunofluorescent staining of vinculin (red) and integrin α6 (green) and DAPI (blue) in 
cells cultured on gels with collagen only for 24 hours, collagen with laminin for 24 hours, or 
collagen only for 6 days. Yellow denotes overlap of vinculin and integrin α6 staining. Scale 
bar = 20 µm. b. Representative Immunofluorescent staining for ECM proteins after 1 day of 
culture (left), decellularized gels after 24 hours (center) or decellularized gels after 6 days 
(right). Collagen 1 = red, pan-laminin = green, DAPI = blue. Scale bar = 100 µm. c-d. Cell 
area during adhesion quantified on 1, 4, 8, and 41 kPa gels functionalized with collagen 1 
only (c) or collagen 1 + laminin (d). N=3 biological replicates, n=75 cells per condition.  
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attempted to remove collagen from the experiment completely, but found that cells did not 
adhere to laminin-only hydrogels (data not shown). This was not surprising given the 
documented role of laminin being somewhat anti-adhesive [238]. In sum, cells upregulate 
integrin α6 expression on soft substrates, which correlates with secretion of extracellular 
 
laminin. This coordination appears to take several days, but the mechanosensitivity effect on 
cell spreading can be accelerated by adding β1-chain-containing laminin to the culture 
substrata.  
3.4.2 Cell Response to EGF Stimulation Mirrors Mechanosensing on Laminin 
Given the prevalence of EGF in the tumor microenvironment and its known role in 
promoting cancer cell motility, we posited that the mechanosensitive expression of EGFR 
alongside the laminin-binding integrin α6 implied that they mechanotransduce under a related 
pathway. Similar to previous reports, we found that MDA-MB-231 cells spread to a smaller 
area on hydrogels upon addition of EGF prior to and during adhesion [55], achieving a 
similar size to cells on soft, laminin-coated gels without EGF (Figure 3-7 a). EGFR is known 
Figure 0-6. Media changes do not result in deposited matrix. a. Immunofluorescent 
staining for ECM proteins after 6 days of culture prior to decellularization. Fibronectin = 
green, DAPI = blue. Scale bar = 100 µm. b. 2D PEG-PC gels were protein coated with 10 
µg cm-² collagen 1, but no cells were seeded on the gels. Media containing 10% FBS was 
changed every 2 days for 6 days. Gels were then fixed and stained collagen 1 (green) and 
laminin (red), and nuclei were labeled with DAPI. Scale bar = 100 µm. 
 
77 
 
to associate with the α6β4 integrin heterodimer to enhance clustering and response to EGF 
[239], and in agreement with this report, we found that the addition of EGF increased the 
association of integrin α6 with EGFR in our system (Figure 3-9 a). We separately analyzed 
the protein expression of integrin α6 and EGFR in variants of the MDA-MB-231 cell line 
selected for their ability to metastasize specifically to the brain, bone, and lung [1-3].  The 
brain tropic cells, which metastasize to the softest of these sites, have the highest expression 
of both integrin α6 and EGFR (Figure 3-9 b).  
To test the necessity of integrin α6 in the observed response to EGF, we generated a 
stable shRNA knockdown cell line (shITGA6, Figure 3-9 c-e). We quantified adhesion of the 
shITGA6 cells to collagen-functionalized gels, and found that they spread to a larger area 
Figure 0-7. Addition of EGF mimics mechanosensing on soft, laminin containing 
surfaces. a. Cell area during adhesion with soluble EGF compared to data from Fig. 1d-e. 
N=2, n=50. b. Cell area during adhesion of integrin α6 knockdown cells (shITGA6) 
compared to scramble control cells (shSCR). N=2, n=50 cells. c. Cells were pretreated with 
lapatinib for 30 minutes prior to seeding onto 1 and 41 kPa gels functionalized with collagen 
1 and laminin and traced to quantify cell area over time. N=2, n=50 cells. d. Cells were 
pretreated with EGF for 30 minutes prior to seeding onto 1 and 41 kPa gels functionalized 
with collagen 1 and laminin and traced to quantify cell area over time. N=2, n=50 cells.  
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during adhesion with EGF stimulation, compared to cells transfected with the scramble 
control (shSCR), suggesting a role for integrin α6 during EGF response on collagen (Figure 
3-7 b). Even though there was no laminin present, others have demonstrated a role for 
integrin α6 in facilitating growth factor response, independent of laminin binding [240]. 
Combined with our data, this implicates a mechanosensitive role for integrin α6 during EGFR 
signaling (Figure 3-7 b). 
3.4.3 EGF Overwhelms Laminin-Based Mechanosensing and Maximizes Cell Motility 
on Soft Substrates  
To further explore the relationship between integrin α6 and EGFR signaling during 
Figure 0-8. EGFR mechanosensitive motility requires integrin α6. a. Representative 
images of cells seeded onto gels of 1and 41 kPa functionalized with collagen 1 and EGF 
stained for vinculin (red), EGFR (green), F-actin (purple), and DAPI (blue). b. Area was 
quantified 40 minutes after adhesion to 10 µg/cm2 collagen 1 with no EGF, soluble EGF 
(sEGF), or bound EGF (bEGF). Statistics are shown relative to the control bar. N=2, n=50 
cells. c. Parental MDA-MB-231 cell speeds were quantified on 10 µg/cm2 collagen 1 with 
no EGF, with 10 ng/mL soluble EGF, 20 ng/cm² bound EGF. shITGA6 cell speeds were 
quantified on 10 µg/cm2 collagen 1 + 20 ng/cm² bound EGF. N=2, n=48 cells. Asterisks 
denote significance (p<0.05) relative to the no EGF control at the same stiffness. 
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adhesion, we functionalized hydrogels with collagen 1 and laminin, and treated the cells with 
lapatinib, a dual tyrosine kinase inhibitor against EGFR and HER2. This approach allowed 
cells to engage integrin α6 during adhesion, while preventing EGFR signaling by obstructing 
ATP-binding on the intracellular domain of EGFR and HER2. When pretreated with 
lapatinib, we found that cells adhering on 41 kPa hydrogels spread to a significantly larger 
Figure 0-9. Extension of integrin α6 cell assays. a. Co-immunopreciptation of EGFR and 
integrin α6 either without EGF (-) or with EGF (+). Lysates were pulled down with Rabbit 
IgG and agarose protein A beads (IgG), EGFR antibody with agarose protein A beads 
(EGFR), or with sepharose beads with pre-conjugated EGFR antibody (Seph). b. Western 
blot of integrin α6 and EGFR from parental MDA-MB-231 cells (231), and cells selected for 
tissue specific metastasis to the bone (BoM), brain (br), or lung (LM2) by the Massagué 
group, assayed on TCPS [1-3]. c. mRNA expression of integrin α6 determined via qRT-PCR 
in integrin α6 knockdown cells (shTGA6) and scramble control (shSCR). Data is normalized 
to shSCR cells. d. Surface expression (determined by FACS) of scramble control and 
shITGA6 knockdown cells. e. Permeabilizing the cell membrane before fixing and 
immunofluorescent staining confirmed that there is less integrin α6 associated with focal 
adhesions in the knockdown cells compared to a scramble shRNA control. Cells were 
immunofluorescently stained for insoluble vinculin (red), insoluble integrin α6 (green) and 
DAPI (blue). f. Cells were cultured on collagen with either no EGF (left), 100 ng mL-1 
soluble EGF for 10 minutes (middle), or 20 ng cm-² EGF bound to the surface for 24 hours 
(right). Scale bar = 20 µm. Fixed cells were stained for vinculin (red), EGFR (green), and 
DAPI (blue).  Data gathered in collaboration with Dr. Lauren Barney and Dr. Christopher 
Hall. 
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area than cells on 1 kPa hydrogels (Figure 3-7 c). This result mimics the adhesion we 
observed of cells on laminin without supplemented EGF or lapatinib (Figure 3-5 d). Further, 
when we supplemented cells with soluble EGF on the surfaces functionalized with collagen 1 
and laminin, cells on both 1 and 41 kPa spread to a smaller area (Figure 3-7 d). This EGF-
induced reduction in spreading is similar to our observations of cells on collagen 1 only in the 
presence of soluble EGF (Figure 3-7 a). Together, these data suggest that, even in the 
presence of laminin, adhesion signaling through EGFR dominates, but in the absence of 
exogenous EGF, signaling via mechanosensitive integrin α6 controls cell spreading during 
adhesion. 
We observed that soluble EGF (sEGF) caused rapid internalization of EGFR, within 
10 minutes of administration (Figure 3-9 f). To promote sustained EGFR signaling to 
examine its relationship with integrin α6 [239], we covalently linked both collagen 1 and EGF 
to the surface of the hydrogels. This EGF presentation minimized EGFR internalization and 
localized both pEGFR(Y1068) and total EGFR to regions of vinculin staining (Figure 3-8 a). 
EGFR receptor internalization was required for EGF to moderate adhesion, as only cells 
supplemented with soluble EGF showed measurable differences in cell area after 40 minutes 
(Figure 3-8 b). However, bound EGF had a measurable effect on cell motility (Figure 3-8 c). 
First, we observed a biphasic trend in cell speed with respect to stiffness. This phenomenon 
has previously been described in many cell types, including smooth muscle cells [45] and 
glioma cells in both 2D [241] and 3D [242]. In this migration study, only collagen 1 was 
present, suggesting that collagen-binding integrins contributed to this mechanosensitive 
motility after 24 hours [70]. Our data agree with literature reports demonstrating that cells 
seeded on collagen 1 exhibit mechanosensitive motility [243], but do not differ in adherent 
area between 1 and 30 kPa in some melanoma cell lines [244]. The addition of bound EGF 
increased cell motility across the stiffness range tested here (Figure 3-8 e), and shifted the 
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biphasic curve to softer substrates, requiring us to expand the mechanical range of the 
hydrogels to capture the full curve [51]. We also observed a role for integrin α6 in regulating 
this EGF-dependent motility, as shITGA6 cells were less responsive to EGF than the control 
(Figure 3-8 c). The scramble control cells, which peaked at 34 µm/hr on 1 kPa gels, were 
more responsive to EGF than the shITGA6 cells. Interestingly, shITGA6 cells don‟t respond 
to changes in stiffness from 1 to 18 kPa, either in control media, or in response to soluble 
EGF (data not shown). Together, this data suggests that the addition of EGF alters 
mechanosensitive motility and that the MDA-MB-231 breast cancer cells are dependent on 
Figure 0-10. Calpain 2 is downstream of both mechanosensitive integrin α6 and EGFR. 
a. Clustering of PCR data on genes expressed after 24 hours of culture on gels 
functionalized with 10µg/cm2 collagen 1 (data in Fig. 1a). b. Calpain 2 activity during 
adhesion was measured by evaluating the ratio of autolyzed/full length calpain 2 via western 
blot in both the adhered and suspended cell fractions during the first 60 minutes, or just the 
adhered fraction after 24 hours. N=2. c-d. Cell area was quantified during adhesion in the 
presence of an ERK1/2 inhibitor or calpain 2 inhibitor on 1 kPa (c) and 41 kPa (d) gels. 
N=2, n=50. e. Cell migration speeds quantified the presence of an ERK1/2 or calpain 2 
inhibitor. N=2, n=48. f. Representative western blot for full length and autolyzed calpain 2, 
with loading control GAPDH. In order of lanes from left to right: 1 kPa with collagen 1, 41 
kPa with collagen 1, TCPS, 1 kPa with collagen 1 + 100ng/mL soluble EGF for 10 minutes, 
41 kPa with collagen 1 + 100ng/mL soluble EGF for 10 minutes, TCPS + 100ng/mL soluble 
EGF for 10 minutes, 1 kPa with collagen and laminin, 41 kPa with collagen and laminin. 
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integrin α6 for this response.    
3.4.4 Calpain 2 is Downstream of both EGFR and Integrin α6 Mechanosensing 
Inspired by the trends observed in the RNA-Seq data (Figure 3-2), we clustered our 
PCR data from the 24 hour time point, which uncovered that ITGA6 and EGFR expression 
clustered with the intracellular protease CAPN2 (Figure 3-10 a). Calpain 2, which has been 
implicated in focal adhesion formation and disassembly, is thought to play an important role 
in breast cancer cell motility and metastasis [245]. Because calpain 2 is activated by ERK 
[246], we performed phospho-analysis of multiple kinases in integrin- and EGFR-dependent 
pathways (Figure 3-11 a). Steady-state phosphorylation of EGFR, MEK, and ERK increased 
on stiffer surfaces, as previously demonstrated [37, 186, 247] (Figure 3-11 b). However, we 
observed the opposite trend with the activation of calpain 2 (Figure 3-11 c).  
We observed higher calpain 2 activity (autolysis) during adhesion to the soft 
hydrogels compared to tissue culture plastic (Figure 3-10 b). Although repeated multiple 
times, this trend was not statistically significant. There was a functional role for calpain 2 
during mechanosensing on the gels, however, as a pharmacological inhibitor to either calpain 
2 or ERK had no effect on cell spreading on 1 kPa gels, but resulted in significantly larger 
cells on 41 kPa gels (Figure 3-10 c-d). In parallel, to provide evidence of the necessity of 
calpain 2 in responding to EGF stimulation, we generated a CAPN2 knockdown cell line 
(Figure 3-12 a-c), and observed that those cells were less responsive to EGF than the 
scramble control cells during adhesion, independent of stiffness (Figure 3-12 d). Further, 
calpain 2 inhibition was sufficient to limit cell response to soluble EGF using a 
pharmacological inhibitor (Figure 3-12 e). However, when we limited calpain 2 activity in 
integrin α6 knockdown cells, the effect of larger cells during adhesion was exaggerated.  
We further hypothesized that altering calpain 2 activity could disturb the typical 
biphasic relationship between cell migration speed and matrix stiffness given its known role 
83 
 
in mediating focal adhesion turnover [246]. Inhibiting ERK activity entirely eliminated the 
durokinesis effect, and calpain 2 inhibition shifted the migration curve maximum to lower 
stiffnesses (Figure 3-10 e). The limiting step during motility on stiff surfaces is retraction of 
the rear edge [248], and here we demonstrate that inhibiting calpain 2 reduces cell migration 
on stiffer substrates, likely because of this reduced ability to turn over adhesions. We then 
Figure 0-11. Quantification of signaling during cell adhesion in the presence of 
mechanical and biochemical stimuli. a. Signaling diagram of analytes quantified across 
several integrin- and growth factor-related pathways. b. Luminex bead-based ELISA of 
CREB (pS133), JNK (pT183/pY185), NFκB (pS536), EGFR (pan-Tyr), GSK3B (pS9), p38 
(pT180/pY182), AKT (pS473), MEK (pS222), p70S6k (pT412), STAT3 (pS727), STAT5 
(pY694/699), and ERK (pT185/pY187) during adhesion to TCPS or gels of 1 or 41 kPa 
with 10µg/cm2 collagen 1 on the surface. Both the suspended and adhered fractions were 
collected at 5 minutes. c. Representative western blot shows full length and autolyzed 
calpain 2. 
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compared migration speeds of the integrin α6 knockdown and scramble control cells from 
figure 3-8, in response to the calpain 2 inhibitor. We found that the scramble control cells 
responded to the inhibitor similarly to the parental cells, although the addition of soluble EGF 
was able to partially overcome that inhibition (data not shown). However, the shITGA6 cells 
exhibited slower migration at 18 kPa even in the control media, so the calpain 2 inhibitor had 
no additional effect. 
After 24 hours of culture on PEG-PC gels with collagen 1 or collagen 1 and bound 
EGF, cells adopted a normal morphology with no noticeable protrusions (Figure 3-12 f). 
However, in the presence of lapatinib, ERK inhibitor, or calpain 2 inhibitor, we observed that 
cells left behind long, stable protrusions at the rear of the cell (Figure 3-12 f), indicative of 
their inability to release adhesion sites [249]. There were minimal observable differences in 
morphology as a function of stiffness, regardless of the pharmacological treatment applied. 
This suggests that at these concentrations, the inhibitors impact focal adhesion turnover 
enough to functionally alter motility with marginal impacts on morphology at these 
stiffnesses.  
While we demonstrated earlier that integrin α6 is necessary for both mechanosensitive 
and EGFR-mediated adhesion, this data suggests that EGFR activates calpain 2 to regulate 
mechanosensitive motility in breast cancer cells. To some extent on collagen-functionalized 
hydrogels, and particularly on plastic, calpain 2 activity was low, and EGF stimulation 
increased calpain 2 activity on the hydrogels (Figure 3-10 f). Finally, when we supplemented 
the gels with laminin, calpain 2 activity was maximized on both stiffness gels, suggesting an 
additional role for integrin α6 engagement to activate calpain 2. Interestingly, when integrin 
α6 is knocked down in a stable manner, the cells still exhibit calpain 2 activity, suggesting 
that the cells might be compensating for the lack of integrin α6 signaling via another 
mechanism, not explored here (Figure 3-12 g). Together, these data suggest that the 
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mechanosensitive receptors integrin α6 and EGFR both activate calpain 2 to facilitate 
Figure 0-12. Knockdown of calpain 2 limits response to EGF on hydrogels. a-b. mRNA 
expression (a; determined via qRT-PCR) and protein expression (b; determined by western 
blot) of scramble control (shSCR) and calpain 2 knockdown (shCAPN2) cells. c. 
Permeabilizing the cell membrane before fixing and immunofluorescent staining confirmed 
that there is less calpain 2 associated with focal adhesions in the knockdown cells compared 
to a scramble shRNA control. Cells were immunofluorescently stained for insoluble ERK 
(red), insoluble calpain 2 (green) and DAPI (blue).  d. shCAPN2 cells are less responsive to 
EGF during adhesion than the shSCR control cells. All area measurements are normalized 
to time 0. e. Adhesion of scramble control cells (shSCR) or integrin α6 knockdown cells 
(shITGA6) was quantified on gels of 1 and 41 kPa functionalized with 10 µg/cm2 collagen 
1. Cells were pre-treated with either 10 µg/mL calpain 2 inhibitor or 10 µg/mL calpain 2 
inhibitor + 100 ng/mL soluble EGF. f. Cell morphology was analyzed 24 hours after seeding 
onto PEG-PC gels of 1 or 41 kPa functionalized with either 10ug/cm2 collagen 1 or 
10ug/cm2 collagen 1+ 20 ng/cm2 EGF. Cells on collagen only were dosed with lapatinib, 
ERK inhibitor, or calpain 2 inhibitor 22 hours after seeding onto PEG-PC gels of 1 or 41 
kPa. Cell morphology was analyzed 2 hours after treatment with inhibitors. g. Western blot 
on scramble control cells or integrin α6 knockdown cells on 1 kPa gels functionalized with 
10 µg/cm2 collagen 1 (with or without 100ng/mL soluble EGF) or 10 µg/cm2 collagen 1 + 
0.5 µg/cm2 laminin, compared to TCPS. Data gathered in collaboration with Dr. Christopher 
Hall.  
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stiffness-dependent adhesion and migration.   
3.5 Discussion 
 
This work demonstrates integrin α6 and calpain 2 as mechanosensitive proteins 
important for stiffness-driven breast cancer cell adhesion and migration (Figure 3-13 a). The 
mechanosensitivity of calpain 2 is a new finding, as well as the role of integrin α6 in EGFR 
signaling that facilitates cell adhesion (Figure 3-13 b, Figure 3-1). EGF is known to enhance 
breast cancer cell adhesion and motility, and here we demonstrate that mechanosensitive 
integrin α6 and EGFR both signal through calpain 2.  We also contribute that in the absence 
Figure 0-13. Mechanosensitive signaling is dependent on laminin and substrate 
stiffness. a. Breast cancer cells on soft gels, or any stiffness gel supplemented with EGF, 
were small and motile. Cells on soft gels produced their own laminin to engage α6, or we 
added it exogenously. Our data suggests this increases activation of ERK and Calpain 2, 
which feeds back to increase turnover of focal adhesions. b. During adhesion to substrates, 
cells were more responsive to laminin on soft substrates but did not adhere as well on stiff 
substrates with a calpain 2 inhibitor. Cell adhesion was facilitated in the presence of EGF 
on both soft and stiff gels. After 24 hours on gels, calpain 2 activity decreased with 
increasing stiffness, while EGFR phosphorylation increased with stiffness without added 
EGF. Cell motility had a biphasic dependence on substrate stiffness.  
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of EGF stimulation, integrin α6 and calpain 2 regulate stiffness-dependent adhesion and 
motility (Figure 3-13 b).  
We focused this study on breast cancer cells because of the important roles for ECM 
binding and stiffness in metastasis. Cancer metastasis begins with individual or collective 
groups of cells migrating away from the primary tumor site [18, 250, 251]. This motility is 
driven in part by cell-ECM adhesion via integrins and the creation and turnover of focal 
adhesions, both of which are known to be sensitive to the stiffness of the surrounding ECM 
[252]. Integrins have well-documented responses to changes in the microenvironment 
stiffness. As two examples, the expression of integrins α2, α3, and β1 is higher in mouse 
mammary epithelial cells cultured on TCPS compared to cells on a soft basement membrane-
like matrix [70], and integrin α5 expression was found to increase 5-fold on a 10 kPa stiffness 
compared to 1 kPa in cancer cells [69] and over a similar range in fibroblasts [253]. Most of 
this work has focused on collagen- and fibronectin-binding integrins, with the exception of 
one paper on integrin α6 in fibroblasts, where expression increased with stiffness, resulting in 
increased invasion [254]. We demonstrate here the mechanosensitivity of integrin α6 in breast 
cancer cells, and the downstream regulation of cell adhesion, migration, and response to EGF 
(Figure 3-5 a, Figure 3-7 b). Integrin α6 is a laminin-binding subunit, and so many of the 
stiffness-sensitive phenotypes we observed either required, or were exaggerated by, addition 
of laminin to the culture substrate. However, cells exhibited mechanosensitive behavior on 
collagen alone when cells were on hydrogels for longer times. For example, we observed a 
biphasic relationship in migration speeds on collagen 1 only (Figure 3-12 e). We present data 
that on soft surfaces, cells produce extracellular laminin and engage integrin α6 in these 
instances, and that knocking down integrin α6 expression limited response to EGF (Figure 3-
8 c).  
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Previous work has established the role of integrin α6 in key aspects of the metastatic 
cascade. Low integrin α6 expression inhibits the migration and proliferation necessary for 
establishing metastases at distant secondary sites [255]. Additionally, integrin α6 expression 
can protect cells from radiotherapy treatment both through PI3K and MAPK activity [256]. 
In a cohort of 80 patients, integrin β4 was co-expressed with integrin α6 and laminin in 
primary tumors, and co-expression of α6β4 with laminin production was significantly 
correlated with breast cancer relapse and death [236, 257]. This is further supported by other 
work in breast cancer, that elucidates the role of laminin-511 in cell adhesion and migration 
[222], which are key phenomena in the metastatic cascade. Our data demonstrate that this is a 
mechanoresponsive effect, as the most laminin is secreted by the breast cancer cells on the 
softest substrate (Figure 3-5 b). Interestingly, this phenomenon is not maintained in other 
secreted ECM proteins, such as collagen 1 (Figure 3-5 b) or fibronectin (Figure 3-6 a), 
suggesting a key role for integrin α6 binding to laminin on soft surfaces. This is possibly 
mediated through the mechanically responsive transcription factor, TAZ [258], which has 
been shown to regulate laminin production [259]. Here we found that both integrin β4 
expression and laminin production increased after 6 days of culture on soft gels (Figure 3-3 b, 
Figure 3-5 b), where EGF enhances migration in an integrin α6-dependent manner (Figure 3-8 
c). 
We further observed that during cell adhesion, integrin α6 engagement with laminin 
decreased cell size and facilitated adhesion similarly to EGF (Figure 3-7 a-b). Smaller cells 
can be correlated with a cancer stem cell and invasive phenotype [121], and our work 
suggests integrin-mediated mechanotransduction contributes to that behavior. The α6β4 
integrin dimer associates with EGFR [239], and we observed that integrin α6 engagement 
increased the sensitivity to EGF (Figure 3-8 c). Further, our data agrees with other work, 
which has demonstrated that the integrin dimer α6β4 plays an important role in cell response 
89 
 
to growth factors, even in the absence of laminin [240]. We also observed that integrin α6 
adhesion shows a similar phenotypic response on soft hydrogels as EGF stimulation.  
Downstream of integrin α6 engagement and EGFR phosphorylation, cells activate 
calpain 2, which facilitates focal adhesion turnover, and therefore, motility (Figure 3-10 e-f). 
EGFR phosphorylation is necessary for mechanosensing [224] and activity in downstream 
effectors, including MEK, ERK, and calpain 2 at the cell membrane [260, 261], to cleave 
focal adhesion proteins vinculin, talin, paxillin, and FAK [262, 263]. Additionally, recent 
work has demonstrated that calpains are recruited to protrusions containing integrin β4 [264]. 
During adhesion, we saw that calpain 2 activity was higher in cells on the hydrogels 
compared to TCPS, which was consistent with RNA levels (Figure 3-3 a-b, Figure 3-11 c). 
Calpain 2 inhibition during adhesion resulted in larger, less motile cells on stiff substrates. 
The opposite trend in adhesion was observed when activating this pathway, as cells spread to 
a smaller area at both 1 and 41 kPa in the presence of soluble EGF (Figure 3-7 a). Together, 
these data suggest that EGFR phosphorylation could be a stronger activator of calpain 2 than 
stiffness. Previous work has shown that calpain 2 has a significant correlation with an 
epithelial-to-mesenchymal transition [265] and lymphatic or vascular invasion, where 
patients with basal-like tumors and high calpain 2 expression had a significantly worse 
prognosis [113]. Others have also found that this is an isoform-specific effect, as calpain 2, 
but not calpain 1, was upregulated in gastric cancer compared to healthy tissue [266]. Our 
work demonstrates a mechanosensitive role for calpain 2, downstream of both integrin α6 and 
EGFR, providing further evidence for its potential as a druggable target for metastatic breast 
cancer.   
3.6 Conclusions 
 
Mechanical forces have long been thought to play a role in tumor progression, and 
here we shed new light on two mechanoresponsive proteins that influence breast cancer cell 
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motility: integrin α6 and calpain 2. First, enhanced integrin α6 expression on soft substrates is 
associated with increased adhesion and laminin secretion. Second, we find that both integrin 
α6 and EGFR activate calpain 2 in a mechanosensitive manner, which mediates cleavage of 
focal adhesion proteins necessary for motility. Others have suggested targeting calpains to 
inhibit cancer cell invasion [267], and here we provide a mechanosensitive role of calpain 2 
using tunable hydrogel substrates.  
3.7 Future work 
Targeting features of the extracellular matrix to limit cancer metastasis has met with 
little success this far. However, mediating the ability of cells to interact with the 
microenvironment has resulted in several clinically approved drugs. For example, Lapatinib, 
the dual-kinase HER2/EGFR inhibitor is widely used, although patients tend to develop 
resistance, as discussed in depth in chapter 2. Further, lapatinib can have varied effects on the 
cell phenotypes observed in this chapter, like cell migration (Figure 3-14). There are few 
good strategies to predict the dose of drug that will reach the tumor, and this data shows that 
low doses have little effect on cell motility at 24 hours in our system, but can instead 
Figure 0-14. Lapatinib dose and timing impacts cell motility. Cells were dosed with 1, 5, 
10, or 20 µM laminin at 2, 6, or 24 hours prior to the start of cell migration. Cell migration 
was tracked over 12 hours on TCPS. 
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dramatically increase cell motility on a rigid surface at short times. Therefore, more work is 
needed to better understand how altering tumor cell interaction with the microenvironment, 
by targeting mechanosensitive kinases or proteases, is necessary for the advancement of the 
field.  
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CHAPTER 4 
SOFT MATERIAL CONDITIONING OF BREAST CANCER CELLS 
ALTERS METASTATIC POTENTIAL 
 
4.1 Abstract 
Mechanical features of the tumor microenvironment have been largely neglected in 
the study of tumor evolution. A breast cancer cell population evolves in parallel at the 
primary tumor and metastatic sites, so we hypothesized that the timing of dissemination and 
secondary site tissue stiffness influences whether individual cell clones survive and grow out 
to form lethal metastases. Changes in stiffness alter many cell behaviors that are essential for 
success in the metastatic cascade, such as growth, motility, and ECM remodeling. We 
employed biomaterials to mechanically condition breast cancer cell lines over several 
passages, ultimately driving short and long term changes in cell behavior. We separately 
demonstrated that subclones exhibit a range of growth rates and migration behaviors that 
potentially explain the altered phenotypes we observed over time. We then challenged our 
mechanically conditioned populations with culture back on rigid plastic, and found they 
retain motility and chemotactic behaviors, but revert back to their original proliferation and 
wound healing phenotypes. These phenotypes were compared to primary breast tumor cells 
from am MMTV-PyMT model, where we found that cells that had never been exposed to 
rigid plastic looked most similar to cells that we had mechanically conditioned on soft, 1 kPa 
hydrogels over several months. Together, this data suggests that breast cancer cells adapt to 
local stiffness over the extended times they reside at a metastatic site, which drives 
population-level changes that result in altered growth and motility.   
In order to explore the role of tumor evolution, the most important parameter to 
consider is the timing of cell exposure to biomaterials and the length of conditioning (Figure 
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4-1). We changed this feature of the model in a few specific ways. First, stable cancer cell 
lines were conditioned on biomaterials for several months and assayed at early- and late-
stage conditioning, before being re-challenged with brief culture on extremely rigid plastic to 
test cell memory of their previous environments. The second mechanism of changing the 
experimental timing, is by working with primary tumor cells that have never been 
conditioned or grown on rigid TCPS. Here, we observed low growth of our primary tumor 
cells in culture, so they were only exposed to biomaterials for short periods of time before 
being assayed, which yielded similar, although not identical phenotypes to existing cell lines 
conditioned over months after coming off plastic. In addition to time, we chose to explore the 
role of soft biomaterial environments, because similarly to drug treatment stress, soft 
environments can limit cell growth (Figure 4-1). This challenge to cell adhesion and growth 
over time likely promotes population-level alterations in phenotype over time, to better 
understand how tissue stiffness changes tumor evolution over long time scales.  
4.2 Introduction 
Figure 0-1. Exploring the role of the 
Extracellular Matrix in Tumor 
Evolution. One feature that makes 
breast cancer difficult to treat is the 
heterogeneity in genotype and phenotype 
that is present both within a single 
tumor, as well as between tumors and 
patients. The drug resistance and 
evolution fields have evaluated several 
mechanisms of clonal narrowing and 
expanding in response to specific 
stresses, like drug treatment and 
hypoxia. However little to no work has 
been done to explore the role of tissue 
stiffness in these processes. To explore 
these phenomena, we altered the 
stiffness of 2D hydrogels, and 
conditioned cells on these biomaterials 
for varied lengths of time, ranging from 
weeks to months.   
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Cancer cells respond to the mechanical properties of the extracellular matrix (ECM) 
[9], but little is known about how these physical features drive cellular and tumor evolution. 
Breast tumors are highly heterogeneous and drug treatment is known to enhance mutagenesis 
and clonal selection [73]. For example, treatment with EGFR inhibitors frequently results in 
secondary genetic mutations or amplification of parallel pathways, resulting in resistance 
[268-270]. Further, these drug resistant populations can be obtained and isolated from 
outgrowth of persisting subclones after drug treatment [119]. The role of these different 
persisting clones is not fully understood, but they have been implicated in drug resistance and 
metastasis [72]. Independent of drug treatment, genetic lineage tracing has been used to 
identify several branch points, within the primary tumor and at distant metastatic sites [71]. 
However, tumor evolution is not linear, and two landmark studies recently demonstrated that 
breast cancer cells leave the primary tumor at very early time points [74, 75], and undergo 
parallel evolution at the secondary site.  
The mechanical properties of the ECM inform cell migration, growth, drug 
resistance, and metastasis [9, 52, 271, 272]. Upon initial malignant transformation, a tumor 
cell might reside in a soft, healthy-like ECM, which can either stiffen in situ [273], or the 
tumor cell can migrate to a distant site, with distinct mechanical properties. The most 
frequent breast cancer metastatic sites have distinct stiffness profiles, ranging from extremely 
soft brain tissue to stiffer tissues in the lung [10, 12].  Response to the ECM is mediated, at 
least in part, through focal adhesions, where changes in matrix stiffness induce 
conformational changes of receptors and associated intracellular proteins that enable binding 
of structural proteins, like vinculin, actin, and myosin, and activate signaling molecules, like 
Akt, ERK, and calpains [41, 253, 256, 274, 275]. Engaging structural cell elements enables a 
force balance, where cell assembly of actin-myosin fibers pull on the ECM to initiate 
processes like matrix remodeling and cell migration [241]. Increased stiffness also enhances 
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integrin clustering [276] and survival and growth signaling via downstream cascades like Akt 
and RAF [129].  
Because each secondary site has unique physical properties, the length of time that a 
cell or cell cluster resides there likely impacts cell behavior. Cancer cells adapt to a soft 
biomaterial environment over time, and are still changing after 3 passages on compliant 
polyacrylamide substrates [108]. In addition to extended exposure to the mechanical 
properties of the secondary site, recent work demonstrates that cells retain a memory of their 
mechanical environment, termed mechanical memory [106, 277]. It is important to note here 
that this memory scales with the length of conditioning. Together, these studies suggest that 
the mechanics of the secondary tissue site and cell residence time can have a dramatic impact 
on cell phenotype. 
While several groups have independently examined the impact of tissue stiffness, 
timing, or cell clonality on cancer dissemination, to the best of our knowledge, this is the first 
study to examine the combined effects of these parameters on breast cancer metastasis. Here 
we mechanically conditioned breast cancer cells on soft or stiff biomaterials over several 
months to select for a population that is less proliferative in a rigid environment, but more 
motile when assayed on soft biomaterials. This top-down approach was compared to a 
limiting dilution selection of single subclones, which exhibited a range of proliferation and 
migration similar to those cells selected on biomaterials. Together this work suggests that the 
mechanical properties of the secondary site can select for survival and growth of a set of 
subclones, which might be altered with time and the diversity of clones that are seeded at a 
distant metastatic site.  
4.3 Materials and Methods 
4.3.1 Synthesis of poly(ethylene glycol)-phosphorylcholine (PEG-PC) Hydrogels  
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PEG-PC gels were formed as previously described [51]. For this application, a 
17wt% solution of 2-methacryloyloxyethyl phosphorylcholine (PC) (730114-5g, Sigma 
Aldrich, St. Louis, MO) in pH 7.4 phosphate buffered saline (PBS) was mixed with varying 
concentrations of poly(ethylene glycol) dimethacrylate (PEGDMA) (Sigma Aldrich). This 
solution was filtered through a 0.22 µm PVDF syringe filter, and excess oxygen was 
removed by sparging with nitrogen for 30 seconds. 20wt% Irgacure 2959 (BASF, Florham 
Park, NJ) was dissolved in 70% ethanol and added to the polymer solution in a ratio of 40 µL 
Irgacure to 1 mL of polymer solution. 50 µL of this final hydrogel precursor solution was 
sandwiched between a 3-(trimethoxysilyl)propyl-methacrylate treated 15 mm diameter 
coverslip and an untreated coverslip and UV polymerized for 20 minutes. Gels were swelled 
in PBS for at least 48 hours before functionalizing the surface using 0.3 mg/mL Sulfo-
SANPAH (c1111-100mg, ProteoChem, Hurricane, UT) in 50 mM HEPES buffer at pH 8.5, 
under UV for 10 minutes. Gels were then flipped onto droplets to achieve a final protein 
concentration of either 5 or 10 µg/cm² collagen 1 (A1048301, Thermo Fisher Scientific). 
Gels were incubated with protein overnight in a hydrated chamber at room temperature, 
washed in PBS, and sterilized under germicidal UV for 1 hour before cell seeding.  
4.3.2 Cell Culture 
All cell culture reagents were purchased from Thermo Fisher Scientific (Waltham, 
MA) unless otherwise specified. MDA-MB-231 cells were a generous gift from Sallie 
Schneider at the Pioneer Valley Life Sciences Institute and Hs578T cells were provided by 
Mario Niepel. All cells were cultured in Dulbecco‟s modified eagle medium (DMEM) with 
10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S) at 37°C and 5% CO2. 
For extended culture conditions, cells were passaged as usual on PEG-PC gels of 1 kPa or 41 
kPa functionalized with 10 µg/cm2 collagen 1, alongside cells grown on tissue culture 
polystyrene (TCPS). For cell mechanical memory assays, after growth on biomaterials, cells 
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were plated back onto TCPS. Cells were maintained and passaged as usual. Cells were 
assayed for motility and invasion as described below. 
4.3.3 Subclonal Cell Selection 
mCherry labeled MBA-MD-231 cells were selected in RPMI with 10% FBS and 1% 
P/S. RFP labeled Hs578T cells were cultured in DMEM with 10% FBS and 1% P/S. 
Individual cell lines were plated at the density of 1 cell/well in 96-well plates. Plates were 
imaged to identify wells containing exactly 1 cell. Cell culture media was replenished every 
2-3 days. Subclones were expanded from 96-well plates to 12-well plates to 6-well plates to 
one 10-cm dish. Each plate transfers was performed when the cells were confluent. 
4.3.4 Proliferation Assays 
2D cell proliferation assays were performed on TCPS in a 96-well plate. Cells were 
seeded at a density of 3,125 cells/cm2 and growth between day 1 and day 4 was quantified 
using a Cell Titer 96 MTS assay (Promega, Madison, WI). For comparison to proliferation on 
2D PEG-PC hydrogels, cells were seeded at a density of 260 cells/cm2 in a 24 well plate on 
gels of 1, 8, 41, or 500 kPa functionalized with 5 µg/cm2 collagen 1, and on TCPS. 10 
random images per well were quantified on day 1 and day 6 to calculate the fold change in 
cell number. To quantify 3D growth, cells were suspended at 2x in cold serum free media, 
and mixed 1:1 with Matrigel (Corning Life Sciences, Corning, NY). 10 µL gels were formed 
at 37°C for a final cell concentration of 100 cells/µL.  
4.3.5 Random Cell Migration 
 Cells were seeded onto gels functionalized with 10 µg/cm² collagen 1 at a density of 
5,700 cells/cm2 and allowed to adhere for 24 hours. Cells were imaged at 15 minute intervals 
for 12 hours on the Zeiss Axio Observer Z1 microscope (Carl Zeiss AG). n≥ 48 cells per 
condition were quantified using the manual tracking plugin for Image J (NIH, Bethesda, 
MD). 
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4.3.6 Collective Motility 
 Cells were seeded onto TCPS at a density of 30,000 cells/cm2 and allowed to adhere 
for 24 hours. 1 hour prior to the assay start, a scratch was made in the confluent cell layer 
with a p200 pipette tip. The same frame of cells was imaged at time 0 and after 12 hours with 
the Zeiss Axio Observer Z1 microscope (Carl Zeiss AG) and the width of the scratch was 
determined using Image J (NIH). The percent wound closure after 12 hours was determined.  
4.3.7 Traction Force 
 Traction force was analyzed using a polydimethylsiloxane micropost array (PMA) 
method as described previously [278, 279]. Briefly, PMA substrate was prepared on a 
coverslip (25 mm, round) and mounted onto a 35-mm petri dish with a 20-mm hole for high 
magnification imaging. Flat PDMS stamps were coated with fibronectin (50 μg mL-1) for 
surface functionalization of PMA via microcontact printing. PMA were labeled with DiI 
solution (5 μg mL-1; Life Technologies) for 1 hr. Non-specific protein absorption were 
blocked by 0.2% (wt/vol) F127 Pluronic solution (Sigma) for 30 min. Cells were seeded with 
a density of 0.1M/ml. Phase images were taken using a 40 × objective (Leica DMi8) after 24 
h. All images were analyzed using a custom-developed MATLAB program (MathWorks), as 
described previously. 
4.3.8 ECM Remodeling 
Cells were grown into spheroids over 14 days in lyophilized poly(N-
isopropylacryamide)-poly(ethylene glycol) (polyNIPAAM, Cosmo Bio USA, Carlsbad, CA), 
as previously described [60]. Briefly, cells were suspended in polyNIPAAM solution placed 
on ice at a density of 167,000 cells/mL and each gel was made at a volume of 150 μL. 
Gelation occurred after 5 minutes at 37ºC, and gels were swollen in cell culture medium. 
Spheroids were harvested by placing plates on ice for 5 minutes in cold serum free media, 
then diluting the mixture further and allowing spheroids to settle for 30 minutes on ice. The 
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supernatant was removed and spheroids collected from 1 polyNIPAAM gel were 
resuspended in 45 µL of fresh media then gently mixed and plated in a 1:1 mixture of 
Matrigel:spheroids+media. Spheroids were allowed to settle to the plate before it was placed 
at 37°C to sandwich the spheroids between the TCPS and Matrigel. Cells were allowed to 
remodel their ECM for 4 days prior to staining for collagen (ab6308, Abcam), pan-laminin 
(ab11575, Abcam), F-actin (A22287, Thermo Fisher Scientific), and DAPI and imaging on a 
Zeiss Cell Observer SD (Carl Zeiss AG).   
4.3.9 Cell Invasion  
 MDA-MB-231 cells were seeded into the top of a Boyden chamber in serum free 
media, at a density of 200,000 cells/mL. The bottom chamber was filled with media 
containing 10% FBS. Cells were allowed to invade through 8 um pores for 24 hours, then the 
top chamber was removed, and the bottom chamber washed 1x in PBS and fixed in 4% 
formaldehyde. Cells and nuclei were permeabilized with Tris-buffered saline (TBS) with 
0.5% Triton-X for 20 minutes, then washed briefly in TBS with 0.1% Triton-X (TBS-T). 
Nuclei were stained with DAPI (1:5000 in PBS) and the entire well was imaged on the Zeiss 
Axio Observer Z1 microscope for manual quantification of invading cells.  
4.3.10 qRT-PCR  
 Total RNA was isolated and qRT-PCR performed as previously described [55]. 50 ng 
cDNA was amplified using 10 pmol specific primers (Table S1) and the Maxima Sybr green 
master mix (Thermo Fisher Scientific) on a Rotor-Gene Q thermocycler (Qiagen, Valencia, 
CA) as follows:  50°C for 2 minutes, 95°C for 10 minutes followed by 45 cycles at 95°C for 
10 seconds, 58°C for 30 seconds, and 72°C for 30 seconds.  Both β-actin and ribosomal 
protein S13 were included as reference genes to permit gene expression analysis using the 2-
ddCt method.   
4.3.11 Animal Xenografts 
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All animal experiments were in accordance with institutional guidelines and approved 
by the Institutional Animal Care and Use Committee at the University of Massachusetts 
Amherst. UMass has an approved Animal Welfare Assurance (#A3551-01) on file with the 
NIH Office of Laboratory Animal Welfare. MDA-MB-231 cells were suspended in a 1:1 
Serum Free Media: Matrigel (Corning, Corning, NY) mix, and 103 cells were subcutaneously 
injected into the mammary fat pad of 6-12 week old female NOD scid gamma mice from a 
breeding colony. Each mouse was injected with two tumors. All mice were housed in 
ventilated cages with sterile bedding, food, and water. Injected cells were grown in vivo until 
tumors reached 500 mm3. A minimum of 6 tumors were analyzed for each condition, and 
each tumor was considered one replicate.  
4.3.12 Primary Mouse Tumor Cell Culture 
MMTV-PyMT mice were sacrificed and tumors extracted within 24 hours. Tumors 
were finely minced with a scalpel, and incubated at 37°C for 1 hour in digestion media, 
which is DMEM:F12 containing: 5% FBS, 5 µg/mL Bovine insulin, 50 µg/mL Gentamicin, 2 
mg/mL trypsin, and 1 mg/mL collagenase. Samples were spun down at 400G for 10 minutes, 
and resuspended in fresh DMEM:F12 media containing 10% FBS and 1% P/S. Once larger 
pieces settled (~5 minutes), supernatant containing spheroids and single cells was plated onto 
TCPS or biomaterials of 1 kPa or 41 kPa functionalized with 10 µg/cm2 collagen 1. Cells 
were maintained as usual, and passaged once onto new biomaterial surfaces where indicated.   
 4.3.13 Statistical Analysis 
 One-way Analysis of Variance (ANOVA) with a Tukey post-test was performed on 
paired samples using Prism v5.04 (GraphPad software, La Jolla, CA). Prism was used to 
perform two-way ANOVA where indicated. Data reported is the mean and reported error is 
standard deviation with significance values of p ≤ 0.05 as *, p ≤ 0.01 as **, and p ≤ 0.001 as 
***. 
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4.4 Results 
4.4.1 Design of an extended culture system to model breast cancer metastasis 
To test the combined role of stiffness and timing on cell phenotype, we devised 3 
systems that employed interactions between biomaterials and breast cancer cells. First, we 
plated 2 triple negative breast cancer cell lines, MDA-MB-231 and Hs578T cells, on 
biomaterials of 1 kPa and 41 kPa, in addition to a tissue culture polystyrene (TCPS) control, 
and passaged cells at these stiffnesses over several months to condition them to those 
mechanical environments (Figure 4-2 ai). We were particularly interested in triple negative 
breast cancer, as basal-like populations have been reported to show extreme stiffening 
behavior via high levels of collagen deposition [280]. Second, after these populations had 
been isolated by adhesion and/or growth on these biomaterials, we plated the cells back onto 
the original, rigid TCPS to determine which phenotypes were maintained in the cell‟s 
mechanical memory (Figure 4-2 aii). Finally, to study cell populations that had never been 
selected for or grown on TCPS, we isolated primary breast tumor cells from an MMTV-
PyMT model. Due to their low growth rates in vitro, we initially isolated these primary cells 
onto either 1 kPa or 41 kPa hydrogels or onto TCPS, then passaged them onto one of those 3 
conditions to determine the role of the stiffness used to isolate the cells and the stiffness used 
to assay the cells in informing breast cancer cell phenotype (Figure 4-2 aiii). Because the cell 
lines grow more rapidly, which allows for selection over time (Figure 4-2 b), we assayed 
these populations for phenotypes like growth, motility, chemotaxis, and ECM remodeling to 
identify conditions necessary for onset of phenotypic changes and sustained alterations in 
behavior after we re-challenged those cells with culture on extremely rigid TCPS (Figure 4-2 
c).  
Heterogeneity makes treatment of breast cancer challenging, because the diversity of 
genotypes and phenotypes lend themselves to clones that survive and thrive in a wide variety 
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of conditions. However, this variety of cell behaviors poses an additional challenge in the lab. 
This problem is particularly present in attempts to examine population-level phenotypic 
changes in the lab, as the behavior of one individual cell can look extremely different than 
the population mean. For example, cells migrate at speeds ranging from 5 to 80 µm/hour, 
even while the population mean only varies by about 50%, patterns that persist even between 
individually isolated subclones that are genetically distinct. One strategy employed here to 
overcome this experimental challenge was to employ systems that give either a binary output, 
or focus on population level behaviors, rather than tracking individual cells. For example, 
application of a boyden chamber system measures the number of cells that are able to 
chemotax towards FBS, out of the whole population, which gives a binary read out on a 
single cell basis (a cell either migrates across the porous membrane towards the 
chemoattractant or it does not migrate) and this assay also measures population level 
changes, as the number of cells invading changes between conditions, while the number of 
cells seeded into the experiment is held constant. A second experiment that is not binary, but 
asses whole-population rather than single cell behavior is a wound healing assay. Cells 
migrate to fill in the space left by a scratch, but the speed of any single cell has relatively 
little bearing on how much of the wound is ultimately closed over the course of the assay. 
Tracking single cells still provides useful information on the range of behaviors that a 
heterogeneous cell population is capable of achieving, so here we have employed a 
combination of single cell tracking and measurement of population-level changes to capture 
the variety, but also acquire consistent and representative measurements of cell behavior 
before, during, and after mechanical conditioning. 
4.4.2 Extended mechanical conditioning alters cancer cell growth and ECM remodeling 
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We set out to identify the role of extended exposure to varied ECM mechanics in cell 
proliferation, as an essential piece of metastatic outgrowth. After culturing cells on 
biomaterials as outline in figure 4-2 ai, we plated cells onto TCPS, and assayed growth. We 
found that MDA-MB-231 cells grown on soft biomaterials were less proliferative on rigid 
TCPS than cells maintained entirely on TCPS (Figure 4-3 a), but cells did not retain memory 
of this phenotype when re-challenged with growth over multiple passages back on TCPS 
Figure 0-2. Biomaterial culture to mimic physiological mechanical cues in breast 
cancer. a. Cancer cell lines have been isolated from patients and cultured on TCPS for 
decades. (i) These cells were plated and cultured on biomaterials of 1 kPa and 41 kPa for 
extended lengths of time, then (ii) transferred back to TCPS for further culture. Separately, 
(iii) primary mouse breast tumor cells were isolated and cultured on biomaterials of 1 kPa 
and 41 kPa, or on TCPS. b. Cells were cultured on biomaterials to „condition‟ them to a 
given platform, and then re-plated onto TCPS to determine „memory‟. c. cells were assayed 
for several phenotypes (Boyden invasion, ECM remodeling, Scratch Assay, In vivo, 3D 
proliferation, Integrin PCR, Motility on Gels, and 2D proliferation) through the 3 stages of 
early conditioning, late conditioning, and memory. 
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(Figure 4-5 a). However, as cells in the tumor microenvironment grow in 3D, we 
encapsulated single cells in Matrigel and tracked cluster diameter over 10 days. There was no 
difference in cell growth in this soft, 3D environment in MDA-MB-231 or Hs578T cells 
(Figure 4-3 b). We also examined ECM remodeling, as breast cancer patients have highly 
heterogeneous expression of the protein Rho-Kinase (ROCK), which is necessary for tension 
generation (Figure 4-4 a). Cell spheroids grown from cells isolated at each of these 
Figure 0-3. Extended Mechanical Pressure Alters Cancer Cell Growth and 
Migration. a. Cell growth on TCPS was assayed with an MTS assay after MDA-MB-231 
and Hs578T cells were grown on 1 kPa (red), 41 kPa (blue), or TCPS. b. Cell growth was 
assayed in 3D in Matrigel by measuring spheroid diameter over 10 days post-seeding. c. 
MDA-MB-231 cells were injected orthotopically and allowed to grow until a palpable 
tumor formed. Tumor growth was measured over time by volume. N=1, n=6 tumors per 
condition. d. Cell traction forces were analyzed via micropillar deformations and 
normalized over the cell area. N=1, n>12 cells per condition e. Cell migration was 
analyzed from cells harvested from 1 kPa, 41 kPa or TCPS cultures, over a range of 
stiffnesses spanning from 1 kPa to 64 kPa. f. Primary mouse tumor cells from an MMTV-
PyMT model were seeded onto an initial biomaterial (x-axis; from) for one passage, and 
transferred to a new biomaterial for assay (color coded; on). Cells were tracked for 
migration speeds over 12 hours at each condition. For a,b,c,e,f; N>=2. Data gathered in 
collaboration with Dr. Christopher Hall, Peiran Zhu, and Tianfa Xie. 
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conditions exhibited differential ECM remodeling when plated into a rigid TCPS 
environment, overlaid with Matrigel (Figure 4-4 b). To capture more physiological aspects of 
the microenvironment that might promote or inhibit cell growth, we created orthotopic 
tumors in the 4th mammary fat pad of NSG mice and measured tumor size over time. Here 
we also found no difference in growth rates between the 3 populations conditioned on either 
1 kPa or 41 kPa, or maintained on TCPS (Figure 4-3 c). Together, this data suggests that 
while a rigid 2D environment discriminates between cell populations based on their 
mechanical background, growth in a soft, 3D, physiological environment is less dependent on 
that priming.   
4.4.3 Culture on soft biomaterials promotes motility at conditions similar to growth 
conditions 
 In addition to growth, traction and motility are essential steps in the metastatic 
cascade, so we set out to examine the impact of mechanical conditioning on cell migration. 
First, we assayed traction force with micropillars, and found that at this particular 
combination of material stiffness and post deformability, cells grown on soft 1 kPa hydrogels 
Figure 0-4. ECM remodeling is dependent on culture stiffness. a. Scores of ROCK 
protein expression from The Human Protein Atlas in normal breast tissue compared to 
breast cancer samples. b. Spheroids derived from cells grown on 1 kPa, 41 kPa, or TCPS 
and sandwiched between TCPS and Matrigel, then shown in brightfield (top) or 
immunofluorescently stained (bottom) for collagen (red), pan-laminin (green), F-actin 
(purple), and DAPI (blue). Separately, MMTV-PyMT mouse breast tumor primary cell 
spheroids were embedded in Matrigel and imaged on day 1 (top) and day 14 (bottom).  
 
 
106 
 
exhibited more traction forces than cells coming from stiffer environments (Figure 4-3 d). 
Interestingly, other groups have demonstrated that MDA-MB-231 and other metastatic cells 
exhibit overall higher traction than non-metastatic cell lines [212]. With this traction force 
data in hand, we also aimed to quantify the expression of integrin receptors in these cell 
populations to relate our work to extensive computational modeling of the motor-clutch 
model of cell migration. Cells heterogeneously altered expression of many integrin subunits, 
with upregulation of integrin genes for receptors that bind to several different ECM proteins, 
such as collagen (ITGB1), fibronectin (ITGA5), and laminin (ITGB4) (Figure 4-5 b). Each of 
the subunits mentioned above also maintained slightly increased expression when probed for 
mechanical memory. Integrins and traction are linked, as different integrin affinity for ECM 
proteins regulates cell force generation [281]. We then sought to assemble these analyses of 
the motor parameters (traction) and clutch parameters (integrin expression) into a functional 
migration assay.  
We first observed a biphasic relationship between stiffness and motility for cells that 
were always maintained on TCPS, which has been previously described in this system and 
others [45, 275]. The stiffness that produces optimal migration, however, varies widely 
across cell types, so we hypothesized that the stiffness of optimal migration in our cancer cell 
lines could be tuned with extended mechanical cues. Indeed, we found that we could tune the 
stiffness of maximal cell migration of MDA-MB-231 cells by culturing cells on biomaterials 
of 1 kPa or 41 kPa (Figure 4-3 e). We also observed a similar trend in Hs578T cells, although 
the change in speeds was not significant (Figure 4-6 a). We were surprised to find that cells 
grown on 41 kPa exhibited maximal migration speeds on 41 kPa biomaterials, which is stiffer 
than the 18 kPa hydrogel where cells from TCPS migrated fastest. One possible explanation 
is that the hydrogels were functionalized with a high amount of additional collagen 1, which 
was not provided to the cells grown on TCPS. Additionally, we decided to grow cells on 
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much stiffer gels, of 500 kPa, and then similarly assayed those cells for motility from 1 to 64 
kPa (Figure 4-6 b). We found that the cells grown on 500 kPa hydrogels followed a stiffness-
dependent migration profile very similar to cells grown on 41 kPa, suggesting we were above 
a „saturation stiffness‟ (Figure 4-6 b). This saturation phenomena has been observed in other 
phenotypes, such as fibroblasts matching their stiffness to the stiffness of their substrate, 
which was only observed below 20 kPa [39].  
4.4.4 Primary tumor cells are smaller and motile on Soft Biomaterials 
Figure 0-5. Proliferation and Integrin Expression show little mechanical memory. a. 
MDA-MB-231 Cells were conditioned on biomaterials over 15 weeks and assayed for 
proliferation on rigid TCPS over 15 weeks (left of x-axis break). Then those same cells were 
plated back onto TCPS and cultured on TCPS over time, and assayed regularly for growth 
on TCPS as a test of cell memory (right of x-axis break). b. After 80 doublings on 
biomaterials of 1 kPa and 41 kPa, MDA-MB-231 cells were assayed for gene expression of 
integrin subunits, as compared to expression on TCPS. After being grown on biomaterials to 
late passages, cells were plated back onto TCPS and cultured there for 25 doublings before 
integrin expression was re-examined.  Data gathered in collaboration with Sarah Duquette 
and Dr. Christopher Hall. 
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One major limitation of working with stable human cell lines, is that they have been 
selected for and grown on TCPS for long times before commencement of this study. To 
better understand if the results presented here represent physiological behaviors, we 
compared our data to primary tumor cells from an MMTV-PyMT model, as these cells have 
never been exposed to TCPS. We began by seeding cells directly onto 1 kPa or 41 kPa 
biomaterials after isolation, and seeded a fraction of the cells on TCPS for comparison, as 
shown in figure 4-2 aiii. Initially, isolated cells exhibited an epithelial morphology and 
maintained strong cell-cell contacts, so we could not assay single cell migration at passage 0. 
Instead, we observed spreading of cell clusters starting 24 hours after initial seeding on 
biomaterials of 1 kPa or 41 kPa, as compared to TCPS. Interestingly, we found that cell 
clusters on soft biomaterials spread much more over the course of this assay than cells on the 
stiffer surfaces (Figure 4-7 a-b). Once these cells spread from clusters into a monolayer on 
our biomaterials, we passaged them from each of our 3 substrates (1 kPa, 41 kPa, TCPS) onto 
a new set of 3 substrates, giving us 9 total conditions with each isolation condition divided 
into 3 assay conditions. We observed that cells were alive and exhibiting membrane ruffling 
Figure 0-6. Motility is altered by culture on biomaterials. a. Hs578T cells were grown on 
1 kPa (red), 41 kPa (blue), or TCPS (black) for 6-8 passages, then assayed for random 
motility on hydrogels ranging from 1 kPa to 64 kPa. b. MDA-MB-231 cells were grown on 
hydrogels of 500 kPa (orange) and their motility was compared to cells maintained on 41 
kPa (blue) and TCPS (black), 41 kPa and TCPS lines also shown in figure 4-2 e.  
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at all 9 conditions, but most were non-motile. However, cells that were isolated at the softest 
 
Figure 0-7. Primary breast tumor cells respond differentially to soft materials and 
TCPS. a-b. Spheroids isolated from primary MMTV-PyMT cells were seeded directly 
onto substrates of 1 kPa (red), 41 kPa (blue), or TCPS (black) (a). After adhesion, 
spheroid spreading was measured by change in area over 12 hours (b). c-f. After 1 passage 
on a biomaterial surface of 1 kPa (red), 41 kPa (blue), or TCPS (black), mouse primary 
tumor cells were transferred to a new surface of 1 kPa, 41 kPa, or TCPS, as indicated on 
the X-axis, and traced to determine cell area (c,e) and circularity (d,f). N=2, g-h. MDA-
MB-231 cells selected on biomaterials of 1 kPa, 41 kPa, or TCPS were each seeded onto a 
new surface and traced to determine cell area (g) and circularity (h). i-j. Two-way 
ANOVA was performed on data from c and d (i) and g and h (j), with tables reporting the 
percent contribution to variance of the interaction between current and past platforms, the 
current platform only, or the past platform only. P<0.05, *, p<0.01, **. Data analysis was 
done with assistance from Rainy Wortelboer.  
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1 kPa condition and re-plated onto 1 kPa gels for the assay were significantly more motile, 
migrating about twice as fast as cells at the other conditions (Figure 4-3 f).  
The motility we observed was not correlated with other shape parameters, like cell 
area and circularity (Figure 4-7 c-f). We probed these shape parameters at passage 1 across 
the 9 conditions described above. A two-way ANOVA revealed significant dependence of 
cell circularity on the assay platform, but no significant relation between the stiffness that we 
used to isolate the primary cells and their morphology at the time of assay (Figure 4-7 i). 
Upon comparing this data to the human cell lines selected on soft biomaterials, we observed 
similar trends in the cell area, with the largest contribution to variance coming from the assay 
platform (Figure 4-7 g,j). However, circularity of these MDA-MB-231 cells was significantly 
dependent on the substrate the cells came from, but not their current assay condition, in 
contrast to our primary cell data (Figure 4-7 h,i). This suggests that at the short times we 
were able to observe primary cells, they relied primarily on their current stiffness for 
mechanical cues, but when cell lines were conditioned over many passages, they derived 
important information from the stiffness of their substrate over time.  
4.4.5 Cells adopt a material-dependent phenotype over time 
Since we had observed changes in 2D proliferation and in motility after cells were 
cultured on biomaterials, we set out to identify the time-dependence of these phenotypes. To 
do this, we identified cells early during the cell conditioning process (40-60 doublings), cells 
at late stages of the conditioning process (130-160 doublings) (Figure 4-2 ai), and also 
examined cells during the memory stage (25-35 doublings back on TCPS) (Figure 4-2 aii). 
First, we assayed cells for invasion through 8 µm pores towards media containing 10% FBS, 
and found that they were equally chemotactic across all 3 populations at the early stage, but 
culture substrate mechanics began to differentiate between populations at the later time point 
(Figure 4-8 a). Further, these cells did retain a memory of that culture substrate after being 
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plated back onto TCPS and cells from 1 kPa and 41 kPa were less invasive than those that 
Figure 0-8. Cells adopt a material-dependent phenotype over time. a. Cell populations 
were assayed early (after 40-60 doublings on biomaterials), late (130-160 doublings on 
biomaterials) or to determine memory (25-35 doublings back on TCPS)  for chemotactic 
invasion towards 10% FBS. b. Cell populations were assayed in the same time frames as (a) 
with a wound healing assay. c. MDA-MB-231 cells seeded onto biomaterials and assayed 
for random motility on substrates of 1 kPa or 41 kPa either early (40-60 doublings on 
biomaterials), or assayed at the same conditions for memory (25-35 doublings back on 
TCPS). For a(early), b and c, N=2. For a(late conditioning & memory), and c (memory, 41-
>1 and 1->41), N=1. p<0.05, *; p<0.01, **; p<0.001, ***. Data was collected with 
assistance from Sarah Duquette and analysis was done with assistance from Rainy 
Wortelboer.  
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were cultured on TCPS for the entire length of the study (Figure 4-8 a). While we observed a 
similar trend during the conditioning phase of these cells in the wound healing phenotype, 
cell mechanical memory did not play a role after cells were plated back onto TCPS. In fact, 
cells coming from 1 kPa and 41 kPa closed significantly more of the wound than cells from 
TCPS during this memory stage (Figure 4-8 b). Wound healing relies on both cell growth and 
migration over the 12 hour assay, and we had separately noted that the cell proliferation 
phenotype in 2D reverted back to look like the original cell population, and cell memory did 
not play a role. This suggests that the reversion in wound healing is at least partly due to the 
reversion in cell growth rates. We also looked back at the random motility phenotype 
observed in figure 4-3 e. We observed that this motility phenotype had a much earlier onset 
than changes in invasion, as cells from soft biomaterials were significantly more motile when 
assayed at that same stiffness as compared to cells from TCPS, and cells do exhibit memory 
of this phenotype (Figure 4-8 c). Here we have identified 3 cell phenotypes that are key 
pieces of the metastatic cascade, with early onset changes in motility and late onset 
alterations in chemotaxis and wound healing. Interestingly, cells only retained memory of 
motility and chemotactic behavior, not that of cell proliferation and wound healing.  
4.4.6 Clonally isolated cells exhibit a range of phenotypic behaviors mimicking 
mechanical selection 
Most cells that successfully colonize distant tissue sites arrive there as part of a larger 
cluster containing cells that are not clonally identical. Several recent publications have shown 
at least 2 distinct populations in micrometastases, each with unique roles that contribute to 
metastatic efficiency [282, 283]. However, the ratios of those populations change over time at 
the secondary site, suggesting a selection mechanism dependent on features of the 
microenvironment. Here we employed techniques commonly used in the field of drug 
resistance, to isolate individual cell clones by extreme limiting dilution. These subclones 
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were then grown out into larger populations to better assay their range of phenotypes. We 
first noted that they have very different growth rates, and we quantified the variation in 
doubling time (Figure 4-9 a). We found a range of proliferation rates that suggests the 
possibility that a less heterogeneous population could emerge from our parental line over 
more than 10 passages, equating to an average of about 50 cell-doublings. Additionally, we 
assayed these populations for motility and, as expected, there is a large degree of variability 
in the migrations speeds of individual cells even within a single clone (Figure 4-9 b). Mean 
cell speed of the clones varied by 30-50%, which indicates that while each clone is able to 
achieve a large range of migration speeds, there are differences between clones in overall 
motility (Figure 4-9 b). Finally, we looked at collective cell motility of each single clone, to 
determine if cell-cell contacts between cells from the same subclone could facilitate a wound 
healing phenotype, which relies on a combination of cell growth and migration. We similarly 
found a range of behaviors, which seemed to mimic the trends observed in figure 4-9 a and b. 
For all 3 of these phenotypes, cells selected on soft biomaterials fall in the range of 
individually isolated cell clones, while looking distinct from cells grown entirely on TCPS.  
After we identified a high degree of variation in single clones when assayed for 
growth and motility on rigid TCPS, we hypothesized that these clones might also 
demonstrate varied mechano-responsiveness when plated onto biomaterials. Proliferation of 
cells grown on TCPS increased at higher stiffnesses, similar to previous reports (Figure 4-9 
d) [128, 186]. However, we found this profile was altered in different subclones. For 
example, clone 1-10B barely grew at all, while clone 1-8D grew on TCPS, but not on any of 
the biomaterials. Additionally, clone 1-5C seemed to grow similarly across all 5 substrates 
examined here. We further assayed the cells selected on biomaterials for comparison, and 
found that the cells grown on 1 kPa or 41 kPa hydrogels behaved most similar to clone 1-11G 
and 1-5C, respectively (Figure 4-9 d). Together, these clonal comparisons demonstrate the 
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possibility of selection of a subset of cells out of a heterogeneous population during culture 
on soft biomaterials, and the individual subclones mimic the growth and motility phenotypes 
seen in populations after extended cell growth on soft hydrogels.   
4.5 Discussion 
Here we set out to identify a set of phenotypes that are altered over time with 
exposure to soft biomaterials. We used two independent approaches to identify the 
heterogeneity that contributes to change over time; a top-down approach which identified 
stiffnesses of interest which were used to apply selection pressures to these cell populations, 
Figure 0-9. Clonally isolated cells exhibit a range of phenotypic behaviors mimicking 
mechanical selection. a. Doubling time for isolated subclones (all in black) compared to 
doubling time for MDA-MB-231 cells selected on materials of 1 kPa (red) and 41 kPa 
(blue), with the origin cells on TCPS (gray). b. Cell subclones and conditioned MDA-MB-
231 cells were tracked for migration speeds on TCPS. c. Wound healing was assayed for 
clones on TCPS. Box shows 25-75% and whiskers show 10-90%. Data for MDA-MB-231 
cells grown on biomaterials are shown in red for 1 kPa, blue for 41 kPa, and gray for TCPS. 
d. Growth rates were calculated for cells on biomaterials of 1 kPa, 8 kPa, 41 kPa, 500 kPa 
and TCPS for isolated MDA-MB-231 subclones (1-10B, 1-8D, 2-5D, 202G, 1-11G, and 1-
5C) and for MDA-MB-231 cells grown on biomaterials for extended lengths of time (1 kPa, 
41 kPa, TCPS). For all conditions, N=>2. Cell subclones were generated by Ning-Hsuen 
Tseng and data analysis was completed with assistance from Rainy Wortelboer.  
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and a bottom-up approach that selected individual clones by limiting dilution to identify the 
existing population-level heterogeneity. We demonstrated that the range of growth and 
motility phenotypes that were isolated with this bottom-up approach is sufficient to explain 
the changes in cell behavior observed over time on soft biomaterials. However, the top-down 
approach most closely mimics in vivo metastatic seeding, as the most successfully formed 
metastases arise from multi-clonal clusters at both the invasion and seeding steps [282]. 
Further understanding this clonal diversity and the role of tissue mechanics in selecting these 
populations can build upon existing efforts to use circulating tumor cells to predict patient 
outcomes [284].  
Heterogeneous populations arise within a primary tumor and increasingly small 
subsets of these cells leave the primary tumor, survive vascular or lymphatic travel, reside as 
disseminated cells at distant sites, and ultimately form macrometastases [282, 285]. Transfer 
of multiclonal populations to a new environment can result in erosion of the original tumor 
diversity. For example, patient-derived xenograft models, which are thought to most closely 
recapitulate the original microenvironment, can result in tumors comprised of clones that 
made up less than 5% of the original tumor after several passages [286]. Here we observed 
subclones with widely varied proliferation rates on both TCPS and hydrogels, indicating that 
it is likely that extended culture on biomaterials would shift the population make up towards 
those that better adhere to, and grow on, soft biomaterials (Figure 4-9 a, Figure 4-9 d). 
However, reducing studies down to a single clone misses key pieces of information as 
emerging work demonstrates that two or more distinct subclones can work cooperatively to 
facilitate growth and drug resistance. As examples, in chronic lymphocytic leukemia, patients 
with independently evolving subclones had worse clinical outcomes than patients without 
independent subclonal driver mutations [49], and minor EGFR mutant clones contributed to 
overall tumor growth via a paracrine mechanism in glioblastoma [287]. While we are likely 
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narrowing the diversity of subclones in our conditioned populations, it is highly improbable, 
if not impossible, that we are selecting for a single subclone. This at least partially explains 
the continued heterogeneity in our results and the memory of some phenotypes, but not 
others after re-challenging cells with culture on rigid TCPS.   
Here our data indicates that cells altered their motility based on culture conditions 
beginning early in conditioning, and sustained that mechanical memory over several 
doublings back on TCPS. We observed that the stiffness of maximum migration was shifted 
to the left for cells grown on 1 kPa hydrogels, and to the right for cells grown on stiffer gels 
of 41 kPa and 500 kPa (Figure 4-3 e, Figure 4-6 b). We noted that the maximum migration of 
cells grown on TCPS fell between these conditioned populations, at 18 kPa, and predict this 
is related to the collagen 1 functionalization that we provided to cells grown on biomaterials, 
but not to cells grown on TCPS. Cell migration is frequently described by a motor-clutch 
model, where parameters of cell traction (motor) scale with parameters of cell adhesions 
(clutch) [288]. Our tension data in a micropillar study indicate that cells from soft materials 
generate slightly more tension in this particular environment (Figure 4-3 d), although they 
seem to generate less tension and engage in less ECM remodeling on rigid TCPS surfaces 
(Figure 4-4 b). Other groups have reported decreases in integrin β1 expression on soft ECMs 
at short time points [289], but we noted that cells eventually recovered or slightly increased 
mRNA levels over several passages on our collagen 1 functionalized biomaterials, signifying 
an increase in the number of available clutch molecules (Figure 4-5 b). In order to maintain 
homeostasis, changes in clutch parameters must be offset by changes in either other clutch 
parameters or motor parameters [241]. Because the changes in traction forces that we 
observed between our 3 populations were small relative to the variation in phenotype, we 
hypothesize that our cells best fit into a clutch-clutch model, although we do not probe 
broader clutch-related changes in this work. A related phenotype, chemotaxis towards FBS, 
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was also retained in cell memory even after cells were re-challenged with culture on TCPS 
(Figure 4-8 a). Other groups have demonstrated that stiffer substrates enhance chemotaxis in 
immune cells [290] and limit chemotaxis in mesenchymal stems cells [291], but to the best of 
our knowledge, this is the first work to show that cells can be primed by a substrate to still 
invade towards a chemo-attractant several passages later.   
While we observed stable phenotypes in cell motility and chemotaxis, growth and 
wound healing behavior appeared to be more transient. For the purpose of our study, we 
define memory as sustained presentation of altered phenotypes after cells from soft 
environments are challenged with extremely rigid culture conditions for at least 5 passages. 
Mechanical conditioning induced short term changes in cell growth, in 2D but not 3D, and in 
wound healing, but cells exhibited little or no memory of past stiffnesses after 25-35 
doublings back on TCPS (Figure 4-8 b). However, we did observe differences between 
isolated subclones assayed for proliferation on both rigid TCPS and softer biomaterials 
(Figure 4-9 d). Higher stiffnesses are known to drive increased proliferation [272], and our 
data indicates that when assayed on rigid surfaces, mechanically conditioned cells do not 
retain a memory of the substrate where they were grown. Other groups have shown that 
serially passaging breast tumor cells in rats resulted in increased growth and invasion over 
time [292]. One study warrants robust comparison to our work, as they passaged breast 
cancer cells up to 4 times over 12 weeks in brain, lung, or bone marrow tissue that was 
implanted in a subcutaneous skin fold chamber [293]. They observed early, but transient, 
changes in ion transport and homeostasis, and longer term upregulation of gene ontologies 
associated with cell-matrix adhesions and chemotaxis, which tracks closely to the data 
presented here. Other recent work found changes in MDA-MB-231 cell proliferation after 3 
passages on polyacrylamide gels, but, similarly to our work, cells retained little memory 
when they were seeded back onto TCPS [108]. Additionally, collective motility is enhanced 
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in a 3D model at high collagen concentrations [294] and cells respond to substrate stiffness 
much more efficiently in a collective cell migration model [295], which may explain the 
propensity of our populations to show short-term dependence on culture stiffness but 
demonstrate no memory of that phenotype (Figure 4-8 b). Overall, our data demonstrate that 
cells respond to mechanical conditioning over time, but only retain memory of those 
phenotypes in a subset of behaviors that are ultimately necessary for breast cancer metastasis.  
A recurring problem in the emerging field of mechanical memory is that standard cell 
isolation and maintenance protocols require exposing cells to an extremely rigid TCPS 
substrate before conditioning the cells in a biomaterial environment. To that end, we 
compared data from established breast cancer cell lines to primary breast cancer cells that 
were isolated and assayed on our hydrogels. Importantly, MMTV-PyMT tumors retain 
several features of human breast cancer that drive metastasis, including collagen organization 
and early dissemination [296, 297]. One group has cultured primary breast carcinoma cells in 
natural ECM gels, and found that collagen, but not basement membrane induced migration 
[18]. Our system allows the decoupling of stiffness and integrin binding sites, so here we 
functionalized all of the surfaces with collagen 1 to promote migration, and tested the unique 
role of stiffness. We found that primary mouse tumor cells were only motile when they were 
both isolated and assayed at the softest condition (Figure 4-3 e). Additional work has been 
done in mesenchymal stem cells that were also isolated directly on substrates designed to 
match physiological stiffnesses [298]. That group identified multiple levels of memory, 
starting from early onset (transcription factor translocation to the nucleus), to those at longer 
time frames (changes in gene expression). Here we suggest a mechanism that occurs over 
longer periods via selection of subclones that preferentially adhere to and proliferate on soft 
biomaterials. There are likely contributions from all of these factors (transcription factor 
localization, gene expression, and selection) in the phenotypes observed. For example, as the 
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wound healing phenotype is reversible, this is likely driven by changes in gene expression 
across the population. In contrast, memory of chemotaxis behavior suggests more stable 
selection, likely for cells with an advantage in both growth and response to soluble factors. 
These stable changes could be a result of selection for cells with higher copy numbers of key 
growth factor receptors, like EGFR.  
Memory of a previous mechanical environment may determine metastatic success or 
failure based on whether cells are disseminated from a very soft or very stiff tumor, where 
stiffer tumors [120] and high expression of the cross-linking enzyme lysyl oxidase [299] are 
associated with worse prognosis. In stem cells, memory of a previous stiffness is maintained 
by YAP transcription factor nuclear localization, which impacts differentiation in a time-
dependent manner [106]. This has further been demonstrated as a mechanism for epithelial 
reprogramming in a wound-healing environment [300]. While little has been done to translate 
this work to stiffness changes during tumor progression and metastasis, one group has 
observed YAP/TAZ dependent memory and noted an impact on motility in non-malignant 
epithelial cells and invasive tumorigenic cells [277]. YAP/TAZ nuclear translocation has 
previously been linked to mechanical signaling via control of focal adhesion dynamics [301] 
and matrix production [259] at short time points. While localization may play a role in our 
system, the long timeframe required to observe many phenotypic changes indicates that gene 
expression changes and clonal selection may better explain the functional downstream 
changes that result from conditioning cells using biomaterials (Figure 4-1).  
4.6 Conclusions 
Serial passage of breast cancer cells on soft biomaterials promotes a phenotype of 
low motility and growth on TCPS, enhanced motility at physiological stiffnesses, and mimics 
behavior of primary mouse tumor cells that have never been exposed to extremely rigid 
TCPS. Culture in soft environments can yield short term decreases in cell proliferation and 
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related behaviors, although this phenotype is not retained over long periods of time, 
suggesting that proliferation is more dependent on the current environment than past 
mechanical cues. However, motility and chemotaxis change based on mechanical priming, 
suggesting memory is important for those phenotypes. While more work is needed to fully 
characterize the impact on overall risk and its‟ relation to tissue specific metastasis, this study 
demonstrates that mechanical conditioning has a broad effect on cell phenotype, with a subset 
of those behaviors retained even as cells are challenged with new mechanical cues. 
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CHAPTER 5 
CONCLUSIONS AND ONGOING WORK 
 
5.1 Abstract 
Breast cancer is really a collection of many diseases and that heterogeneity makes it 
difficult to treat.  While clinical and molecular subtyping provides a host of information to 
treat a patient, this analysis neglects many druggable aspects of a tumor or the metastases. 
The field of medicine has become exceptionally proficient at treating primary breast tumors 
through methods including; early detection, resection, radiation, cytotoxic drugs, and targeted 
therapeutics, but preventing or treating disseminated tumor cells and ultimately macro-
metastases at essential organs has remained elusive. The work in this dissertation aims to 
broaden the scope of options available by applying engineering methods to this challenging 
medical problem. I have successfully identified mechanisms of drug resistance in biomaterial 
systems and targets that respond to mechanical forces in the tumor microenvironment, as 
important contributions to the large body of research that is characterizing and treating breast 
cancer. 
5.2 Overall Conclusions 
5.2.1 Microenvironment mediated drug resistance via MEK 
We combined biomaterial platforms, drug screening, and systems biology to identify 
mechanisms of extracellular matrix-mediated adaptive resistance to RTK-targeted cancer 
therapies. Drug response was significantly varied across biomaterials with altered stiffness, 
dimensionality, and cell-cell contacts, and kinome reprogramming was responsible for these 
differences in drug sensitivity. Screening across many platforms and applying a systems 
biology analysis were necessary to identify MEK phosphorylation as the key factor 
associated with variation in drug response. This method uncovered the combination therapy 
122 
 
of sorafenib with a MEK inhibitor, which decreased viability on and within biomaterials in 
vitro, but was not captured by screening on tissue culture plastic alone. This combination 
therapy also reduced tumor burden in vivo, and revealed a promising approach for combating 
adaptive drug resistance. MEK has independently emerged as a therapeutic target, but is an 
interesting candidate for combination therapy here because sorafenib and the MEK inhibitor 
target two nodes within the same pathway, while most combinations aim to target different, 
but redundant, pathways.  
Combing therapies is an established method to combat adaptive resistance, but 
screening on TCPS is not a perfect tool and does not mimic physiological conditions. 
Therefore, interdisciplinary approaches that combine drug screening, systems biology and 
biomaterials engineering are important. However, building these systems adds time and cost 
to the drug screening process and may not always be necessary. For example, we 
demonstrated that the biomaterial platform did not impact cell response to doxorubicin, 
where screening on TCPS alone was sufficient. Additionally, our group has previously 
identified JNK phosphorylation as a resistance mechanism to sorafenib in very stiff 
environments, but that work combined with our data here has demonstrated that this could be 
identified using just 2D systems, and the efficacy of that combined therapy was evident on 
TCPS. 
5.2.2 Integrating tumor genetics and ECM properties 
 Stiffness is one features of the tumor microenvironment that is known to influence 
cell phenotype. Relating this information to cancer cell genetics is important because while 
engineers have characterized the impact of physical forces in and around the tumor, clinicians 
use sequencing and expression information to inform treatment decisions. For instance, 
predicting where a patient might develop metastasis would be useful for monitoring and 
treating that patient, but that information is not immediately obvious from a biopsy of the 
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primary tumor. Engineers have worked to develop in vitro techniques to predict this tropism, 
but this is not yet applied clinically [55]. This combination of the study of features of the 
tumor cell and the surrounding matrix is key for integrating current genetic analysis with 
emerging knowledge in mechanobiology.  
Here, I have worked to identify a set of genes and their resulting proteins that respond 
to the mechanical properties of their environment and have a functional impact on cell 
behavior. I focused on genes that mediate cell interaction with the ECM, like integrins, and 
the resulting signaling cascades. While most work thus far has focused on collagen binding 
integrins, here I identified integrin α6, a laminin binding subunit, as mechanosensitive and 
confirmed its necessity in EGFR signaling in our system. The ligands for these two surface 
receptors (laminin and EGF respectively) are abundant in the tumor microenvironment, and 
so their relation has important implications for cell adhesion and motility in dissemination. 
Further, these two pathways converge at the intracellular protease calpain 2, which is known 
to be responsible for focal adhesion turnover. Cells were more sensitive to pharmacological 
calpain 2 inhibition in stiffer environments, more reminiscent of late-stage primary tumors. 
Together, these offer new potential drug targets that are unique to the stiff tumor 
microenvironment that is rich in laminin and EGF. 
5.2.3 Mechanical Forces Direct Metastasis 
 Disseminated breast cancer cells reside at the secondary tissue sites for extended 
periods of time, undergoing evolution and selection at those distant sites as well. Each of the 
most common sites of breast cancer metastasis (bone marrow, brain, liver, and lung) has a 
distinct stiffness range, so we designed a set of biomaterials to isolate those tissue properties, 
and then grew cells in those environments for extended lengths of time. I have demonstrated 
that the clonal diversity in growth and motility of the parental cell line is sufficient to account 
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for selection of subpopulations over the course of 32 passages (equating to approximately 
160 cell doublings) on biomaterials. I identified that cell growth and collective migration on 
rigid TCPS is limited in cells selected on biomaterials compared to those maintained on 
TCPS. However, cells grown on soft biomaterials were more motile when re-plated back 
onto the same, soft hydrogels, a behavior that was similar to mouse primary cells that had 
never been exposed to rigid TCPS. As the most successfully metastasizing cells likely arrive 
at the secondary site as multi-clonal clusters, tumor evolution dynamics at the secondary 
tumor site are important in understanding how to best target the cells contributing to 
metastasis and poor patient outcomes.  
Clinically-oriented work is beginning to understand how drug treatment drives cell 
selection and tumor evolution, and here I‟ve identified the role of stiffness on these 
processes, in a time-dependent manner. Cells residing in a stiffer metastatic niche may be 
more successful at responding to growth signals in their environment, as indicated by cell 
chemotaxis experiments, and they may also have an advantage in migration and proliferation. 
This aligns with other recent work that demonstrates the importance of a fibrotic pre-
metastatic niche in recruiting and supporting disseminating cancer cells. Together, this 
demonstrates that significant tumor-level evolution occurs at the disseminated rather than 
primary tumor site, and that targeting the ECM at common sites of metastasis may be a 
promising therapeutic strategy.  
5.3 Future Work and Overcoming limitations 
5.3.1 Breast cancer as a global disease 
While the majority of breast cancer research occurs in western nations, globally 1 in 8 
women will be diagnosed with breast cancer. Outside the scope of this work, the standard of 
care varies dramatically between countries, but early systematic studies have begun to 
identify scientific similarities and differences in breast cancer development in these different 
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populations. For example the age of diagnosis is significantly lower in black women born in 
East African nations. Understanding these scientific parameters is important, because in the 
United States, women typically begin getting mammograms at age 45, which can provide 
early diagnosis and identify other risk factors, like increased breast density [48].  
 Beyond the public health challenges facing breast cancer patients in developing 
nations, there is limited research on genetic and mechanical forces that drive breast cancer in 
non-western populations. For example, the standard reference genome used for mutational 
and transcriptomics studies is comprised of 11 white individuals from upstate New York, 
which is not representative of a global population. Here we were able to identify somatic 
mutations through comparing cancerous tissue to a matched normal sample, but this limits 
the number of samples that can be included in such studies. Understanding the change in 
Ethiopian breast tumors over time and expanding the available population for sampling will 
benefit future work to build a diverse set of reference genomes to better understand breast 
cancer on a global level.  
 One benefit from studying diverse populations is that the types of therapeutics are 
often different for these groups. For example, African American breast cancer patients tend 
to have higher expression of ECM related genes, like those associated with angiogenesis. 
However, inhibitors of these processes have had little clinical success, effectively ending 
these efforts. Using genetic and phenotypic methods to better understand the relationship 
between the impacts of the tumor microenvironment on aggressive breast cancer and the 
differences in those cancers developed by women born in East Africa, black women born in 
the United States, and white women born in the United States will be of immense benefit.  
5.3.2 Development of mechanical drug targets 
The field of mechanobiology has identified several mechanisms by which cells 
translate extracellular forces to biochemical signaling and changes in gene expression 
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programs. Early clinical work has focused on targeting intuitive mechano-transducers, like 
ROCK [302], where inhibitors have already been approved for other indications. In this work 
I have contributed new potential drug targets that respond to the mechanics of their 
environment, and may show differential expression in tumor ECMs. For example, earlier 
work proposed calpain 2 as a promising target, but in vitro work had suggested likely off-
target effects, as calpain 2 is a key regulator of motility in immune and endothelial cells too 
[245]. However, knowledge of tumor mechanics can assist in preferential targeting of 
diseased tissues. Additionally, a common target in breast cancer is EGFR, which is known to 
have altered expression and activity at different stiffnesses [186], which may have 
implications for efficacy and resistance. Understanding the mechanical influence on signaling 
allows a level of specificity for cancer cells over strategies that disrupt the rest of the 
extracellular matrix and stroma that remodel that matrix [9, 303]. This knowledge of the 
tumor microenvironment, such as stiffness and abundance of laminin and EGF, can instead 
be used to limit cancer cell adhesion and motility in a manner that is unique to the tumor. 
However, integrins are incredibly difficult to target, with all clinical successes thus far 
targeting integrins on cells in suspension in the blood, rather than in solid tissues, including 
tumors [304]. Therefore, targeting parallel or downstream nodes, as described in this work, 
may hold more promise. In the future, the analysis I have done here should be further 
expanded to include other tissue parameters, like dimensionality and an expanded set of 
signaling molecules, to identify new therapies and therapeutic combinations.  
5.3.3 Further Exploration of Clonality and Heterogeneity in Breast Cancer 
Treatment of breast cancer frequently results in resistance and recurrence, either 
through redundant signaling or via genetic mutations that occur or are selected for over time, 
known as tumor evolution. This is a key clinical challenge because the diversity of 
populations within a tumor means there is a chance some cells may already exhibit resistance 
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to frontline therapies, but also any residual cells may develop further mutations that promote 
resistance to whole classes of therapies and further support cell survival and growth, even in 
the presence of other cellular stresses. Even before treatment, cell growth results in somatic 
mutations through standard proliferative processes, but the addition of stress via drug can 
accelerate the accumulation of potentially advantageous mutations [72]. This evolution does 
not only occur at the primary tumor, and recent work has demonstrated that cells likely 
disseminate from primary breast tumors early [74, 75]. This work, coupled with sequencing 
of tumors over time demonstrates parallel evolution can occur with a few mutations shared 
by the primary tumor and metastasis, but a broad range of mutations being unique to each 
location [71]. Further, in depth genetic analysis of patients over the course of their treatment 
shows the rise of new mutations within a single patient as they are treated with sequential 
drugs and drug cocktails [73]. All of this data highlights the necessity of understanding the 
functional distinctions between subclones to better treat patients.  
Here I have investigated the role of cell clonality in key phenotypes associated with 
metastasis, including migration, proliferation, and response to extracellular features of the 
tumor microenvironment (Figure 5-1). However, more work will need to be done to 
understand how these parameters relate to successfully metastasizing populations in vivo and 
how they promote drug response in a complex tumor environment. For instance, recent work 
has demonstrated that cells appear as multi-clonal clusters during all stages of metastatic 
spread; from local invasion, travel through the vasculature, and seeding at distant secondary 
sites [282]. This suggests that each clone may play a distinct role in providing growth signals, 
chemotactic signatures for immune or stromal cells, ECM production and deposition, and 
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tumor growth – all of which are necessary for survival and outgrowth of disseminated tumor 
cells. Interestingly, each subclone maintains a degree of heterogeneity in cell migration, 
suggesting any given cell can both produce and receive several cues from the extracellular 
space, including cell-cell contacts, or soluble factors (Figure 5-2 a). Here, we have done a 
preliminary experiment with mixing of 4 or 7 subclones, which can achieve increased 
proliferation, more similarly to the heterogeneous parental line (Figure 5-2 b). Additionally, a 
lot of work has been done to understand the rise of drug resistant clones in tumors, but this 
research has focused almost exclusively on cells grown on stiff, 2D, tissue culture 
polystyrene, which is not representative of the tumor microenvironment [119]. Here I have 
Figure 0-1. Mimicking mechanical selection of cells with extreme limiting dilution 
techniques. Work in this dissertation has examined mechanical selection of cells on soft 
biomaterials over time. These populations are preferentially motile at the stiffness where 
they were selected, and were less migratory and proliferative in rigid environments. Initial 
work demonstrates that isolated subclones collected via limiting dilution analysis show 
similar heterogeneity to cells selected using substrate mechanics. Future work is necessary 
to determine the role that different subclones play in metastatic populations and to 
determine treatable features of aggressive breast cancer cell populations.  Project 
conceived and initiated in collaboration with Ning-Hsuen Tseng.   
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done some work to characterize single clone response to features of the tumor 
microenvironment, like protein type and presence of EGF (Figure 5-2 c-d). This is an 
important dimension to add because tissue stiffness can alter resistance by changing 
expression and activity of key kinome signaling nodes for targeted therapeutics, and can 
change proliferation rates for evasion of cytotoxic drugs [72, 128, 270]. However, this has yet 
to be applied to understanding clonal selection for drug resistant populations or to induce 
secondary genetic alterations that allow the survival of persister cells, both of which could be 
enhanced by the reduced kinome signaling in 3D materials, or by an increased sensitivity to 
apoptotic signaling in similar systems. The set of material systems that I have described in 
this work allow for the isolation of specific features of the extracellular matrix, and can help 
Figure 0-2. Subclones respond differentially to the tumor microenvironment. a. 
Clonally isolated MDA-MB-231 cells exhibit variability in cell migration as measured by 
the coefficient of variation. b. Subclone growth rates were measured when seeded as the 
parental population, a mixture of 7 subclones, a mixture of 4 subclones, or the 1-10B 
subclone only. c-d. MDA-MB-231 subclones  were seeded onto TCPS passively coated with 
ECM proteins (collagen 1-Col, fibronectin-FN, or laminin-Lam) and either left in standard 
media (control) or with added EGF (EGF). Cells were separated tracked for migration 
speeds (c) or counted to determine growth (d). 
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identify the role of ECM in driving clonal selection, metastasis, and drug response of cancer 
cells.  
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CHAPTER 6 
FUTURE DIRECTTIONS EXPLORING MECHANICAL FORCES 
 
6.1 Inclusion of Additional Mechanical Forces: Shear Flow Enhances Cell Motility 
through Calpain 2 
6.1.1 Introduction 
Cells experience many types of mechanical forces during metastasis. One force that is 
not explored in this work but is of interest to the field is shear flow, which cells experience in 
both the interstitial space and in the vascular or lymphatic system [305]. Most research on 
shear flow to date has focused on cells in the vasculature, like endothelial and smooth muscle 
cells, as these forces are essential to development, homeostasis, and understanding healthy 
vasculature, which then allows us to better understand disease phenotypes like atherosclerosis 
[306] and tumor angiogenesis [307].  
Sub-cellular structure response to shear flow can be translated from endothelial and 
immune cell studies to better understand the impact of interstitial and vascular or lymphatic 
flow on cancer cells. For example, laminar flow promotes a healthy endothelial cell 
phenotype, while turbulent flow over atheroprone cells induced YAP/TAZ activation and 
translocation to the nucleus, driving proliferation and pro-inflammatory phenotypes [308]. 
Further work in cancer cells has demonstrated that flow across the top surface of a cell 
seeded onto a 2D surface can result in strain on focal adhesions, resulting in increased cell 
invasion through increased length, but not number, of invadopodia [309]. This increased 
force across a focal adhesion promotes stability, and shifts mechanosensitive cell migration. 
Additionally, shear stress can also impact cell proliferation and cell-cycle arrest through 
altered cyclin and cyclin-dependent kinase (Cdk) expression, downstream of integrin 
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signaling [310]. MDA-MB-231 breast cancer cells exposed to shear forces showed enhanced 
adhesion under low-flow conditions, and increased the activity of PI3K and Akt, also through 
integrin clustering and downstream signaling [311]. Integrin engagement and force 
transmission is a key part of the shear-sensing machinery, but is difficult to target, and has 
had little clinical success thus far.  
To that end, we set out to identify other components of the shear-sensing machinery 
in breast cancer, which may make more easily druggable targets. We designed and 
characterized a flow system that recapitulates some aspects of in vivo blood flow and 
demonstrated increased cell migration under high-flow conditions. This shear-effect was 
nullified in a cell line with reduced calpain 2 expression. We attempted to stimulated 
increased migration at the no-shear condition via two known mechanisms of activating 
calpain 2 – through the EGFR-ERK axis and via exogenous calcium. EGF-dependent calpain 
2 signaling partially rescued the increased motility and smaller cell morphology, suggesting 
that increased flow either replenished the supply of EGF to a cell or resulted in signaling 
downstream of EGFR through other mechanisms, such as integrin clustering. Here we 
propose calpain 2 as a shear-dependent target, although more work is needed to elucidate the 
full therapeutic potential.   
6.1.2 Methods 
6.1.2.1 Device Fabrication 
An inverse mold of the desired polydimethylsiloxane channel (PDMS, Dow Corning, 
Midland, MI) was designed in FreeCad and printed on a LulzBot Taz4 (Aleph Objects, 
Loveland, CO) in acrylonitrile butadiene styrene (ABS, Aleph Objects). The inside surface 
was smoothed by pipetting 3 mL of acetone into the mold, letting it sit for 15 seconds, and 
then pouring out the acetone. After 3 acetone washes, the entire mold was sprayed liberally 
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with 70% ethanol and allowed to set for at least 24 hours. PDMS was mixed in a 10:1 weight 
ratio of polymer: curing agent and poured into the mold, completely filling the mold. The 
PDMS solution was degassed in a vacuum chamber at room temperature for 30-60 minutes. 
Then it was cured at 60°C for at least 16 hours. A 1.5 mm biopsy punch was used to make 
holes at either end of the chamber, the PDMS was sterilized with 70% ethanol, then both the 
PDMS and a cleaned 50 mm x 75 mm glass slide were UV ozone treated (Bioforce 
Nanosciences, Salt Lake City, UT) for 20 minutes. The PDMS and glass were immediately 
placed together and allowed to set overnight under a weight.  
6.1.2.2 Cell Culture 
All cells were cultured in DMEM buffered with sodium bicarbonate, with 10% Fetal 
Bovine Serum (FBS) and 1% Pen/Strep (P/S) at 37°C and 5% CO2. All experiments were 
performed in DMEM buffered with HEPES, with 10% FBS and 1% P/S at 37°C. MDA-MB-
231 cells were a generous gift from Dr. Sallie Schneider at the Pioneer Valley Life Sciences 
Institute, and transfected with shRNA to calpain 2 or a scramble control as previously 
described [275]. 
6.1.2.3 Cell Migration  
MDA-MB-231 cells transfected with shRNA to either calpain 2 (shCAPN2) or a 
scramble control (shSCR) were seeded into the device at 4,400 cells/cm2 in media buffered 
with HEPES and allowed to adhere for 24 hours. 12 mL of fresh media was prepared to flow 
over the cells, either with FBS and P/S only (control), with FBS, P/S and 100ng/mL of EGF 
(+EGF), or with FBS, P/S and 3mM CaCl2 (+CaCl2). Two syringe pumps (from 
syringepump.com) were set to „recirculation‟, with a direction change with every 10 mL 
pumped. The syringes were connected to the 1.5 mm holes in the device via tubing (Cole 
Parmer, Vernon Hills, IL) and flow was started. 1 hour after the initiation of flow, the cells 
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were imaged every 15 minutes for 12 hours on a Zeiss Axio Observer. Individual cells were 
tracked and quantified using IMARIS. 
6.1.3 Results and Discussion 
6.1.3.1 Characterization of Flow Cell and Physiological Relevance 
In order to study the impact of shear forces on breast cancer cells, we designed a 
recirculating flow system to allow for continuous and indefinite perfusion of media across a 
defined surface (Figure 6-1 a). Cells were seeded onto the glass bottom of the device as 
single cells on the 2D surface. Media was flowed through the channel at volumetric flow 
rates ranging from no flow to 1000 µL/min. This flow rate showed a clear correlation with 
the average linear speed of 20-µm-diameter beads (Figure 6-1 b), selected due to their 
similarity to the size of cells. The recirculation system used here uses a back-and-forth 
motion, which requires an occasional change in the direction of the fluid flow. To this end, 
we characterized the behaviors of the beads in flow to understand the impact of the 
directional change on the fluid velocity. We identified a 10-15 second stoppage of flow each 
time the flow changed directions (Figure 6-1 c) although this had minimal impact on the 
average velocity of particles in flow as characterized in figure 6-1 b. To determine the 
physiological relevance of this system, we compared the wall shear rate and Reynolds 
number to reported values for different locations in the vascular system of humans (Figure 6-
1 d). Importantly, the Reynolds number fell within the laminar regime, which was confirmed 
by observation of the 20 µm beads flowing with a clear parabolic profile. Here the Reynolds 
number was above that in capillaries, although far below the reported values for veins and 
arteries. However, wall shear fell below most healthy physiological values, but closely 
matches reported experimental values experienced by circulating tumor cells [312].  
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The effect of such shear forces has been reported to have contrasting impacts cancer 
metastasis. Shear decreased the viability of melanoma cells in circulation and increased 
sensitivity to apoptosis signaling cascades [313, 314]. However, flow can induce autologous 
chemotaxis to drive motility away from the tumor [315], and shear forces promote adhesion 
Figure 0-1. Matching flow cell properties to blood flow in vivo. a. The recirculating 
flow system designed for this work relies on a base glass slide and a 
poly(dimethylsiloxane) (PDMS) base with an empty channel that is 4 mm high, 3 mm 
wide, and 6 cm long. Two syringe pumps communicate to direct volumetric flow with 
direction changes every 10 mL dispensed. b. 20 µm beads flowed through the device at 
volumetric flow rates ranging from 100 to 1000 µL per minute, which resulted in linear 
bead velocities of about 0.5 to 4.5 µm per second through the channel. c. Reversal of 
the flow at base rate of 750 µL per minute results in a temporary stoppage of bead flow, 
which is resumed over less than 40 seconds. d. Published data on physiological wall 
shear and Reynolds number in human blood flow, as compared to calculations for this 
flow system. Data gathered in collaboration with Elizabeth Swanson.  
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of cancer cells to the vessel wall, an essential precursor to extravasation [316]. Further, shear 
stress has been reported to facilitate both upstream and downstream migration relative to the 
direction of flow. While autologous chemotaxis drives downstream cell migration as 
described above, cells also undergo a process called rheotaxis, where focal adhesions on the 
upstream side of the cell are under more tension, driving an increase in cell protrusions, local 
actin polymerization, and mechanosensitive signaling [109]. Together, this suggests that the 
impact of shear forces on cell movement and survival is a balance of opposing behaviors, and 
is extremely context-dependent. To that end, we sought to isolate the impact of shear on cell 
migration specifically through the protease calpain 2, which we have previously identified as 
mechanosensitive.  
6.1.3.2 Cancer Cell Response to Shear is Mediated by EGF-Calpain 2 Signaling 
Endothelial cells, which line blood vessels, are known to be exposed to high levels of 
shear in blood flow. Many groups have worked to characterize their response to those shear 
forces, such as sprouting and migration via the intracellular protease calpain 2 [317]. 
However, many other cell types also travel through the vasculature, like immune cells, 
mesenchymal stem cells, and circulating tumor cells. Here we focused on tumor cell 
migration in response to varied shear flow rates to better understand the biochemical impacts 
of vascular dissemination of breast cancer cells. First, we identified that increased flow rate 
resulted in increased migration speed in a control cell (shSCR) population (Figure 6-2 a). The 
intracellular protease calpain 2 has been proposed as necessary for cell migration in flow in 
many cell types, including immune and endothelial cells. Here, we used a calpain 2 
knockdown cancer cell line (shCAPN2), and tracked migration both with and without shear 
flow. In the absence of shear flow, calpain 2 expression had no impact on cell migration, but 
at high flow rates, shCAPN2 cells migrated much slower than the control cell population 
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(Figure 6-2 a), suggesting cancer cells use similar motility mechanisms as immune and 
endothelial cells in the presence of shear force.  
Calpain 2 is known to be activated both by calcium signaling and in response to 
epidermal growth factor (EGF). In highly motile T lymphocytes, which frequently travel 
through the vasculature, extracellular calcium is essential to activation of calpain 2 [318]. 
Figure 0-2. Calpain 2 mediates flow-dependent increases in motility. a. Either control 
cells (shSCR) or calpain 2 knockdown cells (shCAPN2) were seeded at 8,000 cells per 
device, allowed to adhere for 24 hours and then flow was applied for 1 hour prior to 
imaging for 12 hours. b. Control cells at 0 µL per minute flow were analyzed for migration 
speeds either with control media, with added EGF, or with added CaCl2 in the media. c-g. 
Wind-rose plots of random cell migration (top) and cell morphology (bottom) under the 
following conditions: shSCR cells with no flow (c), shSCR cells at 750 µL/min (d), 
shCAPN2 cells at 750 µL/min (e), shSCR cells under no flow with EGF (f), and shSCR 
cells under no flow with CaCl2 (g).  
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Calpain 2, also known as m-calpain, is activated by millimolar (mM) levels of cytoplasmic 
calcium, so the exogenous concentration of CaCl2 in this study was increased to 3 mM. This 
concentration of calcium cannot be sustained within a cell under physiological conditions, 
but local regions of high calcium can be transiently induced in the presence of shear [319]. In 
endothelial cells, shear flow of 10 dynes/cm2 induced such localized pockets of high Ca2+ and 
recruitment of calpain 2 to the edge of the cell, so we hypothesized a similar mechanism may 
have been directing migration in our cancer cell population [320]. We exposed our control 
cell population to media containing either added EGF (+EGF) or added calcium (+CaCl2) in 
the device, but with no shear flow. Here we found that the addition of EGF, but not calcium, 
at least partially mimicked the effect of increased shear on cell migration (Figure 6-2 b).  
We also noted differences in cell morphology under shear and these different 
biochemical treatments. The shSCR cells at high flow were much smaller than no flow or low 
calpain 2 conditions, which we have previously demonstrated is linked to a more motile and 
aggressive phenotype in MDA-MB-231 breast cancer cells (Figure 6-2 c-e) [275].  Similarly 
to our motility results, cells treated with EGF, but not CaCl2, mimicked this morphology 
(Figure 6-2 f-g). Our data indicates that shear forces increase cell migration via calpain 2 
signaling at high flow rates, which may be an important contributor to cell invasion away 
from the primary tumor and extravasation and seeding at the secondary tumor site. 
6.1.4 Conclusions and Future Work 
Breast cancer cells experience shear forces at a primary tumor mass and as they travel 
through the vascular or lymphatic systems to a metastatic site. Little work has been done to 
understand how cancer cells respond to this class of mechanical forces. Previous work has 
identified several integrin-signaling mechanisms that drive cancer cell shear-sensing, but as 
integrins are difficult to target, particularly within a solid tumor environment, here we 
suggest calpain 2 as a potential target that is required for non-specific integrin turnover, and 
139 
 
responds to changes in stiffness in the tumor microenvironment in addition to shear flow 
[275].  
 Future work will need to fully characterize the mechanisms of inhibiting calpain 2 in 
a tumor-like or flow-based system to confirm EGFR-ERK inhibition, and not calcium 
chelators, are the appropriate signaling mechanism. Further, in situ systems of extravasation 
will assist in tissue-level analysis of calpain 2-based motility. For example,  previous work 
out of the Kamm Lab has designed high throughput studies of cell extravasation from a 
vascular network, which provides a good platform for validation of this work in a 3D system 
[19]. Further, vascularization of synthetic tissue mimics will contribute knowledge of the 
tissue-specific nature of metastasis and any relation to extravasation in that process. This 
work demonstrates a shear-based role for calpain 2 in cell motility, and future studies can 
further elucidate this process and potentially use it to target metastasizing cancer cells.  
6.2 Ethiopian Breast Cancer and its Relation to Changes in the Extracellular Matrix 
6.2.1 Introduction 
Estrogen receptor positive (ER+) tumors, comprise as much as 80% of breast cancers 
in the United States [321], but little information exists to determine if this is mirrored 
globally. Further, only 30% of familial breast cancers can be traced to a known genetic 
mutation [322], and that number is even lower in non-western populations, as a recent study 
in Korea found that less than 22% of familial breast cancer could be traced to a BRCA1/2 
mutation [323]. Most current work on health disparities in cancer treatment have little ability 
to distinguish between discrepancies in access to high-quality care and genetic mutations that 
disproportionately affect an understudied population. For example, in Ethiopia, women wait 
an average of 1.5 years from noticing a lump to seeking treatment [324]. While this proposed 
work does not resolve those potential contributions to clinical outcome, here we present a 
study to isolate somatic mutations that may contribute to poor prognosis.  
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Recent work has begun to control for several non-biological variables, including 
income disparities in diagnosing and treating breast cancer in African American women 
[325]. Here, we probe the biophysical signature of breast cancer in Ethiopian women. About 
85% of the Ethiopian population lives in rural areas, which rely on small household farms for 
food and income [326]. There has been a recent increase in the use of chemical pesticides at 
such farms in Ethiopia [327], where there are also over 250 sites with at least 1,500 tonnes of 
obsolete pesticides (defined as old, banned, or not identifiable) in rural areas. Many of these 
pesticides have also been identified as endocrine disrupting chemicals (EDCs), and the recent 
uptick has been mirrored by an increase in endocrine related diseases, including, but not 
limited to, breast cancer [328] and thyroid disorders [329, 330].  
 One mechanism of EDC action is binding to the estrogen receptor to mimic presence 
of the hormone, which stimulates cell growth and can induce new mutations. One example of 
an ER-binding chemical, bisphenol A (BPA), has a well-documented effect on the 
development of breast cancer through increased cell proliferation and Akt signaling, and this 
effect is most dramatic when exposure occurs during development [331]. Exposure to BPA 
during development can also alter the collagen localization. While the overall number of 
visible collagen fibers was decreased after exposure to BPA, the density of fibers 
immediately surrounding the epithelial ducts was significantly higher in animals that were 
exposed to EDCs [332]. This may be due to increased expression of transglutaminase 2 
(tgm2) in response to BPA, but only in ER+ epithelial cells, not in the local stroma [333]. 
Transglutaminase 2 catalyzes crosslinking of the ECM, which could lead to a local stiffening 
effect [334]. Additionally, exposure to commonly used pesticides, like Fenvalerate, has been 
shown to promote cell proliferation and collagen production, similar to BPA [335]. Other 
endocrine disrupting pesticides, like Diazinon, induce lesions with increased macrophage 
infiltration, a process known to cause regions of stiff and fibrotic tissue [336]. Therefore we 
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hypothesize that use of pesticides with endocrine disrupting function may serve to stiffen 
hormone-responsive tissue in young women, leading to an increase in ER+ breast cancer. 
While the studies described above focused on expression of key genes and proteins, our 
approach here is to identify mutations that contribute to this aggressive, ER+ breast cancer 
phenotype in Ethiopian women.  
This disparity is further compounded in the laboratory as researchers further explore 
causes and treatments for breast cancer, as many commonly used panels are limited to the 
most common genetic markers in European populations.  As a result and due to lack of robust 
research initiatives, these panels exclude markers for other populations. Several published 
and commercially available panels attempt to characterize the key genes in malignant 
transformation [337, 338], but often fall short in non-European populations [323, 339]. 
Additional data bases, such as COSMIC (Catalog of Somatic Mutations in Cancer) are 
working to further annotate mutations that appear to have a causal, rather than just 
correlative, relationship with cancer [340]. However, one major limitation of such projects 
are that they provide and compile a large amount of information on well characterized 
mutations, rather than addressing the large portion of cancer patients whose tumors are not 
driven by those specific changes.  Gene and protein characterization is the most commonly 
used clinical tool to inform patient treatment, but this focus on properties of the cancer cell 
only provides part of the picture, and looking at how the surrounding microenvironment 
impacts cell behavior can assist in understanding the disease and its variation between 
populations.  
6.2.2 Methods 
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6.2.2.1 Sample Collection  
42 pairs of tumor and matched normal tissue were collected by graduate students at 
the Black Lion Hospital in Addis Ababa, Ethiopia. Samples were placed in Phosphate 
buffered saline (PBS) after surgery, and stored down to -80°C. Samples were minimally 
thawed and sections collected for transport to labs in the United States. Small pieces of the 
tumor samples were paraffin embedded and sent to the Cooperative Human Tissue Network 
(CHTN) for hormone receptor characterization.  
6.2.2.2 Whole Exome Sequencing  
Small pieces of tumor tissue and matched normal tissue for samples 3, 5, 6, and 40, 
were digested with a DNAeasy blood and tissue kit (69504, Qiagen, Germantown, MD), and 
assayed for quantity using a Qubit Fluorometer. DNA was sheared to fragments of 
approximately 150 base pairs using ultrasound pulses of 30 seconds on followed up 30 
seconds off, for a total ultrasound exposure of 10 minutes.  Samples were then amplified and 
selected for coding regions with an Illumina Exome TRUseq kit. Samples were run on mid 
output flow cells on the NextSeq 500 at the University of Massachusetts Genomics Resource 
Lab. Fastq files were checked for quality, and aligned to the hg38 human reference genome 
with Bowtie2 and Samtools on the Massachusetts Green High Power Computing Center 
[230, 341]. Samples were filtered with bcftools and annotated with SNPEff using the online 
tool „Galaxy‟ [342-344].  
6.2.3 Results and Discussion 
Women in Ethiopia develop extremely aggressive breast cancer, and this can occur at 
a very young age. The most comprehensive study to date followed 1,070 Ethiopian women 
and determined 2 key contributors to an increased hazard ratio were being diagnosed younger 
than 50 years old, and being diagnosed with stage 3 breast cancers [345]. Our survey of the 
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literature revealed that the average age of breast cancer diagnosis in Ethiopian women is 42 
years old [346], with almost 2/3 of cases being diagnosed under 50 years old [347] (Figure 6-
3 a-b). This matches anecdotal evidence of extremely aggressive breast cancer diagnoses in 
very young women. In the United States and Europe, hormone receptor negative breast 
cancer is considered to the most aggressive, and is over represented in African American 
populations [325]. However, the hormone receptor status of Ethiopian women maps more 
closely to that of white women in the United States, while breast cancer in other African 
Figure 0-3. Ethiopian patients are diagnosed with ER+ breast cancer at a young age. a-
b. Two published clinical data sets show that women born in both East- and West-Africa are 
diagnosed with breast cancer at a much younger age than their American- and Jamaican 
born counterparts. Data is plotted from Jiagge et al (a) and Jemal and Fedewa (b). c-d. 
Ethiopian women, and more broadly, East-African women, are diagnosed with hormone-
receptor positive breast cancer at rates more similar to White Americans than other groups 
examined here. Data is plotted from  Jiagge et al (c) and Jemal and Fedewa (d). In a and c, 
white numbers on the bars represent the number of patients that contribute to that data from 
each population examined.  
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countries, like Ghana, has a profile closer to that of African American women (Figure 6-3 c). 
Jemal and Fedewa further make a robust comparison between women of different races and 
birth locations, and found East African born black women (with the majority of their 
sampling coming from Ethiopia) had levels of ER expression most similar to that of white 
women born in the United States (Figure 6-3 d). This indicates that there are both germline 
and environmental components to the percent of breast cancer cases that are hormone 
receptor positive.  
Figure 0-4. Mutated genes in Ethiopian breast cancer minimally overlap with 
commercial SNP panels. a. 6 ER+ Ethiopian breast cancer cases were selected for 
analysis via exome sequencing. The work here derives from sequencing of 3 of these 
patients, cases 3, 5, and 6. Estrogen receptor status (ER) and progesterone receptor status 
(PR) are given in terms of intensity, % staining, and overall result. b. The somatic 
mutations from those 3 Ethiopian patients were compared to mutations on commercial 
SNP panels that are commonly used to study breast cancer in European and North 
American populations. Colors are matched to samples in a. c. The list of 18 genes that 
harbor mutations that are shared between all 3 patients and the commercial SNP panels. 
Data analyzed in collaboration with the Cooperative Human Tissue Network facilities at 
the University of Virginia, Dr. Courtney Babbitt, and Trisha Zintel.  
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Because of these notable comparisons between Ethiopian women and American 
women, we chose to more closely examine gene panels currently used in the United States 
[337, 338, 348]. First, we selected 3 patients with ER+ staining as our initial sequencing 
cohort, and sequenced both the cancerous tissue, as well as the matched normal sample  
(Figure 6-4 a). We then identified genes containing functional mutations of interest, such as 
non-synonymous mutations, lost start codons, or gained stop codons. When we compared 
these genes to those identified by commercial panels, we found a total of 18 genes that 
overlapped, with a very low confidence threshold applied to our samples (Figure 6-4 b-c). 
This small fraction of overlap from the thousands of genes that we identified as potentially 
containing driver mutations in our patient samples, indicates that breast cancer in Ethiopian 
born women is still genetically very different from that of US born women. This analysis 
relied on comparison of the tumor samples to the matched normal tissue to identify somatic 
mutations. Future work should also work to identify germline mutations that may also 
increase a women‟s risk for developing breast cancer. However, there are few or no good 
reference genomes for non-white individuals thus far, and a recent global analysis discovered  
that most populations differ from the standard reference genome by 4.1 to 5.0 million base 
pairs, which is consistent with standard human migration models [349].  In that study, 
individuals from Africa had the largest number of variation sites from the reference genome.  
In addition to detecting genetic drivers, high penetrance mutations in understudied 
populations can identify new therapeutic targets. This has previously been done with an 
activating mutation in ER+ breast cancer [350], but that work still focused on populations 
primarily of European descent. There is mounting evidence that the current diagnostics may 
not capture breast cancer as it presents in African American women [351], highlighting a 
severe limitation of current genetic panels and treatment options. Treatment targeting the 
tumor microenvironment, particularly in pathways that are over expressed in African 
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American women, such as angiogenesis and chemotaxis [339], have seen little clinical 
success thus far. Here we aim to better capture the spectrum of mutations in non-white, non-
BRCA familial breast cancer using whole exome sequencing techniques [7]. One previous 
example of a small genetic population with non-BRCA familial history of breast and ovarian 
cancer lays the groundwork for future studies and identified several genes in DNA repair, cell 
signaling, and apoptosis that were possible predictors for heritable cancer risk [352, 353].  
6.2.4 Conclusions and Future Directions 
Breast cancer is a global disease that will ultimately affect 1 in 8 women during her 
life time. While most research has focused on western populations, adopting a methodology 
that examines the global nature of the disease is critical to understanding how breast cancer 
manifests across populations. Anecdotal and statistical evidence demonstrates that women in 
East Africa, and specifically in Ethiopia, are diagnosed with aggressive disease at a very 
young age. Further, in Ethiopia hormone receptor positive tumors are common, which exists 
in contrast to HR+ tumors in the US being the least aggressive and the statistical evidence 
that African Americans are more likely to be diagnosed with triple negative breast cancer. 
Further, pesticide use and improper disposal is common in rural farming communities, which 
make up a majority of the population in Ethiopia. Many of these pesticides are endocrine 
disrupting chemicals, which can interrupt or mimic the effect of estrogen, leading cells to 
remodel their extracellular matrix. We set out to identify the relationship between the breast 
cancer cells and patient interaction with the environment by performing whole exome 
sequencing on ER+ tumors from patients in Ethiopia. 
Here we demonstrate that in ER+ Ethiopian tumors, there are a set of somatic 
mutations that minimally overlap with existing genetic panels. Comparing the mutated genes 
identified here to several commercially available SNP panels, of the 109 genes on at least one 
panel, 53 genes were not mutated in any of the patients, with only 18 genes mutated in all 3 
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of the Ethiopian patients. We have further identified mutations in genes associated with gene 
ontology groupings involved in decreased KRAS signaling (data not shown). This is a 
promising target, as supplemented by ongoing research in Ethiopia, which identified 
cytokeratin 18 as a promising biomarker [354]. This methodology is further corroborated by 
additional studies that examine the frequency of mutations in non-white populations [322, 
323]. Together, the exposure to endocrine mimicking agents, which has been shown to 
facilitate changes in the extracellular matrix, along with identifications of somatic mutations 
within the cancer cells themselves, provides a promising platform to identify and target breast 
cancer in an Ethiopian population.   
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